Phase I studies with bendamustine: An update

Seminars in Oncology 29, 15-18

DOI: 10.1053/sonc.2002.34874

Citation Report

#	Article	IF	Citations
1	The role of tumor vascularisation in benign and malignant cardiovascular neoplasms: A comparison of cardiac myxoma and sarcomas of the pulmonary artery. Oncology Reports, 1994, 20, 309.	1.2	4
2	Role of angiogenesis in tumor growth and metastasis. Seminars in Oncology, 2002, 29, 15-18.	0.8	2,158
3	Analysis of c-kit protein expression in small-cell lung carcinoma and its implication for prognosis. Human Pathology, 2002, 33, 1182-1187.	1.1	88
4	c-Met: structure, functions and potential for therapeutic inhibition. Cancer and Metastasis Reviews, 2003, 22, 309-325.	2.7	447
6	Biologic directed therapies in gynecologic oncology. Current Oncology Reports, 2003, 5, 459-467.	1.8	3
7	Role of hypoxia in tumor angiogenesis?molecular and cellular angiogenic crosstalk. Cell and Tissue Research, 2003, 314, 145-155.	1.5	49
8	Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Cancer, 2003, 98, 1377-1385.	2.0	104
9	Optical imaging and tumor angiogenesis. Journal of Cellular Biochemistry, 2003, 90, 484-491.	1.2	31
10	Fibroblast growth factor receptor-1 mediates the inhibition of endothelial cell proliferation and the promotion of skeletal myoblast differentiation by SPARC: A role for protein kinase A. Journal of Cellular Biochemistry, 2003, 90, 408-423.	1,2	63
11	Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers. Critical Reviews in Oncology/Hematology, 2003, 46, 105-115.	2.0	40
12	Molecular basis of angiogenesis and cancer. Oncogene, 2003, 22, 6549-6556.	2.6	287
13	Kit Expression in Small Cell Carcinomas of the Lung: Effects of Chemotherapy. Modern Pathology, 2003, 16, 1041-1047.	2.9	52
14	Translating angiogenesis research into the clinic: the challenges ahead. British Journal of Radiology, 2003, 76, S3-S10.	1.0	36
15	Development of New Agents for the Treatment of Advanced Colorectal Cancer. Clinical Colorectal Cancer, 2003, 3, 154-164.	1.0	5
16	Non steroidal antiâ€inflammatory drugs and COXâ€2 inhibitors as antiâ€cancer therapeutics: hypes, hopes and reality. Annals of Medicine, 2003, 35, 476-487.	1.5	67
17	Lung cancer chemoprevention: moving from concept to a reality. Lung Cancer, 2003, 41, 163-174.	0.9	13
18	IL-2 loaded dextran microspheres with attractive histocompatibility properties for local IL-2 cancer therapy. Cytokine, 2003, 24, 57-66.	1.4	20
19	Effects of Raf Kinase Inhibitor Protein Expression on Suppression of Prostate Cancer Metastasis. Journal of the National Cancer Institute, 2003, 95, 878-889.	3.0	349

#	Article	IF	Citations
20	Knowledge and Truth: Answers or Questions?. Surgical Infections, 2003, 4, 297-309.	0.7	3
22	Radiation Induced-Tubulogenesis in Endothelial Cells is Antagonized by the Antiangiogenic Properties of Green Tea Polyphenol (-) Epigallocatechin-3-Gallate. Cancer Biology and Therapy, 2003, 2, 640-647.	1.5	51
24	Radiobiology and vascular targeting in glioma. Current Opinion in Neurology, 2003, 16, 651-655.	1.8	2
25	Analysis of Protein Expression and Gene Mutation of c-kit in Colorectal Neuroendocrine Carcinomas. American Journal of Surgical Pathology, 2003, 27, 1551-1558.	2.1	38
26	Roxatidine- and Cimetidine-Induced Angiogenesis Inhibition Suppresses Growth of Colon Cancer Implants in Syngeneic Mice. Journal of Pharmacological Sciences, 2003, 93, 321-330.	1.1	50
27	Anti-angiogenic Effects of Dimethyl Sulfoxide on Endothelial Cells. Biological and Pharmaceutical Bulletin, 2003, 26, 1295-1298.	0.6	25
28	Gen- und Immuntherapie des hepatozellulÃren Karzinoms: Fakten und Fiktionen im Jahr 2003. Visceral Medicine, 2003, 19, 253-260.	0.5	0
29	Aging and angiogenesis. Frontiers in Bioscience - Landmark, 2003, 8, s1199-1209.	3.0	82
30	Perioperative Chemotherapy in Advanced Bladder Cancer – Part II: Adjuvant Treatment. Oncology Research and Treatment, 2003, 26, 484-488.	0.8	10
31	Absence of OX-43 antigen expression in invasive capillary sprouts: identification of a capillary sprout-specific endothelial phenotype. American Journal of Physiology - Heart and Circulatory Physiology, 2004, 286, H346-H353.	1.5	14
32	Hyaluronan Degradation in Tumor Growth and Metastasis. Trends in Glycoscience and Glycotechnology, 2004, 16, 171-185.	0.0	4
33	Ultrasonic Analysis of Peptide- and Antibody-Targeted Microbubble Contrast Agents for Molecular Imaging of $\hat{l}\pm\nu$ \hat{l}^2 3 -Expressing Cells. Molecular Imaging, 2004, 3, 153535002004031.	0.7	14
34	Localization of Collagen XVIII and the Endostatin Portion of Collagen XVIII in Aged Human Control Eyes and Eyes with Age-Related Macular Degeneration. Investigative Ophthalmology and Visual Science, 2004, 45, 1544-1552.	3.3	95
35	Angiogenesis: a potential target for therapy of soft tissue sarcomas., 2004, 120, 169-180.		3
36	Angiogenesis in Multiple Myeloma: Implications in Myeloma Therapy. Cancer Reviews: Asia-Pacific, 2004, 02, 119-129.	0.1	2
37	Increased Angiogenesis and Lymphangiogenesis in Inflammatory versus Noninflammatory Breast Cancer by Real-Time Reverse Transcriptase-PCR Gene Expression Quantification. Clinical Cancer Research, 2004, 10, 7965-7971.	3.2	215
38	Antiangiogenic Therapy in Hematologic Malignancies. Current Pharmaceutical Design, 2004, 10, 1221-1234.	0.9	31
39	Inhibition of Epidermal Growth Factor Receptor and Symptom Improvement in Advanced Non-Small Cell Lung Cancer. Seminars in Respiratory and Critical Care Medicine, 2004, 25, 29-32.	0.8	0

#	Article	IF	Citations
41	Fibroblast Growth Factor 2: From Laboratory Evidence to Clinical Application. Current Vascular Pharmacology, 2004, 2, 33-43.	0.8	64
43	Analysis of dynamic contrast enhanced MRI. British Journal of Radiology, 2004, 77, S154-S166.	1.0	69
44	Assessing Cellular Protein Phosphorylation: High Throughput Drug Discovery Technologies. Assay and Drug Development Technologies, 2004, 2, 225-235.	0.6	24
45	Targeting Vascular and Avascular Compartments of Tumors with <i>C. novyi-NT</i> and Anti-microtubule Agents. Cancer Biology and Therapy, 2004, 3, 326-337.	1.5	92
46	Endometriosis and the neoplastic process. Reproduction, 2004, 127, 293-304.	1.1	183
47	Exercise delays allogeneic tumor growth and reduces intratumoral inflammation and vascularization. Journal of Applied Physiology, 2004, 96, 2249-2256.	1.2	65
48	Tumor-Associated Endothelial Cells with Cytogenetic Abnormalities. Cancer Research, 2004, 64, 8249-8255.	0.4	429
50	9- \hat{l}^2 -d-Arabinofuranosyl-2-fluoroadenine Inhibits Expression of Vascular Endothelial Growth Factor through Hypoxia-Inducible Factor-1 in Human Ovarian Cancer Cells. Molecular Pharmacology, 2004, 66, 178-186.	1.0	26
51	Bevacizumab for Patients with Metastatic Renal Cancer: Fig. 1 Clinical Cancer Research, 2004, 10, 6367S-6370S.	3.2	125
52	Effect of Imatinib Mesylate on Neuroblastoma Tumorigenesis and Vascular Endothelial Growth Factor Expression. Journal of the National Cancer Institute, 2004, 96, 46-55.	3.0	150
53	Differential Activation of the Phosphatidylinositol 3′-Kinase/Akt Survival Pathway by Ionizing Radiation in Tumor and Primary Endothelial Cells. Cancer Research, 2004, 64, 5398-5406.	0.4	55
54	On the emergence of multifocal cancers. Journal of Carcinogenesis, 2004, 3, 13.	2.5	7
55	Matrix Metalloproteinase-9 Is Required for Adequate Angiogenic Revascularization of Ischemic Tissues. Circulation Research, 2004, 94, 262-268.	2.0	178
56	Anti-angiogenic gene therapy for cancer (Review). International Journal of Oncology, 2004, 25, 335.	1.4	4
57	The Natural Progression of Microvasculature in Primary Tumor and Lymph Node Metastases in a Breast Carcinoma Model: Relationship between Microvessel Density, Vascular Endothelial Growth Factor Expression and Metastatic Invasion. Cancer Biology and Therapy, 2004, 3, 408-414.	1.5	8
58	Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through $\hat{l}\pm2\hat{l}^21$ integrin. Journal of Cell Biology, 2004, 166, 97-109.	2.3	243
59	Role of infiltrated leucocytes in tumour growth and spread. British Journal of Cancer, 2004, 90, 2053-2058.	2.9	234
60	Soluble factors from human endometrium promote angiogenesis and regulate the endothelial cell transcriptome. Human Reproduction, 2004, 19, 2356-2366.	0.4	32

#	Article	IF	Citations
61	Human T-Cell Lymphotropic Virus Type I-Infected Cells Extravasate through the Endothelial Barrier by a Local Angiogenesis-Like Mechanism. Cancer Research, 2004, 64, 2039-2046.	0.4	53
62	Vascular Endothelial Growth Factor Activation of Sterol Regulatory Element Binding Protein. Circulation Research, 2004, 95, 471-478.	2.0	66
63	The potential of positron-emission tomography to study anticancer-drug resistance. Nature Reviews Cancer, 2004, 4, 457-469.	12.8	35
64	Checkpoint genes, ageing, and the development of cancer. Oncogene, 2004, 23, 7799-7809.	2.6	6
65	Novel endothelial cell markers in hepatocellular carcinoma. Modern Pathology, 2004, 17, 1198-1210.	2.9	78
66	The relationship between hypoxia and angiogenesis. Seminars in Radiation Oncology, 2004, 14, 215-221.	1.0	84
67	Somatostatin analogues: Multiple roles in cellular proliferation, neoplasia, and angiogenesis. , 2004, 102, 61-85.		157
68	Targeted molecules in small cell lung cancer. Seminars in Oncology, 2004, 31, 106-111.	0.8	42
69	Lymphangiogenesis is pivotal to the trials of a successful cancer metastasis. Surgery, 2004, 135, 121-124.	1.0	17
70	Smart Drugs in Prostate Cancer. European Urology, 2004, 45, 1-17.	0.9	32
71	Tyrosine kinase receptors as attractive targets of cancer therapy. Critical Reviews in Oncology/Hematology, 2004, 50, 23-38.	2.0	164
72	Eph Receptor Tyrosine Kinases in Angiogenesis: From Development to Disease. Angiogenesis, 2004, 7, 17-28.	3.7	127
73	Myocardial angiogenesis. Molecular and Cellular Biochemistry, 2004, 264, 35-44.	1.4	37
74	Stabilization of a Progressive Hemangioblastoma under Treatment with Thalidomide. Journal of Neuro-Oncology, 2004, 66, 295-299.	1.4	22
75	Transplanted Bone Marrow Cells Preferentially Home To The Vessels Of In Situ Generated Murine Tumors Rather Than Of Normal Organs. Stem Cells, 2004, 22, 86-92.	1.4	29
76	Establishment of green fluorescent protein-expressing hepatocellular carcinoma cell lines with different metastatic potential: relevant models for in vivo monitoring of metastasis and angiogenesis. Journal of Cancer Research and Clinical Oncology, 2004, 130, 375-82.	1,2	6
77	Gemcitabine plus carboplatin; and gemcitabine, docetaxel, and carboplatin combined chemotherapy regimens in patients with metastatic urothelial carcinoma previously treated with a platinum-based regimen: preliminary report. International Journal of Clinical Oncology, 2004, 9, 125-129.	1.0	18
78	The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis, 2004, 7, 225-233.	3.7	149

#	Article	IF	Citations
79	Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis, 2004, 7, 335-345.	3.7	375
80	Matrix metalloproteinases and matrikines in angiogenesis. Critical Reviews in Oncology/Hematology, 2004, 49, 203-220.	2.0	88
81	Relationship of 99mTc-HYNIC annexin V uptake to microvessel density, FasL and MMP-9 expression, and the number of tumour-infiltrating lymphocytes in head and neck carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 1016-1021.	3.3	11
82	MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 1081-9.	3.3	139
83	Angiopoietins in tumours: the angiogenic switch. Journal of Pathology, 2004, 204, 1-10.	2.1	206
84	Oncolysis by viral replication and inhibition of angiogenesis by a replication-conditional herpes simplex virus that expresses mouse endostatin. Cancer, 2004, 101, 869-877.	2.0	36
85	Anti-tumor activity of a combination of plasminogen activator and captopril in a human melanoma xenograft model. International Journal of Cancer, 2004, 112, 329-334.	2.3	29
86	NS398 reduces hypoxia-inducible factor(HIF)- $1\hat{l}\pm$ and HIF-1 activity: Multiple-level effects involving cyclooxygenase-2 dependent and independent mechanisms. International Journal of Cancer, 2004, 112, 585-595.	2.3	52
87	MAZ51, an indolinone that inhibits endothelial cell and tumor cell growthin vitro, suppresses tumor growthin vivo. International Journal of Cancer, 2004, 112, 986-993.	2.3	59
88	Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transplantation, 2004, 10, 1301-1311.	1.3	241
89	A comparison of Ktransmeasurements obtained with conventional and first pass pharmacokinetic models in human gliomas. Journal of Magnetic Resonance Imaging, 2004, 19, 527-536.	1.9	60
90	The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Critical Reviews in Oncology/Hematology, 2004, 50, 87-100.	2.0	308
91	Methyl Selenium-Induced Vascular Endothelial Apoptosis Is Executed by Caspases and Principally Mediated by P38 MAPK Pathway. Nutrition and Cancer, 2004, 49, 174-183.	0.9	44
92	Recruitment of Bone Marrow-Derived Endothelial Cells to Sites of Pancreatic Â-Cell Injury. Diabetes, 2004, 53, 91-98.	0.3	172
93	Chemoprevention of lung cancer—from biology to clinical reality. Annals of Oncology, 2004, 15, 185-196.	0.6	38
94	Increased osteonectin expression is associated with malignant transformation and tumor associated fibrosis in the lung. Lung Cancer, 2004, 45, 197-205.	0.9	18
95	Carboplatin in Combination with Bendamustine in Previously Untreated Patients with Extensive-Stage Small Cell Lung Cancer (SCLC). Clinical Drug Investigation, 2004, 24, 611-618.	1.1	14
96	Renal cell carcinoma: rationale and development of therapeutic inhibitors of angiogenesis. Hematology/Oncology Clinics of North America, 2004, 18, 1143-1159.	0.9	9

#	Article	IF	Citations
97	Recent advances in management of small-cell lung cancer. Cancer Treatment Reviews, 2004, 30, 521-543.	3.4	69
98	Constitutive and inducible expression and regulation of vascular endothelial growth factor. Cytokine and Growth Factor Reviews, 2004, 15, 297-324.	3.2	146
99	The effects of reduced oxygen tension on swine granulosa cell. Regulatory Peptides, 2004, 120, 69-75.	1.9	68
100	Angiogenesis as an immunopharmacologic target in inflammation and cancer. International Immunopharmacology, 2004, 4, 1537-1547.	1.7	47
101	The neurovascular unit and its growth factors: coordinated response in the vascular and nervous systems. Neurological Research, 2004, 26, 870-883.	0.6	116
102	Molecular therapy in pancreatic adenocarcinoma. Lancet Oncology, The, 2004, 5, 541-549.	5.1	69
103	Reproducibility of physiologic parameters obtained using functional computed tomography in mice. , 2004, , .		1
104	Vessel Density, Proliferation, and Immunolocalization of Vascular Endothelial Growth Factor in Juvenile Nasopharyngeal Angiofibromas. JAMA Otolaryngology, 2004, 130, 727.	1.5	62
105	Ocular Delivery of Angiostatic Agents. International Ophthalmology Clinics, 2004, 44, 41-51.	0.3	2
106	Melanoma on the Move: The Progression of Melanoma. American Journal of Dermatopathology, 2004, 26, 504-510.	0.3	10
107	Cyclooxygenase-2 Expression in Oral Squamous Cell Carcinoma. International Journal of Immunopathology and Pharmacology, 2004, 17, 273-282.	1.0	45
108	Role of monocytes and macrophages in angiogenesis. , 2005, , 127-146.		27
109	Local Delivery of a Synthetic Endostatin Fragment for the Treatment of Experimental Gliomas. Neurosurgery, 2005, 57, 1032-1040.	0.6	23
110	Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Critical Reviews in Oncology/Hematology, 2005, 53, 35-69.	2.0	237
111	Angiogenesis in Craniopharyngiomas: Microvascular Density and Tissue Expression of the Vascular Endothelial Growth Factor (VEGF) and Endostatin. Endocrine Pathology, 2005, 16, 355-362.	5.2	10
112	Improved correlation of histological data with DCE MRI parameter maps by 3D reconstruction, reslicing and parameterization of the histological images. European Radiology, 2005, 15, 1079-1086.	2.3	20
113	Angiogenesis: update 2005. Journal of Thrombosis and Haemostasis, 2005, 3, 1835-1842.	1.9	272
114	Tumor cell-associated neuropilin-1 and vascular endothelial growth factor expression as determinants of tumor growth in neuroblastoma. Neuropathology, 2005, 25, 178-187.	0.7	26

#	Article	IF	Citations
115	Cancer risk of patients with ischaemic syndromes. Journal of Internal Medicine, 2005, 258, 124-132.	2.7	21
116	Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study. British Journal of Cancer, 2005, 92, 645-650.	2.9	66
117	Galectins as modulators of tumour progression. Nature Reviews Cancer, 2005, 5, 29-41.	12.8	1,290
118	Chronic gene delivery of interferon-inducible protein 10 through replication-competent retrovirus vectors suppresses tumor growth. Cancer Gene Therapy, 2005, 12, 900-912.	2.2	32
119	Survival of chronic lymphocytic leukemia cells: CD40L and the vascular endothelial growth factor (VEGF) connection. Leukemia, 2005, 19, 531-532.	3.3	3
120	Arsenic trioxide prevents radiation-enhanced tumor invasiveness and inhibits matrix metalloproteinase-9 through downregulation of nuclear factor ÎB. Oncogene, 2005, 24, 390-398.	2.6	61
121	Vasculostatin, a proteolytic fragment of Brain Angiogenesis Inhibitor 1 , is an antiangiogenic and antitumorigenic factor. Oncogene, 2005, 24, 3632-3642.	2.6	159
122	HIF- $1\hat{i}_{\pm}$, STAT3, CBP/p300 and Ref- 1 /APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene, 2005, 24, 3110-3120.	2.6	353
123	Quantification of Angiogenesis in Otosclerosis. Laryngoscope, 2005, 115, 811-816.	1.1	5
124	Low D2-40 immunoreactivity correlates with lymphatic invasion and nodal metastasis in early-stage squamous cell carcinoma of the uterine cervix. Modern Pathology, 2005, 18, 97-104.	2.9	97
126	Trauma-associated growth of suspected dormant micrometastasis. BMC Cancer, 2005, 5, 94.	1.1	29
127	Anti-angiogenic therapy subsequent to adeno-associated-virus-mediated immunotherapy eradicates lymphomas that disseminate to the liver. International Journal of Cancer, 2005, 113, 670-677.	2.3	19
128	Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma. Cancer, 2005, 104, 2149-2155.	2.0	83
129	VEGF as a predictive marker of rectal tumor response to preoperative radiotherapy. Cancer, 2005, 104, 2517-2521.	2.0	48
130	Colorectal cancer and antiangiogenic therapy: What can be expected in clinical practice?. Critical Reviews in Oncology/Hematology, 2005, 55, 67-81.	2.0	24
131	Progression of head and neck squamous cell cancer. Cancer and Metastasis Reviews, 2005, 24, 107-127.	2.7	51
132	Kinetics of Marked Development of Lung Metastasis of Rat Prostatic Carcinomas Transplanted in Syngeneic Rats. Clinical and Experimental Metastasis, 2005, 22, 309-318.	1.7	2
133	An Orthotopic Model of Human Osteosarcoma Growth and Spontaneous Pulmonary Metastasis. Clinical and Experimental Metastasis, 2005, 22, 319-329.	1.7	200

#	Article	IF	Citations
134	Development of angiogenesis inhibitors to vascular endothelial growth factor receptor 2. current status and future perspective. Frontiers in Bioscience - Landmark, 2005, 10, 1415.	3.0	52
135	The neuroprotective and angiogenesis inhibitory serpin, PEDF: new insights into phylogeny, function, and signaling. Frontiers in Bioscience - Landmark, 2005, 10, 2131.	3.0	74
136	Use of Animal Models to Evaluate Signal Transduction Inhibitors As Modulators of Cytotoxic Therapy. , 2005, , 231-275.		0
137	The postnatal rat aorta contains pericyte progenitor cells that form spheroidal colonies in suspension culture. American Journal of Physiology - Cell Physiology, 2005, 289, C1396-C1407.	2.1	121
138	Targeting Coagulation to the Tumor Microvasculature: Perspectives and Therapeutic Implications From Preclinical Studies. Journal of the National Cancer Institute, 2005, 97, 705-707.	3.0	16
139	The Matrix Metalloproteinase-9/Neutrophil Gelatinase-Associated Lipocalin Complex Plays a Role in Breast Tumor Growth and Is Present in the Urine of Breast Cancer Patients. Clinical Cancer Research, 2005, 11, 5390-5395.	3.2	254
140	Functional CT for Quantifying Tumor Perfusion in Antiangiogenic Therapy in a Rat Model. Radiology, 2005, 237, 151-158.	3.6	111
141	Viral oncolysis by herpes simplex virus and other viruses. Cancer Biology and Therapy, 2005, 4, 524-531.	1.5	36
142	Perfusion Imaging of the Liver: Current Challenges and Future Goals. Radiology, 2005, 234, 661-673.	3.6	263
144	Tumor Dormancy and MYC Inactivation: Pushing Cancer to the Brink of Normalcy: Figure 1 Cancer Research, 2005, 65, 4471-4474.	0.4	94
145	Delivery of Antiangiogenic Agents for Cancer Gene Therapy. Technology in Cancer Research and Treatment, 2005, 4, 331-341.	0.8	5
146	Antitumor Vascular Strategy for Controlling Experimental Metastatic Spread of Human Small-Cell Lung Cancer Cells with ZD6474 in Natural Killer Cell–Depleted Severe Combined Immunodeficient Mice. Clinical Cancer Research, 2005, 11, 8789-8798.	3.2	45
147	Rationale for Antiangiogenic Cancer Therapy with Vaccination Using Epitope Peptides Derived from Human Vascular Endothelial Growth Factor Receptor 2. Cancer Research, 2005, 65, 4939-4946.	0.4	91
148	Update on therapeutic neovascularization. Cardiovascular Research, 2005, 65, 639-648.	1.8	95
149	Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results. Journal of Clinical Oncology, 2005, 23, 5474-5483.	0.8	470
150	The Homeobox Gene Gax Inhibits Angiogenesis through Inhibition of Nuclear Factor-l̂ºB–Dependent Endothelial Cell Gene Expression. Cancer Research, 2005, 65, 1414-1424.	0.4	86
151	A New Perspective on Tumor Endothelial Cells: Unexpected Chromosome and Centrosome Abnormalities: Figure 1 Cancer Research, 2005, 65, 2507-2510.	0.4	151
152	Inhibition of Tumor Growth, Angiogenesis, and Tumor Cell Proliferation by a Small Molecule Inhibitor of c-Jun N-terminal Kinase. Journal of Pharmacology and Experimental Therapeutics, 2005, 313, 325-332.	1.3	61

#	Article	IF	Citations
153	Dynamical Interactions between Multiple Cancers. Cell Cycle, 2005, 4, 764-771.	1.3	3
154	Vector-mediated cancer gene therapy: An overview. Cancer Biology and Therapy, 2005, 4, 512-517.	1.5	82
155	Imaging Angiogenesis: Applications and Potential for Drug Development. Journal of the National Cancer Institute, 2005, 97, 172-187.	3.0	312
157	Angiogenesis: a curse or cure?. Postgraduate Medical Journal, 2005, 81, 236-242.	0.9	83
158	The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development. Clinical Cancer Research, 2005, 11, 7967-7985.	3.2	219
159	Pigment epithelium-derived factor (PEDF)-induced apoptosis and inhibition of vascular endothelial growth factor (VEGF) expression in MG63 human osteosarcoma cells. Life Sciences, 2005, 77, 3231-3241.	2.0	91
160	Growth factors and their relationship to neoplastic and paraneoplastic disease. European Journal of Internal Medicine, 2005, 16, 83-94.	1.0	3
161	Recombinant α2(IV)NC1 Domain Inhibits Tumor Cell-Extracellular Matrix Interactions, Induces Cellular Senescence, and Inhibits Tumor Growth in Vivo. American Journal of Pathology, 2005, 166, 901-911.	1.9	47
162	Hyaluronan metabolism: a major paradox in cancer biology. Pathologie Et Biologie, 2005, 53, 372-382.	2.2	144
163	Correlation between 99mTc-MIBI uptake and angiogenesis in MIBI-positive breast lesions. Nuclear Medicine and Biology, 2005, 32, 465-472.	0.3	6
164	Late stage inhibition of hematogenous melanoma metastasis by cystatin C over-expression. Cancer Cell International, 2005, 5, 14.	1.8	25
165	Evolution of Lymphadenectomy in Surgical Oncology. Surgical Oncology Clinics of North America, 2005, 14, 447-459.	0.6	9
166	Novel Therapies in Lung Cancer. Hematology/Oncology Clinics of North America, 2005, 19, 343-367.	0.9	4
168	A Multitargeted Receptor Tyrosine Kinase Inhibitor, SU6668, Does Not Affect the Healing of Cutaneous Full-Thickness Incisional Wounds in SKH-1 Mice. Journal of Investigative Surgery, 2006, 19, 245-254.	0.6	7
170	Preferential Attachment of Peritoneal Tumor Metastases to Omental Immune Aggregates and Possible Role of a Unique Vascular Microenvironment in Metastatic Survival and Growth. American Journal of Pathology, 2006, 169, 1739-1752.	1.9	159
171	CCI-779 Inhibits Rhabdomyosarcoma Xenograft Growth by an Antiangiogenic Mechanism Linked to the Targeting of mTOR/Hif-1α/VEGF Signaling. Neoplasia, 2006, 8, 394-401.	2.3	136
173	Novel Targeted Therapies for Non–Small Cell Lung Cancer. Thoracic Surgery Clinics, 2006, 16, 353-366.	0.4	1
174	Anti-VEGF Therapies for Diseases of the Retina and Choroid. , 2006, , 309-339.		0

#	Article	IF	Citations
175	The finest branches of the biliary tree might induce biliary vascularization necessary for biliary regeneration. Journal of Hepatology, 2006, 44, 947-955.	1.8	14
176	Blockage of HGF/c-Met system by gene therapy (adenovirus-mediated NK4 gene) suppresses hepatocellular carcinoma in mice. Journal of Hepatology, 2006, 45, 688-695.	1.8	31
177	Drugs for Lung Cancer Treatment. Tuberculosis and Respiratory Diseases, 2006, 60, 123.	0.7	0
178	Cardiac Metastases in Malignant Fibrous Histiocytoma. A Case Report. Tumori, 2006, 92, 76-78.	0.6	7
179	Angiopoietin-1 and vascular endothelial growth factor induce expression of inflammatory cytokines before angiogenesis. Physiological Genomics, 2006, 27, 20-28.	1.0	81
180	Microcirculation patterns in different stages of melanoma growth. Oncology Reports, 2006, 15, 15.	1.2	30
182	Silencing Proteins: Nanotechnological Approaches to Deliver siRNA for Cancer Therapy. , 2006, , 127-153.		0
183	Prognostic Factors and New Methods in Cervical Carcinoma. , 2006, 11, 130-139.		1
184	Protein and Peptide Drugs to Suppress Tumor Angiogenesis. , 2006, , 255-284.		0
185	Vascular endothelial growth factor-A and Poly(A) binding protein-interacting protein 2 expression in human head and neck carcinomas: correlation and prognostic significance. British Journal of Cancer, 2006, 94, 1516-1523.	2.9	21
186	Rapamycin induces regression of endometriotic lesions by inhibiting neovascularization and cell proliferation. British Journal of Pharmacology, 2006, 149, 137-144.	2.7	62
187	Lymphatic microvessel density as prognostic marker in colorectal cancer. Modern Pathology, 2006, 19, 1317-1323.	2.9	103
188	TIMP-3 deficiency in the host, but not in the tumor, enhances tumor growth and angiogenesis. Oncogene, 2006, 25, 650-655.	2.6	48
189	High Expression of CD105 as a Prognostic Predictor of Early Tongue Cancer. Laryngoscope, 2006, 116, 1175-1179.	1.1	41
190	Combining radiotherapy and angiogenesis inhibitors: Clinical trial design. International Journal of Radiation Oncology Biology Physics, 2006, 64, 15-25.	0.4	40
192	VEGF-associated tyrosine kinase inhibition increases the tumor response to single and fractionated dose radiotherapy. International Journal of Radiation Oncology Biology Physics, 2006, 65, 836-841.	0.4	34
193	Therapeutic effects of paclitaxel-containing ultrasound contrast agents. Ultrasound in Medicine and Biology, 2006, 32, 1771-1780.	0.7	148
194	The mesenchyme in cancer therapy as a target tumor component, effector cell modality and cytokine expression vehicle. Cancer and Metastasis Reviews, 2006, 25, 459-467.	2.7	18

#	Article	IF	Citations
195	The inhibition of lung colonization of B16-F10 melanoma cells in EFA-deficient animals is related to enhanced apoptosis and reduced angiogenesis. Clinical and Experimental Metastasis, 2006, 23, 159-165.	1.7	4
196	Tissue kallikrein and kinin receptor expression in an angiogenic co-culture neuroblastoma model. Metabolic Brain Disease, 2006, 21, 242-254.	1.4	8
197	S100A13, a new marker of angiogenesis in human astrocytic gliomas. Journal of Neuro-Oncology, 2006, 80, 251-259.	1.4	41
198	Angiogenesisâ€"understanding the mathematical challenge. Angiogenesis, 2006, 9, 127-138.	3.7	18
199	$\hat{l}\pm v\hat{l}^2$ 3-integrin imaging: a new approach to characterise angiogenesis?. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 54-63.	3.3	139
200	Antiangiogenic Effects of Radiotherapy but not Initial Microvessel Density Predict Survival in Inoperable Oropharyngeal Squamous Cell Carcinoma. Strahlentherapie Und Onkologie, 2006, 182, 149-156.	1.0	12
201	Screening and identification of vascular-endothelial-cell-specific binding peptide in gastric cancer. Journal of Molecular Medicine, 2006, 84, 764-773.	1.7	53
202	Combination of epidermal growth factor receptor inhibitors and antiangiogenic drugs: a model for treatment. Targeted Oncology, 2006, 1, 123-129.	1.7	4
203	The Clinical and Biologic Importance of Neovascularization and Angiogenic Signaling Pathways in Chronic Lymphocytic Leukemia. Seminars in Oncology, 2006, 33, 174-185.	0.8	47
204	The Angiogenic Switch Molecule, Secreted FGF-Binding Protein, an Indicator of Early Stages of Pancreatic and Colorectal Adenocarcinoma. Seminars in Oncology, 2006, 33, 50-56.	0.8	172
205	Angiostatin generating capacity and anti-tumour effects of D-penicillamine and plasminogen activators. BMC Cancer, 2006, 6, 149.	1.1	6
206	Anti-vascular agent Combretastatin A-4-P modulates Hypoxia Inducible Factor-1 and gene expression. BMC Cancer, 2006, 6, 280.	1.1	33
207	Development of antibody-based therapeutics for oncology indications. Drug Development Research, 2006, 67, 699-728.	1.4	3
208	Cellular and molecular mechanisms of nicotine's pro-angiogenesis activity and its potential impact on cancer. Journal of Cellular Biochemistry, 2006, 97, 1370-1378.	1.2	60
209	Paneling human thyroid cancer cell lines for candidate proteins for targeted anti-angiogenic therapy. Journal of Cellular Biochemistry, 2006, 98, 954-965.	1.2	12
210	Adenovirus-mediated intra-tumoral delivery of the humanendostatingene inhibits tumor growth in nasopharyngeal carcinoma. International Journal of Cancer, 2006, 118, 2064-2071.	2.3	31
211	Fibronectin as target for tumor therapy. International Journal of Cancer, 2006, 118, 1331-1339.	2.3	202
212	Small molecule drug activity in melanoma models may be dramatically enhanced with an antibody effector. International Journal of Cancer, 2006, 119, 1194-1207.	2.3	42

#	Article	IF	Citations
213	Outgrowth of human liver metastases after resection of the primary colorectal tumor: A shift in the balance between apoptosis and proliferation. International Journal of Cancer, 2006, 119, 1249-1253.	2.3	118
214	Anti-angiogenic drugs: from bench to clinical trials. Medicinal Research Reviews, 2006, 26, 483-530.	5.0	146
215	Morphological patterns of angiogenesis in ovarian follicle capillary networks. A scanning electron microscopy study of corrosion cast. Microscopy Research and Technique, 2006, 69, 459-468.	1.2	48
216	RE: Correlational of oral tongue cancer inversion with matrix metalloproteinases (MMPs) and vascular endothelial growth factor (VEGF) expression, by Kim S-H, Cho NH, Kim K, et al Journal of Surgical Oncology, 2006, 93, 253-254.	0.8	15
217	High expressions of CD105 and VEGF in early oral cancer predict potential cervical metastasis. Journal of Surgical Oncology, 2006, 94, 413-417.	0.8	53
218	Cancer Dormancy from Mice to Man: A Review. Cell Cycle, 2006, 5, 1772-1778.	1.3	62
219	The response to brain tumor-derived growth factors is altered in radioresistant human brain endothelial cells. Cancer Biology and Therapy, 2006, 5, 1539-1545.	1.5	12
220	pRb2/p130 and VEGF expression in endometrial carcinoma in relation to angiogenesis and histopathologic tumor grade. Cancer Biology and Therapy, 2006, 5, 84-88.	1.5	28
221	Tumor cell dormancy induced by p38SAPK and ER-stress signaling: An adaptive advantage for metastatic cells?. Cancer Biology and Therapy, 2006, 5, 729-735.	1.5	93
222	Opposing Roles of Mitogenic and Stress Signaling Pathways in the Induction of Cancer Dormancy. Cell Cycle, 2006, 5, 1799-1807.	1.3	87
223	The Problem of Cancer Dormancy: Understanding the Basic Mechanisms and Identifying Therapeutic Opportunities. Cell Cycle, 2006, 5, 1740-1743.	1.3	56
224	Is it the primetime for endoglin (CD105) in the clinical setting?. Cardiovascular Research, 2006, 69, 781-783.	1.8	12
225	Systemic Induction of the Angiogenesis Switch by the Tetraspanin D6.1A/CO-029. Cancer Research, 2006, 66, 7083-7094.	0.4	207
226	The effects of the vascular disrupting agents combretastatin A-4 disodium phosphate, 5,6-dimethylxanthenone-4-acetic acid and ZD6126 in a murine tumour: A comparative assessment using MRI and MRS. Acta OncolÅ ³ gica, 2006, 45, 306-316.	0.8	18
227	Multiple signaling pathways are involved in endothelin-1-induced brain endothelial cell migration. American Journal of Physiology - Cell Physiology, 2006, 291, C155-C164.	2.1	16
228	Potential of fibroblasts to regulate the formation of three-dimensional vessel-like structures from endothelial cells in vitro. American Journal of Physiology - Cell Physiology, 2006, 290, C1385-C1398.	2.1	155
229	HSulf-1 Inhibits Angiogenesis and Tumorigenesis In vivo. Cancer Research, 2006, 66, 6025-6032.	0.4	131
230	Suppression of Cell Proliferation and Signaling Transduction by Connective Tissue Growth Factor in Non–Small Cell Lung Cancer Cells. Molecular Cancer Research, 2006, 4, 591-598.	1.5	57

#	Article	IF	CITATIONS
231	Altering the Sphingosine-1-Phosphate/Ceramide Balance: A Promising Approach for Tumor Therapy. Current Pharmaceutical Design, 2006, 12, 4625-4635.	0.9	55
232	Heparanase Induces Vascular Endothelial Growth Factor Expression: Correlation with p38 Phosphorylation Levels and Src Activation. Cancer Research, 2006, 66, 1455-1463.	0.4	234
233	Review of the Effects of Anti-Angiogenic Compounds on the Epiphyseal Growth Plate. Toxicologic Pathology, 2006, 34, 131-147.	0.9	63
234	Angiogenesis in Atherogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 1948-1957.	1.1	114
235	Functional Coupling of p38-Induced Up-regulation of BiP and Activation of RNA-Dependent Protein Kinase–Like Endoplasmic Reticulum Kinase to Drug Resistance of Dormant Carcinoma Cells. Cancer Research, 2006, 66, 1702-1711.	0.4	291
236	Clinical Implications of EGFR Expression in the Development and Progression of Solid Tumors: Focus on Non‧mall Cell Lung Cancer. Oncologist, 2006, 11, 358-373.	1.9	60
237	Correlation between High Vascular Endothelial Growth Factor-A Serum Levels and Treatment Outcome in Patients with Standard-Risk Acute Lymphoblastic Leukemia: A Report from Children's Oncology Group Study CCG-1962. Clinical Cancer Research, 2006, 12, 6978-6984.	3.2	35
238	Mycophenolic Acid Is a Potent Inhibitor of Angiogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2414-2416.	1.1	28
239	Lipopeptide-based liposomes for DNA delivery into cells expressing neuropilin-1. Journal of Drug Targeting, 2006, 14, 694-706.	2.1	22
240	Preparing the "Soil†The Primary Tumor Induces Vasculature Reorganization in the Sentinel Lymph Node before the Arrival of Metastatic Cancer Cells. Cancer Research, 2006, 66, 10365-10376.	0.4	262
241	Tumor-Driven Paracrine Platelet-Derived Growth Factor Receptor \hat{l}_{\pm} Signaling Is a Key Determinant of Stromal Cell Recruitment in a Model of Human Lung Carcinoma. Clinical Cancer Research, 2006, 12, 2676-2688.	3.2	112
242	Obesity and Diabetes. , 2006, , .		4
243	Ocular Angiogenesis. , 2006, , .		5
244	Characterization of the Mouse IFN-λ Ligand-Receptor System: IFN-λs Exhibit Antitumor Activity against B16 Melanoma. Cancer Research, 2006, 66, 4468-4477.	0.4	229
245	Hypoxia-Inducible Factor- $\hat{1}$ ± Promotes Nonhypoxia-Mediated Proliferation in Colon Cancer Cells and Xenografts. Cancer Research, 2006, 66, 1684-1693.	0.4	108
246	Ephrin-A1 Facilitates Mammary Tumor Metastasis through an Angiogenesis-Dependent Mechanism Mediated by EphA Receptor and Vascular Endothelial Growth Factor in Mice. Cancer Research, 2006, 66, 10315-10324.	0.4	122
247	Endorepellin In Vivo: Targeting the Tumor Vasculature and Retarding Cancer Growth and Metabolism. Journal of the National Cancer Institute, 2006, 98, 1634-1646.	3.0	106
248	Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 16266-16271.	3.3	144

#	Article	IF	CITATIONS
249	CCL2 Regulates Angiogenesis via Activation of Ets-1 Transcription Factor. Journal of Immunology, 2006, 177, 2651-2661.	0.4	170
250	Preliminary Report on Analysis of Bladder-Wall Vasculature Using Conjunctival Microvascular Analysis in Patients with and without Transitional-Cell Carcinoma. Journal of Endourology, 2006, 20, 351-355.	1.1	O
251	Mechanism of Reoxygenation after Antiangiogenic Therapy Using SU5416 and Its Importance for Guiding Combined Antitumor Therapy. Cancer Research, 2006, 66, 9698-9704.	0.4	59
252	Antiangiogenic and Antitumor Activities of IL-27. Journal of Immunology, 2006, 176, 7317-7324.	0.4	161
253	ErbB2 Increases Vascular Endothelial Growth Factor Protein Synthesis via Activation of Mammalian Target of Rapamycin/p70S6K Leading to Increased Angiogenesis and Spontaneous Metastasis of Human Breast Cancer Cells. Cancer Research, 2006, 66, 2028-2037.	0.4	182
254	Inhibition of human nasopharyngeal carcinoma growth and metastasis in mice by adenovirus-associated virus–mediated expression of human endostatin. Molecular Cancer Therapeutics, 2006, 5, 1290-1298.	1.9	35
255	A New Mechanism for Prolactin Processing into 16K PRL by Secreted Cathepsin D. Molecular Endocrinology, 2006, 20, 3263-3278.	3.7	44
256	The PERK/eIF2α/ATF4 module of the UPR in hypoxia resistance and tumor growth. Cancer Biology and Therapy, 2006, 5, 723-728.	1.5	307
257	Effect of Tumor Microenvironment Modulation on the Efficacy of Oncolytic Virus Therapy. Journal of the National Cancer Institute, 2007, 99, 1768-1781.	3.0	158
258	Tetrathiomolybdate promotes tumor necrosis and prevents distant metastases by suppressing angiogenesis in head and neck cancer. Molecular Cancer Therapeutics, 2007, 6, 1039-1045.	1.9	67
259	Dynamic Contrast Enhanced Magnetic Resonance Imaging in Oncology:Theory, Data Acquisition,Analysis, and Examples. Current Medical Imaging, 2007, 3, 91-107.	0.4	325
260	Review: Implications of In Vitro Research on the Effect of Radiotherapy and Chemotherapy Under Hypoxic Conditions. Oncologist, 2007, 12, 690-712.	1.9	124
261	High VEGF with Rapid Growth and Early Metastasis in a Mouse Osteosarcoma Model. Sarcoma, 2007, 2007, 1-7.	0.7	23
262	Emerging Roles of Cysteine Cathepsins in Disease and their Potential as Drug Targets. Current Pharmaceutical Design, 2007, 13, 385-401.	0.9	56
263	Emerging Roles of Cysteine Cathepsins in Disease and their Potential as Drug Targets. Current Pharmaceutical Design, 2007, 13, 387-403.	0.9	398
264	New Perspectives in the Treatment of Melanoma: Anti-Angiogenic and Anti-Lymphangiogenic Strategies. Recent Patents on Anti-Cancer Drug Discovery, 2007, 2, 73-78.	0.8	6
265	Adeno-Associated Virus–Mediated Antiangiogenic Gene Therapy with Thrombospondin-1 Type 1 Repeats and Endostatin. Clinical Cancer Research, 2007, 13, 3968-3976.	3.2	39
266	The pathology of tumor stromatogenesis. Cancer Biology and Therapy, 2007, 6, 639-645.	1.5	44

#	Article	IF	CITATIONS
267	Zidovudine and interferon-α treatment induces a high response rate and reduces HTLV-1 proviral load and VEGF plasma levels in patients with adult T-cell leukemia from North East Iran. Leukemia and Lymphoma, 2007, 48, 330-336.	0.6	36
268	Vascularisation of Benign and Malignant Thyroid Nodules: CD US Evaluation. Ultraschall in Der Medizin, 2007, 28, 502-506.	0.8	41
269	Multi-Detector Computed Tomography in Oncology. , 0, , .		6
270	Nuclear Factor-κB–Related Serum Factors as Longitudinal Biomarkers of Response and Survival in Advanced Oropharyngeal Carcinoma. Clinical Cancer Research, 2007, 13, 3182-3190.	3.2	110
271	Kallikrein-binding protein inhibits growth of gastric carcinoma by reducing vascular endothelial growth factor production and angiogenesis. Molecular Cancer Therapeutics, 2007, 6, 3297-3306.	1.9	36
272	NeuropeptideY: Neurogenic Mediator of Angiogenesis and Arteriogenesis. , 2007, , 91-117.		0
274	Combination of Anti-EGFR Drugs and Other Molecular Targeted Agents as Anti-Cancer Strategy. Current Cancer Therapy Reviews, 2007, 3 , $117-126$.	0.2	0
275	Functional VEGF and VEGF receptors are expressed in human medulloblastomas. Neuro-Oncology, 2007, 9, 384-392.	0.6	53
276	The Proangiogenic Phenotype of Tumor-Derived Endothelial Cells is Reverted by the Overexpression of Platelet-Activating Factor Acetylhydrolase. Clinical Cancer Research, 2007, 13, 5710-5718.	3.2	10
277	Tumor Dormancy and Cancer Stem Cells: Implications for the Biology and Treatment of Breast Cancer Metastasis. Breast Disease, 2007, 26, 87-98.	0.4	139
279	Expression levels of eIF4E, VEGF, and cyclin D1, and correlation of eIF4E with VEGF and cyclin D1 in multi-tumor tissue microarray. Oncology Reports, 2007, , .	1.2	19
280	Expression of endothelial PDGF receptors $\hat{l}\pm$ and \hat{l}^2 in breast cancer: Up-regulation of endothelial PDGF receptor \hat{l}^2 . Oncology Reports, 2007, 17, 1115-9.	1.2	22
281	Imaging Biomarker Applications in Oncology Drug Development. Drug Information Journal, 2007, 41, 561-572.	0.5	1
282	Aqueous Humor sCD44 Concentration and Visual Field Loss in Primary Open-angle Glaucoma. Journal of Glaucoma, 2007, 16, 419-429.	0.8	35
283	Nitric Oxide and Its Gatekeeper Thrombospondin-1 in Tumor Angiogenesis: Fig. 1 Clinical Cancer Research, 2007, 13, 795-798.	3.2	62
284	Effects of vascular endothelial growth factor receptor inhibitor SU5416 and prostacyclin on murine lung metastasis. Anti-Cancer Drugs, 2007, 18, 349-355.	0.7	17
285	Targeted agents in the treatment of pancreatic cancer: history and lessons learned. Current Opinion in Oncology, 2007, 19, 390-395.	1.1	9
286	The role of adhesion molecules, $\hat{l}\pm v\hat{l}^23$, $\hat{l}\pm v\hat{l}^25$ and their ligands in the tumor cell and endothelial cell adhesion. European Journal of Cancer Prevention, 2007, 16, 517-527.	0.6	28

#	Article	IF	CITATIONS
287	Sulfoglycolipids as candidate antiangiogenic radiosensitizers. Anti-Cancer Drugs, 2007, 18, 1-5.	0.7	6
288	Dynamic Contrast-Enhanced MRI in Oncology Drug Development. Current Clinical Pharmacology, 2007, 2, 111-122.	0.2	17
289	Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects. Anti-Cancer Drugs, 2007, 18, 1189-1200.	0.7	78
290	Ribonucleotide Reductase: A Critical Enzyme for Cancer Chemotherapy and Antiviral Agents. Recent Patents on Anti-Cancer Drug Discovery, 2007, 2, 11-29.	0.8	81
291	Chemotherapy for Bladder Cancer: Treatment Guidelines for Neoadjuvant Chemotherapy, Bladder Preservation, Adjuvant Chemotherapy, and Metastatic Cancer. Urology, 2007, 69, 62-79.	0.5	183
292	The Elevated Levels of Heat Shock Proteins In Cancer: A Suitable Case For Treatment?., 2007,, 351-366.		2
293	Anti-angiogenic peptides identified in thrombospondin type I domains. Biochemical and Biophysical Research Communications, 2007, 359, 63-69.	1.0	24
294	The effect of anticoagulants on cancer risk and survival: Systematic review. Cancer Treatment Reviews, 2007, 33, 358-368.	3.4	45
295	Cancer dissemination: A consequence of limited carrying capacity?. Medical Hypotheses, 2007, 69, 173-177.	0.8	16
296	Expression of vascular endothelial-cadherin in human hepatocellular carcinoma tissues. Hepatology Research, 2007, 37, 444-453.	1.8	6
297	Inhibition of angiogenesis by a Semliki Forest virus vector expressing VEGFR-2 reduces tumour growth and metastasis in mice. Gene Therapy, 2007, 14, 503-513.	2.3	38
298	PEGylated DX-1000: Pharmacokinetics and Antineoplastic Activity of a Specific Plasmin Inhibitor. Neoplasia, 2007, 9, 927-937.	2.3	36
300	In Vivo Imaging of Cancer Therapy. , 2007, , .		6
301	Metastasis of Prostate Cancer. Cancer Metastasis - Biology and Treatment, 2007, , .	0.1	4
302	The Role of the Bone Marrow Microenvironment in the Pathophysiology of Myeloma and Its Significance in the Development of More Effective Therapies. Hematology/Oncology Clinics of North America, 2007, 21, 1007-1034.	0.9	110
303	Cell Stress Proteins., 2007,,.		9
304	Bendamustine in lymphomas: More to combine?. Leukemia and Lymphoma, 2007, 48, 1264-1266.	0.6	2
305	Integrin Inhibitors Reaching the Clinic. Journal of Clinical Oncology, 2007, 25, 1637-1638.	0.8	116

#	Article	IF	CITATIONS
306	Chrysin inhibits expression of hypoxia-inducible factor- $1\hat{l}\pm$ through reducing hypoxia-inducible factor- $1\hat{l}\pm$ stability and inhibiting its protein synthesis. Molecular Cancer Therapeutics, 2007, 6, 220-226.	1.9	155
307	Small Molecule Signal Transduction Inhibitors for the Treatment of Solid Tumors. Cancer Investigation, 2007, 25, 347-365.	0.6	16
308	The Role of VEGF and EGFR Inhibition: Implications for Combining Anti–VEGF and Anti–EGFR Agents. Molecular Cancer Research, 2007, 5, 203-220.	1.5	378
309	Matrix Metalloprotease–9 in Cerebrospinal Fluid Correlates with Disease Activity in Lymphomatous Meningitis. Clinical Lymphoma and Myeloma, 2007, 7, 305-308.	1.4	4
310	Cell Cycle and Related Protein. Disease Markers, 2007, 23, 433-443.	0.6	2
311	uPAR – uPA – PAI-1 interactions and signaling: A vascular biologist's view. Thrombosis and Haemostasis, 2007, 97, 336-342.	1.8	222
312	Hypoxia and prognosis: the oxygen tension mounts. Frontiers in Bioscience - Landmark, 2007, 12, 3502.	3.0	8
313	Inhibition of tumor growth and tumor metastasis by a Chinese herbal formula - ZYD88, in an animal model with metastatic Lewis lung carcinoma. Oncology Reports, 2007, , .	1.2	0
314	Efeitos do raloxifeno sobre a angiogênese do carcinoma de mama de mulheres menopausadas. Revista Brasileira De Ginecologia E Obstetricia, 2007, 29, .	0.3	0
315	Measuring Tumor Perfusion in Control and Treated Murine Tumors. Journal of Ultrasound in Medicine, 2007, 26, 749-756.	0.8	54
316	Potential implications of vascular wall resident endothelial progenitor cells. Thrombosis and Haemostasis, 2007, 98, 930-939.	1.8	33
317	Angiogenesis in the Caprine Caruncles in Non-Pregnant and Pregnant Normal and Swainsonine-Treated Does. Anatomical Record, 2007, 290, 761-769.	0.8	11
318	The effects of aging on tumor growth and angiogenesis are tumor-cell dependent. International Journal of Cancer, 2007, 120, 753-760.	2.3	44
319	Type I collagen expression contributes to angiogenesis and the development of deeply invasive cutaneous melanoma. International Journal of Cancer, 2008, 122, 1019-1029.	2.3	63
320	Expression pattern of Vasohibinduring chick development. Developmental Dynamics, 2007, 236, 1358-1362.	0.8	18
321	MRI of tumor angiogenesis. Journal of Magnetic Resonance Imaging, 2007, 26, 235-249.	1.9	253
322	Targeting the conversion of ceramide to sphingosine 1-phosphate as a novel strategy for cancer therapy. Critical Reviews in Oncology/Hematology, 2007, 63, 150-159.	2.0	59
323	Calmodulin is essential for angiogenesis in response to hypoxic stress in endothelial cells. Cell Biology International, 2007, 31, 126-134.	1.4	14

#	Article	IF	CITATIONS
324	Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an "angiogenic switch― Leukemia Research, 2007, 31, 899-906.	0.4	67
325	The angiogenic factor thymidine phosphorylase up-regulates the cell adhesion molecule P-selectin in human vascular endothelial cells and is associated with P-selectin expression in breast cancers. Journal of Pathology, 2007, 212, 335-344.	2.1	14
326	Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. Oncogene, 2007, 26, 1357-1360.	2.6	224
327	Deregulation of tumor angiogenesis and blockade of tumor growth in PPARβ-deficient mice. EMBO Journal, 2007, 26, 3686-3698.	3.5	94
328	A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours. British Journal of Cancer, 2007, 96, 1692-1698.	2.9	45
329	An orthotopic xenograft model of intraneural NF1 MPNST suggests a potential association between steroid hormones and tumor cell proliferation. Laboratory Investigation, 2007, 87, 1092-1102.	1.7	33
330	Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer. Journal of Clinical Pharmacy and Therapeutics, 2007, 32, 1-14.	0.7	105
331	Gemcitabine?Oxaliplatin Combination in Heavily Pretreated Metastatic Breast Cancer: A Pilot Study on 43 Patients. Breast Journal, 2007, 13, 165-171.	0.4	12
332	Natural Antioxidant Pedicularioside G Inhibits Angiogenesis and Tumourigenesis in vitro and in vivo. Basic and Clinical Pharmacology and Toxicology, 2007, 102, 071031053307005-???.	1.2	19
333	Clinical Significance of Histone Deacetylase Inhibitors in Cancer., 2007,, 335-361.		0
334	Characterization of the CXCR4 Signaling in Pancreatic Cancer Cells. International Journal of Gastrointestinal Cancer, 2006, 37, 110-9.	0.4	48
335	Phase I Trial of Radiochemotherapy with Bendamustine in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck. Strahlentherapie Und Onkologie, 2007, 183, 128-132.	1.0	22
336	In vivo imaging of tumour angiogenesis in mice with the $\hat{l}\pm\nu\hat{l}^23$ integrin-targeted tracer 99mTc-RAFT-RGD. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 2037-2047.	3.3	62
337	Challenges for patient selection with VEGF inhibitors. Cancer Chemotherapy and Pharmacology, 2007, 60, 151-170.	1.1	77
338	Differential Roles of Angiotensinogen and Angiotensin Receptor type 1 Polymorphisms in Breast Cancer Risk. Breast Cancer Research and Treatment, 2007, 101, 299-304.	1.1	27
339	Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer and Metastasis Reviews, 2007, 26, 241-248.	2.7	364
340	Chemokines: novel targets for breast cancer metastasis. Cancer and Metastasis Reviews, 2007, 26, 401-420.	2.7	155
341	Visualization of nascent tumor angiogenesis in lung and liver metastasis by differential dual-color fluorescence imaging in nestin-linked-GFP mice. Clinical and Experimental Metastasis, 2007, 23, 315-322.	1.7	21

#	Article	IF	CITATIONS
342	Major but not minor hepatectomy accelerates engraftment of extrahepatic tumor cells. Clinical and Experimental Metastasis, 2007, 24, 39-48.	1.7	31
343	Prophylactic naked DNA vaccination with the human vascular endothelial growth factor induces an anti-tumor response in C57Bl/6 mice. Angiogenesis, 2007, 10, 23-34.	3.7	21
344	VEGF: a key therapeutic target for the treatment of cancer-insights into its role and pharmacological inhibition. Targeted Oncology, 2007, 2, 153-164.	1.7	10
345	Contrast-enhanced MR imaging in patients with BI-RADS 3-5 microcalcifications. Radiologia Medica, 2007, 112, 272-286.	4.7	45
346	Assessment of the Early Effects of 5,6-Dimethylxanthenone-4-Acetic Acid Using Macromolecular Contrast Media–Enhanced Magnetic Resonance Imaging: Ectopic Versus Orthotopic Tumors. International Journal of Radiation Oncology Biology Physics, 2008, 72, 1198-1207.	0.4	19
347	Osteopontin: regulation in tumor metastasis. Cancer and Metastasis Reviews, 2008, 27, 103-118.	2.7	287
348	Blood Flow and Glucose Metabolism in Stage IV Breast Cancer: Heterogeneity of Response During Chemotherapy. Molecular Imaging and Biology, 2008, 10, 356-63.	1.3	8
349	Antiangiogenic and growth inhibitory effects of synthetic novel 1, 5-diphenyl-1,4 pentadiene-3-one-3-yl-ethanone pyridine curcumin analogues on Ehrlich ascites tumor in vivo. Medicinal Chemistry Research, 2008, 17, 515-529.	1.1	8
350	Differentiation of infective from neoplastic brain lesions by dynamic contrast-enhanced MRI. Neuroradiology, 2008, 50, 531-540.	1.1	70
351	Bronchial circulation angiogenesis in the rat quantified with SPECT and micro-CT. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1124-1132.	3.3	18
352	68Ga- and 111In-labelled DOTA-RGD peptides for imaging of $\hat{l}\pm\hat{vl}^2$ 3 integrin expression. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1507-1515.	3.3	145
353	What is the impact of biologicals in colorectal cancer?. Targeted Oncology, 2008, 3, 59-69.	1.7	0
354	Functional computed tomography imaging of tumor-induced angiogenesis: preliminary results of new tracer kinetic modeling using a computer discretization approach. Radiation Medicine, 2008, 26, 213-221.	0.8	3
355	Endothelial and Hematopoietic Progenitor Cells (EPCs and HPCs): Hand in Hand Fate Determining Partners for Cancer Cells. Stem Cell Reviews and Reports, 2008, 4, 169-177.	5.6	48
356	Functional analysis of tumor metastasis: modeling colon cancer. Oncology Reviews, 2008, 2, 9-20.	0.8	2
357	High level of endostatin in epididymal epithelium: protection against primary malignancies in this organ?. Histochemistry and Cell Biology, 2008, 130, 527-535.	0.8	8
358	Inhibition of PI3K/AKT and MEK/ERK pathways act synergistically to enhance antiangiogenic effects of EGCG through activation of FOXO transcription factor. Journal of Molecular Signaling, 2008, 3, 7.	0.5	86
359	Glioblastoma stem cells produce vascular endothelial growth factor by activation of a Gâ€protein coupled formylpeptide receptor FPR. Journal of Pathology, 2008, 215, 369-376.	2.1	68

#	Article	IF	CITATIONS
360	Novel interactions of perlecan: Unraveling perlecan's role in angiogenesis. Microscopy Research and Technique, 2008, 71, 339-348.	1.2	85
361	Adenoâ€associated virusâ€mediated expression of kallistatin suppresses local and remote hepatocellular carcinomas. Journal of Gene Medicine, 2008, 10, 508-517.	1.4	31
362	Angiopoietinâ \in and \hat{a} expression in recurrent squamous cell carcinoma of the oral cavity. Journal of Surgical Oncology, 2008, 97, 273-277.	0.8	20
363	Assessment of blood volume, vessel size, and the expression of angiogenic factors in two rat glioma models: a longitudinal <i>in vivo</i> and <i>ex vivo</i> study. NMR in Biomedicine, 2008, 21, 1043-1056.	1.6	98
364	Application of cryobiopsy to morphological and immunohistochemical analyses of xenografted human lung cancer tissues and functional blood vessels. Cancer, 2008, 113, 1068-1079.	2.0	39
365	Integrin α _v β ₃ â€ŧargeted cancer therapy. Drug Development Research, 2008, 69, 329-339.	1.4	267
366	VEGFâ€D promotes tumor growth and lymphatic spread in a mouse model of hepatocellular carcinoma. International Journal of Cancer, 2008, 122, 2471-2481.	2.3	56
367	Novel antiâ€angiogenic peptides derived From ELRâ€containing CXC chemokines. Journal of Cellular Biochemistry, 2008, 104, 1356-1363.	1.2	22
368	Quercetin suppresses hypoxiaâ€induced accumulation of hypoxiaâ€inducible factorâ€1α (HIFâ€1α) through inhibiting protein synthesis. Journal of Cellular Biochemistry, 2008, 105, 546-553.	1.2	66
369	Genetic alterations in juvenile nasopharyngeal angiofibromas. Head and Neck, 2008, 30, 390-400.	0.9	80
370	Quantitative correlation between 1H MRS and dynamic contrast-enhanced MRI of human breast cancer. Magnetic Resonance Imaging, 2008, 26, 523-531.	1.0	34
371	Metastatic Dormancy Imposed by the Primary Tumor: Does it Exist in Humans?. Annals of Surgical Oncology, 2008, 15, 3308-3315.	0.7	48
372	The Progression of Inflammation Parallels the Dermal Angiogenesis in a Keratin 14 ILâ€4â€Transgenic Model of Atopic Dermatitis. Microcirculation, 2008, 15, 49-64.	1.0	41
373	Histone Deacetylase Inhibitors: Mechanisms and Clinical Significance in Cancer: HDAC Inhibitor-Induced Apoptosis. Advances in Experimental Medicine and Biology, 2008, 615, 261-298.	0.8	141
374	The urokinase receptor (uâ€PAR)â€"a link between tumor cell dormancy and minimal residual disease in bone marrow?. Apmis, 2008, 116, 602-614.	0.9	46
375	A New Terrein Glucoside, a Novel Inhibitor of Angiogenin Secretion in Tumor Angiogenesis. Journal of Antibiotics, 2008, 61, 442-448.	1.0	48
376	Endothelial cells expressing Bcl-2 promotes tumor metastasis by enhancing tumor angiogenesis, blood vessel leakiness and tumor invasion. Laboratory Investigation, 2008, 88, 740-749.	1.7	49
377	Identification of VEGF-regulated genes associated with increased lung metastatic potential: functional involvement of tenascin-C in tumor growth and lung metastasis. Oncogene, 2008, 27, 5373-5384.	2.6	71

#	Article	IF	CITATIONS
378	VEGF and Delta-Notch: interacting signalling pathways in tumour angiogenesis. British Journal of Cancer, 2008, 99, 1204-1209.	2.9	166
379	Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours. British Journal of Cancer, 2008, 99, 1579-1585.	2.9	23
380	Time-course-dependent microvascular alterations in a model of myeloid leukemia in vivo. Leukemia, 2008, 22, 59-65.	3.3	24
381	Quantification of VEGF expression in canine mammary tumours. Australian Veterinary Journal, 2008, 86, 279-282.	0.5	14
382	Immunohistochemical evaluation of the microvascular density through the expression of TGF- \hat{I}^2 (CD) Tj ETQq0 0 0 oligodendrogliomas. Neuropathology, 2008, 28, 17-23.	rgBT /Ove 0.7	erlock 10 Tf 34
383	Understanding tumor endothelial cell abnormalities to develop ideal antiâ€angiogenic therapies. Cancer Science, 2008, 99, 459-466.	1.7	107
384	Hyaluronidases in cancer biology. Seminars in Cancer Biology, 2008, 18, 275-280.	4.3	220
385	Metastatic tumours to the oral cavity – Pathogenesis and analysis of 673 cases. Oral Oncology, 2008, 44, 743-752.	0.8	403
386	The Biology of Vascular Endothelial Cell Growth Factor Isoforms. , 2008, , 1-13.		4
387	Metastasis: a current perspective. , 2008, , 1-10.		O
388	Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis. Molecular Cancer, 2008, 7, 16.	7.9	133
389	VEGF and angiogenesis: implications for breast cancer therapy. European Journal of Cancer, Supplement, 2008, 6, 7-13.	2.2	16
390	Eph receptors in breast cancer: roles in tumor promotion and tumor suppression. Breast Cancer Research, 2008, 10, 217.	2.2	79
392	Molecular Imaging II. Handbook of Experimental Pharmacology, 2008, , .	0.9	2
393	Coligand effects on the solution stability, biodistribution and metabolism of the 99mTc-labeled cyclic RGDfK tetramer. Nuclear Medicine and Biology, 2008, 35, 111-121.	0.3	38
394	The enhanced anti-angiogenic and antitumor effects of combining flk1-based DNA vaccine and IP-10. Vaccine, 2008, 26, 5352-5357.	1.7	34
395	Use of resorbable collagen dural substitutes in the presence of cranial and spinal infections—report of 3 cases. World Neurosurgery, 2008, 70, 92-96.	1.3	26
397	The temporal correlation of dynamic contrast-enhanced magnetic resonance imaging with tumor angiogenesis in a murine glioblastoma model. Neurological Research, 2008, 30, 952-959.	0.6	22

#	Article	IF	CITATIONS
398	In Vivo and In Vitro Efficacy of Zoledronate for Treating Oral Squamous Cell Carcinoma in Cats. Journal of Veterinary Internal Medicine, 2008, 22, 158-163.	0.6	28
399	Metronomic Therapy with Cyclophosphamide and Piroxicam Effectively Delays Tumor Recurrence in Dogs with Incompletely Resected Soft Tissue Sarcomas. Journal of Veterinary Internal Medicine, 2008, 22, 1373-1379.	0.6	139
400	Targeted Therapy for Solid Tumors: Current Status. Surgical Oncology Clinics of North America, 2008, 17, 279-301.	0.6	12
401	ASA404: update on drug development. Expert Opinion on Investigational Drugs, 2008, 17, 1547-1551.	1.9	21
402	Heat shock proteins: Stress proteins with Janus-like properties in cancer. International Journal of Hyperthermia, 2008, 24, 31-39.	1.1	132
405	An Autocrine VEGF/VEGFR2 and p38 Signaling Loop Confers Resistance to 4-Hydroxytamoxifen in MCF-7 Breast Cancer Cells. Molecular Cancer Research, 2008, 6, 1630-1638.	1.5	84
406	Phenotypic and Functional Differences between Human Liver Cancer Endothelial Cells and Liver Sinusoidal Endothelial Cells. Journal of Vascular Research, 2008, 45, 78-86.	0.6	32
407	Contrast enhanced MRI and intravital fluorescence microscopy indicate improved tumor microcirculation in highly vascularized melanomas upon short-term anti-VEGFR treatment. Cancer Biology and Therapy, 2008, 7, 1006-1013.	1.5	29
408	Suppression of Lung Tumor Growth and Metastasis in Mice by Adeno-Associated Virus-Mediated Expression of Vasostatin. Clinical Cancer Research, 2008, 14, 939-949.	3.2	50
409	Breast Cancer Treatment in the Era of Molecular Imaging. Breast Care, 2008, 3, 409-414.	0.8	2
410	Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5. Blood, 2008, 111, 1217-1226.	0.6	437
411	IFN- \hat{l}^2 -Dependent Inhibition of Tumor Growth by the Vascular Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA). Journal of Interferon and Cytokine Research, 2008, 28, 133-139.	0.5	27
412	T-CAM, a fastatin-FIII 9-10 fusion protein, potently enhances anti-angiogenic and anti-tumor activity $\hat{l}\pm v\hat{l}^2$ 3 and $\hat{l}\pm 5\hat{l}^2$ 1 integrins. Experimental and Molecular Medicine, 2008, 40, 196.	3.2	2
413	Regulation of Gene Expression in the Tumor Environment. , 2008, , .		0
414	Synergistic Damage of Tumor Vessels with Ultra Low-Dose Endothelial-Monocyte Activating Polypeptide-II and Neovasculature-Targeted Tumor Necrosis Factor-α. Cancer Research, 2008, 68, 1154-1161.	0.4	45
415	Use of H215O-PET and DCE-MRI to Measure Tumor Blood Flow. Oncologist, 2008, 13, 631-644.	1.9	63
416	In Vivo Bioluminescence Imaging Monitoring of Hypoxia-Inducible Factor $1\hat{l}_{\pm}$, a Promoter That Protects Cells, in Response to Chemotherapy. American Journal of Roentgenology, 2008, 191, 1779-1784.	1.0	32
417	Sulforaphane Enhances the Therapeutic Potential of TRAIL in Prostate Cancer Orthotopic Model through Regulation of Apoptosis, Metastasis, and Angiogenesis. Clinical Cancer Research, 2008, 14, 6855-6866.	3.2	124

#	Article	IF	CITATIONS
418	Isoaspartate-Glycine-Arginine: A New Tumor Vasculature–Targeting Motif. Cancer Research, 2008, 68, 7073-7082.	0.4	71
419	Bendamustine as a model for the activity of alkylating agents. Future Oncology, 2008, 4, 323-332.	1.1	7
420	TWIST activation by hypoxia inducible factor-1 (HIF-1): Implications in metastasis and development. Cell Cycle, 2008, 7, 2090-2096.	1.3	266
421	Kaposi's Sarcoma–Associated Herpesvirus Confers a Survival Advantage to Endothelial Cells. Cancer Research, 2008, 68, 4640-4648.	0.4	111
422	Angiostatin: drying out the roots in cardiac muscle. Heart, 2008, 95, 269-270.	1.2	1
423	The proximal promoter region of the human vascular endothelial growth factor gene has a G-quadruplex structure that can be targeted by G-quadruplex–interactive agents. Molecular Cancer Therapeutics, 2008, 7, 880-889.	1.9	159
424	Shikonin, Acetylshikonin, and Isobutyroylshikonin Inhibit VEGF-induced Angiogenesis and Suppress Tumor Growth in Lewis Lung Carcinoma-bearing Mice. Yakugaku Zasshi, 2008, 128, 1681-1688.	0.0	63
425	Salivary protein factors are elevated in breast cancer patients. Molecular Medicine Reports, 0, , .	1.1	32
426	Cyclooxygenase-2 Expression in Pretreatment Biopsy as a Predictor of Tumor Responses After Preoperative Chemoradiation in Rectal Cancer. Archives of Surgery, 2008, 143, 1091.	2.3	22
427	Vascular and Lymphatic Properties of the Superficial and Deep Lamina Propria in Barrett Esophagus. American Journal of Surgical Pathology, 2008, 32, 1454-1461.	2.1	22
428	Antiangiogenic therapy in nonsmall cell lung cancer. Current Opinion in Oncology, 2008, 20, 176-182.	1.1	22
429	Cancer Stem Cells and New Therapeutic Approaches. , 0, , 217-232.		O
430	Effect of endothelial PAS domain protein 1 and hypoxia inducible factor 1α on vascular endothelial growth factor expression in human pancreatic carcinoma. Chinese Medical Journal, 2008, 121, 2258-2264.	0.9	3
432	Hyaluronidases in Cancer Biology. , 2008, , 207-220.		15
434	The Controversial Clinicobiological Role of Breast Cancer Stem Cells. Journal of Oncology, 2008, 2008, 1-12.	0.6	5
435	The Role of PPARs in the Endothelium: Implications for Cancer Therapy. PPAR Research, 2008, 2008, 1-12.	1.1	22
436	Increased Antiangiogenic Protein Expression in the Skeletal Muscle of Diabetic Swine and Patients. Archives of Surgery, 2008, 143, 463.	2.3	20
437	Full PDF of Hematology Reviews 2009, volume 1, issue 1 Hematology Reports, 2009, 1, 1.	0.3	0

#	ARTICLE	IF	CITATIONS
438	Role of Hyaluronan Metabolism in the Initiation, Invasion, and Metastasis of Breast Cancer. , 2009, , 341-360.		0
439	Age-related macular degeneration: experimental and emerging treatments. Clinical Ophthalmology, 2009, 3, 167.	0.9	13
440	Computational modeling in quantitative cancer imaging., 2009,,.		0
441	Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 somatostatin receptor on pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 17769-17774.	3.3	33
442	Communication between bone marrow niches in normal bone marrow function and during hemopathies progression. Hematology Reports, 2009, 1, 14.	0.3	2
443	Conjunctival Melanomas: Can the Cancer Stem Cell Hypothesis be Applied?. Seminars in Ophthalmology, 2009, 24, 161-165.	0.8	2
444	A Novel Antiangiogenic Effect for Telomerase-Specific Virotherapy through Host Immune System. Journal of Immunology, 2009, 182, 1763-1769.	0.4	20
445	S100A2 Induces Metastasis in Non–Small Cell Lung Cancer. Clinical Cancer Research, 2009, 15, 22-29.	3.2	99
446	Intrathecal synthesis of tumor markers is a highly sensitive test in the diagnosis of leptomeningeal metastasis from solid cancers. Clinical Chemistry and Laboratory Medicine, 2009, 47, 874-9.	1.4	38
447	Signal Transducers and Activators of Transcription Mediate Fibroblast Growth Factor–Induced Vascular Endothelial Morphogenesis. Cancer Research, 2009, 69, 1668-1677.	0.4	65
448	VEGF-A Induces Angiogenesis by Perturbing the Cathepsin-Cysteine Protease Inhibitor Balance in Venules, Causing Basement Membrane Degradation and Mother Vessel Formation. Cancer Research, 2009, 69, 4537-4544.	0.4	110
449	EPOX Inhibits Angiogenesis by Degradation of Mcl-1 through ERK Inactivation. Clinical Cancer Research, 2009, 15, 4904-4914.	3.2	22
450	Target-based agents in neo-adjuvant treatment of liver metastases from colo-rectal cancer: Secret weapons in anticancer war?. Cancer Biology and Therapy, 2009, 8, 1709-1718.	1.5	3
451	Novel technologies for antiangiogenic drug delivery in the brain. Cell Adhesion and Migration, 2009, 3, 224-229.	1.1	10
452	Matrix Metalloproteinases in the Urine and Tissue of Patients With Juvenile Polyps: Potential Biomarkers for the Presence of Polyps. Journal of Pediatric Gastroenterology and Nutrition, 2009, 48, 405-411.	0.9	2
453	Modular Protein Engineering in Emerging Cancer Therapies. Current Pharmaceutical Design, 2009, 15, 893-916.	0.9	38
454	Structural Adaptation and Heterogeneity of Normal and Tumor Microvascular Networks. PLoS Computational Biology, 2009, 5, e1000394.	1.5	156
455	Endostatin and angiostatin are increased in diabetic patients with coronary artery disease and associated with impaired coronary collateral formation. American Journal of Physiology - Heart and Circulatory Physiology, 2009, 296, H428-H434.	1.5	81

#	Article	IF	CITATIONS
456	EXPOSURE TO ENVIRONMENTAL TOBACCO SMOKE INDUCES ANGIOGENESIS AND LEUKOCYTE TRAFFICKING IN LUNG MICROVESSELS. Experimental Lung Research, 2009, 35, 119-135.	0.5	20
457	Thrombin induces fibronectin-specific migration of pulmonary microvascular endothelial cells: requirement of calcium/calmodulin-dependent protein kinase II. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2009, 297, L706-L714.	1.3	20
458	Niche-Dependent Tumorigenic Capacity of Malignant Ovarian Ascites-Derived Cancer Cell Subpopulations. Clinical Cancer Research, 2009, 15, 70-80.	3.2	32
459	Decreased Blood Flow with Increased Metabolic Activity: A Novel Sign of Pancreatic Tumor Aggressiveness. Clinical Cancer Research, 2009, 15, 5511-5517.	3.2	150
460	Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice. Molecular Cancer Therapeutics, 2009, 8, 1596-1605.	1.9	58
461	The regulatory mechanism of Hsp90α secretion and its function in tumor malignancy. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 21288-21293.	3.3	226
462	The roles of chemokine CXCL12 in embryonic and brain tumor angiogenesis. Seminars in Cancer Biology, 2009, 19, 111-115.	4.3	65
463	Activity of 2 methoxyestradiol (Panzem® NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: A Hoosier Oncology Group trial. Gynecologic Oncology, 2009, 115, 90-96.	0.6	88
464	Plateletâ€derived microparticles promote invasiveness of prostate cancer cells <i>via</i> upregulation of MMPâ€2 production. International Journal of Cancer, 2009, 124, 1773-1777.	2.3	120
465	Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: A prospective study. International Journal of Cancer, 2009, 125, 1143-1146.	2.3	9
466	Targeted therapies in squamous cell carcinoma of the head and neck. Cancer, 2009, 115, 922-935.	2.0	122
467	Bendamustine, but not fludarabine, exhibits a low stem cell toxicity in vitro. Journal of Cancer Research and Clinical Oncology, 2009, 135, 227-234.	1.2	17
468	High expressions of vascular endothelial growth factor and platelet-derived endothelial cell growth factor predict poor prognosis in alpha-fetoprotein-negative hepatocellular carcinoma patients after curative resection. Journal of Cancer Research and Clinical Oncology, 2009, 135, 1359-1367.	1.2	16
469	Vascular targeted therapies in oncology. Cell and Tissue Research, 2009, 335, 241-248.	1.5	83
470	Nanoparticle-mediated targeting of phosphatidylinositol-3-kinase signaling inhibits angiogenesis. Angiogenesis, 2009, 12, 325-338.	3.7	83
471	Plasminogen fragment K1–3 inhibits expression of adhesion molecules and experimental HCC recurrence in the liver. International Journal of Colorectal Disease, 2009, 24, 837-844.	1.0	4
472	Isoliquiritigenin inhibits migration and invasion of prostate cancer cells: possible mediation by decreased JNK/AP-1 signaling. Journal of Nutritional Biochemistry, 2009, 20, 663-676.	1.9	121
473	Imaging and quantifying the dynamics of tumor-associated proteolysis. Clinical and Experimental Metastasis, 2009, 26, 299-309.	1.7	44

#	Article	IF	CITATIONS
474	From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours. Oncology Reviews, 2009, 3, 79-87.	0.8	3
475	Effect of Small Interference RNA Targeting HIF-1α Mediated by rAAV Combined l-Ascorbate on Pancreatic Tumors in Athymic Mice. Pathology and Oncology Research, 2009, 15, 109-114.	0.9	14
476	The foundations of a unified approach to mathematical modelling of angiogenesis. International Journal of Advances in Engineering Sciences and Applied Mathematics, $2009, 1, 43-52$.	0.7	7
478	The effect of photodynamic therapy on tumor angiogenesis. Cellular and Molecular Life Sciences, 2009, 66, 2275-2283.	2.4	85
479	68Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin $\hat{l}\pm v\hat{l}^2$ 3 PET imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 947-957.	3.3	132
480	Noninvasive imaging of tumor integrin expression using 18F-labeled RGD dimer peptide with PEG4 linkers. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1296-1307.	3.3	115
481	Dkkâ€3 expression in the tumor endothelium: A novel prognostic marker of pancreatic adenocarcinomas. Cancer Science, 2009, 100, 1414-1420.	1.7	47
482	PEDF inhibits growth of retinoblastoma by antiâ€angiogenic activity. Cancer Science, 2009, 100, 2419-2425.	1.7	45
483	The role of VEGF and a functional link between VEGF and p27Kip1 in acute myeloid leukemia. Leukemia, 2009, 23, 251-261.	3.3	29
484	Exploiting the tumor microenvironment in the development of targeted cancer gene therapy. Cancer Gene Therapy, 2009, 16, 279-290.	2.2	11
485	Microenvironmental regulation of metastasis. Nature Reviews Cancer, 2009, 9, 239-252.	12.8	3,157
486	The metastatic niche: adapting the foreign soil. Nature Reviews Cancer, 2009, 9, 285-293.	12.8	1,081
487	The Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor Cediranib (Recentin;) Tj ETQq0 0 0 rg	gBT /Overlo 0.4	ock 10 Tf 50 14
488	A promising new approach of VEGFR2-based DNA vaccine for tumor immunotherapy. Immunology Letters, 2009, 126, 60-66.	1.1	12
489	Molecular Diversity of VEGF-A as a Regulator of Its Biological Activity. Microcirculation, 2009, 16, 572-592.	1.0	119
490	The Role of Lymph Node Metastasis in the Systemic Dissemination of Breast Cancer. Annals of Surgical Oncology, 2009, 16, 3396-3405.	0.7	44
491	Tumor Stem Cells and Metastasis. , 2009, , 47-63.		0
492	Coordination of Intratumoral Immune Reaction and Human Colorectal Cancer Recurrence. Cancer Research, 2009, 69, 2685-2693.	0.4	262

#	Article	IF	Citations
493	Inhibitive Effect of Artemether on Tumor Growth and Angiogenesis in the Rat C6 Orthotopic Brain Gliomas Model. Integrative Cancer Therapies, 2009, 8, 88-92.	0.8	28
495	Drugs targeting integrins for cancer therapy. Expert Opinion on Drug Discovery, 2009, 4, 229-241.	2.5	6
496	Tumour vascularisation: a druggable target. Current Opinion in Pharmacology, 2009, 9, 96-101.	1.7	15
497	Targeted therapies in the treatment of advanced/metastatic NSCLC. European Journal of Cancer, 2009, 45, 2473-2487.	1.3	68
498	64Cu-Labeled CB-TE2A and diamsar-conjugated RGD peptide analogs for targeting angiogenesis: comparison of their biological activity. Nuclear Medicine and Biology, 2009, 36, 277-285.	0.3	87
499	PRO: Patients with Recurrent Ovarian Cancer Should Be Treated with Antiangiogenic Agents in Combination with Chemotherapy. Clinical Ovarian Cancer & Other Gynecologic Malignancies, 2009, 2, 12-15.	0.2	1
500	Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response. Molecular Cancer, 2009, 8, 94.	7.9	48
501	Novel Therapeutic Targets. Cancer Treatment and Research, 2009, 149, 63-84.	0.2	2
502	Development of a Fully Human Anti-PDGFRβ Antibody That Suppresses Growth of Human Tumor Xenografts and Enhances Antitumor Activity of an Anti-VEGFR2 Antibody. Neoplasia, 2009, 11, 594-604.	2.3	55
503	Protective Effects of Mastic Oil From <i>Pistacia Lentiscus</i> Variation <i>Chia</i> Against Experimental Growth of Lewis Lung Carcinoma. Nutrition and Cancer, 2009, 61, 640-648.	0.9	51
504	Autocrine Loop between Vascular Endothelial Growth Factor (VEGF)-C and VEGF Receptor-3 Positively Regulates Tumor-Associated Lymphangiogenesis in Oral Squamoid Cancer Cells. American Journal of Pathology, 2009, 175, 1709-1721.	1.9	43
505	A Key Role for the Integrin $\hat{1}\pm2\hat{1}^21$ in Experimental and Developmental Angiogenesis. American Journal of Pathology, 2009, 175, 1338-1347.	1.9	69
506	Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncology, The, 2009, 10, 559-568.	5.1	398
507	Expression and release of angiopoietin-1 from human neutrophils: Intracellular mechanisms. Growth Factors, 2009, 27, 335-344.	0.5	48
508	Regulation of Membrane-Type 4 Matrix Metalloproteinase by SLUG Contributes to Hypoxia-Mediated Metastasis. Neoplasia, 2009, 11, 1371-IN14.	2.3	95
509	Cross talk Initiated by Endothelial Cells Enhances Migration and Inhibits Anoikis of Squamous Cell Carcinoma Cells through STAT3/Akt/ERK Signaling. Neoplasia, 2009, 11, 583-IN14.	2.3	122
510	High Sensitivity. Investigative Radiology, 2009, 44, 15-22.	3.5	75
511	A Somatostatin Analogue, Octreotide, Inhibits the Occurrence of Second Primary Tumors and Lung Metastasis after Resection of Hepatocellular Carcinoma in Mice. Tohoku Journal of Experimental Medicine, 2009, 218, 155-160.	0.5	15

#	Article	IF	Citations
512	Humanized large-scale expanded endothelial colony–forming cells function in vitro and in vivo. Blood, 2009, 113, 6716-6725.	0.6	201
513	The Immunocompromised Host: Central Nervous System. , 2009, , 1315-1323.		0
514	Targeted therapy for nonsmall cell lung cancer: focusing on angiogenesis, the epidermal growth factor receptor and multikinase inhibitors. Anti-Cancer Drugs, 2010, 21, 151-168.	0.7	9
515	Tyrosine Kinases as Molecular Targets to Inhibit Cancer Progression and Metastasis. Current Pharmaceutical Design, 2010, 16, 1396-1409.	0.9	11
516	Characterization of Molecular and Functional Alterations of Tumor Endothelial Cells to Design Anti-Angiogenic Strategies. Current Vascular Pharmacology, 2010, 8, 220-232.	0.8	34
517	Assessment of Bone Marrow Microvessel Density in Chronic Lymphocytic Leukemia. Applied Immunohistochemistry and Molecular Morphology, 2010, 18, 353-356.	0.6	8
518	Hexane–ethanol extract of <i>Glycyrrhiza uralensis</i> containing licoricidin inhibits the metastatic capacity of DU145 human prostate cancer cells. British Journal of Nutrition, 2010, 104, 1272-1282.	1.2	43
519	Bendamustine in patients with relapsed or refractory multiple myeloma. European Journal of Medical Research, 2010, 15, 13.	0.9	34
520	In Vivo Biological Purging for Lymph Node Metastasis of Human Colorectal Cancer by Telomerase-Specific Oncolytic Virotherapy. Annals of Surgery, 2010, 251, 1079-1086.	2.1	25
521	Comparative effects of EGCG, green tea and a nutrient mixture on the patterns of MMP-2 and MMP-9 expression in cancer cell lines. Oncology Reports, 2010, 24, 747-57.	1.2	42
522	Vascularization predicts overall survival and risk of transformation in follicular lymphoma. Haematologica, 2010, 95, 2157-2160.	1.7	44
523	Synthesis and in-vitro antitumour activity of new naphthyridine derivatives on human pancreatic cancer cells. Journal of Pharmacy and Pharmacology, 2010, 61, 1057-1066.	1.2	7
524	Positron emission tomography tracers for imaging angiogenesis. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 86-103.	3.3	102
525	Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti- $\hat{1}\pm 5\hat{1}^21$ integrin monoclonal antibody (volociximab) in cancer patients. Cancer Chemotherapy and Pharmacology, 2010, 65, 207-217.	1.1	31
526	Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2010, 66, 935-943.	1.1	17
527	Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis. European Journal of Clinical Pharmacology, 2010, 66, 813-821.	0.8	72
528	Oroxylin A inhibits angiogenesis through blocking vascular endothelial growth factor-induced KDR/Flk-1 phosphorylation. Journal of Cancer Research and Clinical Oncology, 2010, 136, 667-675.	1.2	36
529	The effect of endostatin mediated by human mesenchymal stem cells on ovarian cancer cells in vitro. Journal of Cancer Research and Clinical Oncology, 2010, 136, 873-881.	1.2	13

#	ARTICLE	IF	CITATIONS
530	PARP and PARG Inhibitorsâ€"New Therapeutic Targets in Cancer Treatment. Pathology and Oncology Research, 2010, 16, 469-478.	0.9	41
531	The Role of Lymph Node Metastasis in the Systemic Dissemination of Breast Cancer. Indian Journal of Surgical Oncology, 2010, $1,313-322$.	0.3	4
532	FOXO transcription factors and VEGF neutralizing antibody enhance antiangiogenic effects of resveratrol. Molecular and Cellular Biochemistry, 2010, 337, 201-212.	1.4	68
533	Zebrafish Model: Worth Considering in Defining Tumor Angiogenesis. Trends in Cardiovascular Medicine, 2010, 20, 114-119.	2.3	28
534	Inhibition of metastasis, angiogenesis, and tumor growth by Chinese herbal cocktail Tien-Hsien Liquid. BMC Cancer, 2010, 10, 175.	1.1	47
535	GU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer. BMC Cancer, 2010, 10, 397.	1.1	36
536	Mechanism of endothelial progenitor cell recruitment into neo-vessels in adjacent non-tumor tissues in hepatocellular carcinoma. BMC Cancer, 2010, 10, 435.	1.1	32
537	Interleukins, laminin and epstein - barr virus latent membrane protein 1 (EBV LMP1) Promote metastatic phenotype in nasopharyngeal carcinoma. BMC Cancer, 2010, 10, 574.	1.1	32
538	High efficacy and minimal peptide required for the antiâ€angiogenic and antiâ€hepatocarcinoma activities of plasminogen K5. Journal of Cellular and Molecular Medicine, 2010, 14, 2519-2530.	1.6	12
539	Dynamics of microvascular remodelling during tumor growth in bone. Journal of Orthopaedic Research, 2010, 28, 27-31.	1.2	12
540	Cigarette smoke condensate induces nuclear factor kappaâ€b activity and proangiogenic growth factors in aerodigestive cells. Laryngoscope, 2010, 120, 1609-1613.	1.1	15
541	Significance of anti-angiogenic therapy in head and neck cancer—Heterogeneity of tumor endothelium. Japanese Dental Science Review, 2010, 46, 26-32.	2.0	4
542	Methods for the identification of vascular markers in health and disease: From the bench to the clinic. Journal of Proteomics, 2010, 73, 2219-2229.	1.2	10
543	\hat{l}_{\pm} -, \hat{l}^{3} - and \hat{l} -tocopherols reduce inflammatory angiogenesis in human microvascular endothelial cells \hat{a} - \hat{l} -, \hat{l} -1 Journal of Nutritional Biochemistry, 2010, 21, 589-597.	1.9	47
544	Detection of T2 changes in an early mouse brain tumor. Magnetic Resonance Imaging, 2010, 28, 784-789.	1.0	12
545	ELL is an HIFâ€Îα partner that regulates and responds to hypoxia response in PC3 cells. Prostate, 2010, 70, 797-805.	1.2	15
546	Clinical significance of serum vascular endothelial growth factor, endostatin, and leptin levels in children with lymphoma. Pediatric Blood and Cancer, 2010, 55, 1272-1277.	0.8	9
547	Combretastatin Aâ€4 inhibits cell growth and metastasis in bladder cancer cells and retards tumour growth in a murine orthotopic bladder tumour model. British Journal of Pharmacology, 2010, 160, 2008-2027.	2.7	53

#	Article	IF	CITATIONS
548	Recombinant adenovirus encoding vasohibin prevents tumor angiogenesis and inhibits tumor growth. Cancer Science, 2010, 101, 448-452.	1.7	25
549	Inhibitor of DNA binding-4 promotes angiogenesis and growth of glioblastoma multiforme by elevating matrix GLA levels. Oncogene, 2010, 29, 3793-3802.	2.6	48
550	Betulinic acid induces apoptosis and inhibits hedgehog signalling in rhabdomyosarcoma. British Journal of Cancer, 2010, 103, 43-51.	2.9	36
551	Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent. British Journal of Cancer, 2010, 103, 597-606.	2.9	25
552	An Implantable Vascularized Protein Gel Construct That Supports Human Fetal Hepatoblast Survival and Infection by Hepatitis C Virus in Mice. PLoS ONE, 2010, 5, e9987.	1.1	9
553	Pulmonary targeting microparticulate camptothecin delivery system: anticancer evaluation in a rat orthotopic lung cancer model. Anti-Cancer Drugs, 2010, 21, 65-76.	0.7	65
554	Anti-Vascular Endothelial Growth Factor Therapies and Cardiovascular Toxicity: What Are the Important Clinical Markers to Target?. Oncologist, 2010, 15, 130-141.	1.9	110
555	Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2â€"Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors. Clinical Cancer Research, 2010, 16, 3044-3056.	3.2	123
556	IFN- \hat{l}^2 Restricts Tumor Growth and Sensitizes Alveolar Rhabdomyosarcoma to Ionizing Radiation. Molecular Cancer Therapeutics, 2010, 9, 761-771.	1.9	11
557	Cell Cycle Regulator ING4 is a Suppressor of Melanoma Angiogenesis That is Regulated by the Metastasis Suppressor BRMS1. Cancer Research, 2010, 70, 10445-10453.	0.4	49
558	Bevacizumab Increases Risk for Severe Proteinuria in Cancer Patients. Journal of the American Society of Nephrology: JASN, 2010, 21, 1381-1389.	3.0	199
559	Using the Transcription Factor Inhibitor of DNA Binding 1 to Selectively Target Endothelial Progenitor Cells Offers Novel Strategies to Inhibit Tumor Angiogenesis and Growth. Cancer Research, 2010, 70, 7273-7282.	0.4	63
560	Phase I Open-Label Study of Continuous Treatment with BIBF 1120, a Triple Angiokinase Inhibitor, and Pemetrexed in Pretreated Nonâ∈"Small Cell Lung Cancer Patients. Clinical Cancer Research, 2010, 16, 2881-2889.	3.2	92
561	BIBF 1120 for the treatment of non-small cell lung cancer. Expert Opinion on Investigational Drugs, 2010, 19, 789-794.	1.9	13
563	Regulation of the Expression and Activity of the Antiangiogenic Homeobox Gene <i>GAX</i> /i>MEOX2 by ZEB2 and MicroRNA-221. Molecular and Cellular Biology, 2010, 30, 3902-3913.	1.1	77
564	Increased Risk of High-Grade Hypertension With Bevacizumab in Cancer Patients: A Meta-Analysis. American Journal of Hypertension, 2010, 23, 460-468.	1.0	210
565	MS-275 Sensitizes TRAIL-Resistant Breast Cancer Cells, Inhibits Angiogenesis and Metastasis, and Reverses Epithelial-Mesenchymal Transition In vivo. Molecular Cancer Therapeutics, 2010, 9, 3254-3266.	1.9	119
566	Targeting Signal Transduction Pathways in Metastatic Breast Cancer: A Comprehensive Review. Oncologist, 2010, 15, 216-235.	1.9	47

#	ARTICLE	IF	CITATIONS
567	Roles of Arrest-Defective Protein 1225 and Hypoxia-Inducible Factor $1\hat{l}_{\pm}$ in Tumor Growth and Metastasis. Journal of the National Cancer Institute, 2010, 102, 426-442.	3.0	20
568	MR angiogenesis imaging with Robo4― <i>vs</i> . α _V β ₃ â€targeted nanoparticles in a B16/F10 mouse melanoma model. FASEB Journal, 2010, 24, 4262-4270.	0.2	36
569	Growth suppression of cervical carcinoma by pigment epithelium-derived factor via anti-angiogenesis. Cancer Biology and Therapy, 2010, 9, 967-974.	1.5	28
570	Targeting the L-Arginine-Nitric Oxide Pathway for Cancer Treatment. Current Pharmaceutical Design, 2010, 16, 392-410.	0.9	20
571	Fractalkine-Induced Endothelial Cell Migration Requires MAP Kinase Signaling. Pathobiology, 2010, 77, 7-16.	1.9	27
572	Assessment of Non–Small Cell Lung Cancer Perfusion: Pathologic-CT Correlation in 15 Patients. Radiology, 2010, 257, 863-871.	3.6	64
573	Angiopoietin-2 mRNA expression is increased in chronic lymphocytic leukemia patients with poor prognostic features. Hematology, 2010, 15, 210-214.	0.7	8
574	The Potency of Refined Mouse Models: Implications for Clinical Trials. Current Cancer Therapy Reviews, 2010, 6, 62-80.	0.2	1
575	Crosstalk between Blood Vessels and Tumor Microenvironment. Oral Science International, 2010, 7, 1-10.	0.3	7
576	Differentiation of tubercular infection and metastasis presenting as ring enhancing lesion by diffusion and perfusion magnetic resonance imaging. Journal of Neuroradiology, 2010, 37, 167-171.	0.6	27
577	Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends in Molecular Medicine, 2010, 16, 133-144.	3.5	603
578	Targeting multiple angiogenic pathways for the treatment of neuroblastoma. Journal of Pediatric Surgery, 2010, 45, 1103-1109.	0.8	6
579	In vitro antiproliferative and antiangiogenic effects of synthetic chalcone analogues. Toxicology in Vitro, 2010, 24, 1347-1355.	1.1	65
580	PRSS3 promotes tumour growth and metastasis of human pancreatic cancer. Gut, 2010, 59, 1535-1544.	6.1	66
581	Rational combinations in metastatic breast cancer: bevacizumab with chemotherapy. Community Oncology, 2010, 7, 253-262.	0.2	O
582	Possible Benefits of Curcumin Regimen in Combination With Taxane Chemotherapy for Hormone-Refractory Prostate Cancer Treatment. Nutrition and Cancer, 2010, 62, 148-153.	0.9	19
583	Platelet-Derived Growth Factor-B Normalizes Micromorphology and Vessel Function in Vascular Endothelial Growth Factor-A-Induced Squamous Cell Carcinomas. American Journal of Pathology, 2010, 176, 981-994.	1.9	33
584	COX-2 and Prostaglandin EP3/EP4 Signaling Regulate the Tumor Stromal Proangiogenic Microenvironment via CXCL12-CXCR4 Chemokine Systems. American Journal of Pathology, 2010, 176, 1469-1483.	1.9	97

#	Article	IF	CITATIONS
585	Angiopoietin/Tie2 Signaling Transforms Capillaries into Venules Primed for Leukocyte Trafficking in Airway Inflammation. American Journal of Pathology, 2010, 176, 2009-2018.	1.9	29
586	The Role of Angiogenesis in Neuroendocrine Tumors. Endocrinology and Metabolism Clinics of North America, 2010, 39, 839-852.	1.2	8
587	Drug-DNA Interaction Protocols. Methods in Molecular Biology, 2010, , .	0.4	13
589	Modeling tumor growth and treatment response based on quantitative imaging data. Integrative Biology (United Kingdom), 2010, 2, 338.	0.6	12
590	Imaging tumour physiology and vasculature to predict and assess response to heat. International Journal of Hyperthermia, 2010, 26, 264-272.	1.1	5
591	Late anastomotic colonic dehiscence due to antiangiogenic treatment, a specific drug-class complication requiring specific treatment: An example of pazopanib complication. Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 135-139.	0.7	16
592	Wound Healing after Trauma May Predispose to Lung Cancer Metastasis. American Journal of Respiratory Cell and Molecular Biology, 2011, 44, 591-596.	1.4	61
593	PRO: Patients With Recurrent Ovarian Cancer Should be Treated With Antiangiogenic Agents in Combination With Chemotherapy. Clinical Ovarian Cancer & Other Gynecologic Malignancies, 2011, 4, 70-73.	0.2	0
594	VEGF and IL-18 in induced sputum of lung cancer patients. Cytokine, 2011, 54, 277-281.	1.4	20
595	Sorafenib tosylate and paclitaxel induce anti-angiogenic, anti-tumour and anti-resorptive effects in experimental breast cancer bone metastases. European Journal of Cancer, 2011, 47, 277-286.	1.3	43
596	A model of vascular tumour growth in mice combining longitudinal tumour size data with histological biomarkers. European Journal of Cancer, 2011, 47, 479-490.	1.3	52
597	Haematologic toxicities associated with the addition of bevacizumab in cancer patients. European Journal of Cancer, 2011, 47, 1161-1174.	1.3	39
598	Current status and future perspectives of in vivo small animal imaging using radiolabeled nanoparticles. European Journal of Radiology, 2011, 78, 287-295.	1.2	48
599	Effects of Interferons $\hat{l}\pm /\hat{l}^2$ on the Proliferation of Human Micro- and Macrovascular Endothelial Cells. Journal of Interferon and Cytokine Research, 2011, 31, 451-458.	0.5	19
600	The role of Twist1 in hepatocellular carcinoma angiogenesis: a clinical study. Human Pathology, 2011, 42, 840-847.	1.1	27
601	Selective inhibition of cyclooxygenase-2 suppresses metastatic disease without affecting primary tumor growth in a murine model of Ewing sarcoma. Journal of Pediatric Surgery, 2011, 46, 108-114.	0.8	15
602	Toona sinensis (leaf extracts) inhibit vascular endothelial growth factor (VEGF)-induced angiogenesis in vascular endothelial cells. Journal of Ethnopharmacology, 2011, 134, 111-121.	2.0	60
603	Inhibitory effects of Physalis angulata on tumor metastasis and angiogenesis. Journal of Ethnopharmacology, 2011, 135, 762-771.	2.0	44

#	Article	IF	Citations
604	Tumor angiogenesis: molecular pathways and therapeutic targets. Nature Medicine, 2011, 17, 1359-1370.	15.2	1,518
605	Recent Advances in Anti-Angiogenic Therapy of Cancer. Oncotarget, 2011, 2, 122-134.	0.8	114
606	PET Imaging of Integrin Positive Tumors Using ¹⁸ F Labeled Knottin Peptides. Theranostics, 2011, 1, 403-412.	4.6	30
607	Modeling Tumor Angiogenesis with Zebrafish. , 2011, , .		1
608	Plasmid-based STAT3-siRNA efficiently inhibits breast tumor growth and metastasis in mice. Neoplasma, 2011, 58, 538-547.	0.7	16
609	Detection of M2-Macrophages in Uveal Melanoma and Relation with Survival. , 2011, 52, 643.		185
610	Breast Tumor Angiogenesis and Tumor-Associated Macrophages: Histopathologist's Perspective. Pathology Research International, 2011, 2011, 1-13.	1.4	18
611	Safety and Pharmacokinetics of Motesanib in Combination with Panitumumab and Gemcitabine-Cisplatin in Patients with Advanced Cancer. Journal of Oncology, 2011, 2011, 1-11.	0.6	6
612	Angiogenic and lymphangiogenic cascades in the tumor microenvironment. Frontiers in Bioscience - Scholar, 2011, S3, 216-225.	0.8	24
613	Radiolabeled Cyclic RGD Peptides as Radiotracers for Imaging Tumors and Thrombosis by SPECT. Theranostics, 2011, 1, 58-82.	4.6	124
614	Coexpression of PDGFR-Alpha, PDGFR-Beta and VEGF as a Prognostic Factor in Patients with Hepatocellular Carcinoma. International Journal of Biological Markers, 2011, 26, 108-116.	0.7	22
615	Signal Transduction Pathways in Breast Cancer – Drug Targets and Challenges. , 0, , .		О
616	Down-Regulation of miR-101 in Endothelial Cells Promotes Blood Vessel Formation through Reduced Repression of EZH2. PLoS ONE, 2011, 6, e16282.	1.1	96
617	Oleanolic Acid Initiates Apoptosis in Non-Small Cell Lung Cancer Cell Lines and Reduces Metastasis of a B16F10 Melanoma Model In Vivo. PLoS ONE, 2011, 6, e28596.	1.1	80
618	Pigment epithelium-derived factor inhibits angiogenesis and growth of gastric carcinoma by down-regulation of VEGF. Oncology Reports, 2011, 26, 681-6.	1.2	22
619	PI3K/AKT/mTOR Pathway in Angiogenesis. Frontiers in Molecular Neuroscience, 2011, 4, 51.	1.4	1,002
620	Localization and characterization of lymphatic vessels in oral and cervical squamous cell carcinoma. Experimental and Therapeutic Medicine, 2011, 2, 793-797.	0.8	8
621	Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with ⁶⁴ Cu″abeled bevacizumab in colorectal cancer xenografts. Cancer Science, 2011, 102, 117-121.	1.7	52

#	Article	IF	CITATIONS
622	<i>In vitro</i> and <i>in vivo</i> evaluation of the antiâ€angiogenic actions of 4â€hydroxybenzyl alcohol. British Journal of Pharmacology, 2011, 163, 835-844.	2.7	43
623	Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nature Medicine, 2011, 17, 320-329.	15.2	1,296
624	Transgenic expression of human cathepsin B promotes progression and metastasis of polyoma-middle-T-induced breast cancer in mice. Oncogene, 2011, 30, 54-64.	2.6	83
625	Prognostic significance of BRMS1 expression in human melanoma and its role in tumor angiogenesis. Oncogene, 2011, 30, 896-906.	2.6	49
626	Altered angiogenesis in the tumor microenvironment. Pathology International, 2011, 61, 630-637.	0.6	27
627	The further study on radioiodinated peptide Arg-Arg-Leu targeted to neovascularization as well as tumor cells in molecular tumor imaging. Journal of Radioanalytical and Nuclear Chemistry, 2011, 290, 623-630.	0.7	5
628	Bevacizumab can induce reactivity to VEGF-C and -D in human brain and tumour derived endothelial cells. Journal of Neuro-Oncology, 2011, 104, 103-112.	1.4	27
629	Meta-analysis of the association between VEGF-634 G>C and risk of malignancy based on 23 case–control studies. Journal of Cancer Research and Clinical Oncology, 2011, 137, 1027-1036.	1.2	29
630	Molecular mechanisms of liver metastasis. International Journal of Clinical Oncology, 2011, 16, 464-472.	1.0	27
631	Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials. European Journal of Clinical Pharmacology, 2011, 67, 613-623.	0.8	87
632	Collagen induced arthritis increases secondary metastasis in MMTV-PyV MT mouse model of mammary cancer. BMC Cancer, 2011, 11, 365.	1.1	40
633	Antiangiogenic properties of Koetjapic acid, a natural triterpene isolated from Sandoricum koetjaoe Merr. Cancer Cell International, 2011, 11, 12.	1.8	25
634	Antiangiogenesis agents avastin and erbitux enhance the efficacy of photodynamic therapy in a murine bladder tumor model. Lasers in Surgery and Medicine, 2011, 43, 651-662.	1.1	24
635	Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. Hepatology, 2011, 53, 483-492.	3.6	97
636	PET imaging of tumor angiogenesis in mice with VEGFâ€A–targeted ⁸⁶ Yâ€CHXâ€A″â€DTPAâ€bevacizumab. International Journal of Cancer, 2011, 128, 920-926.	2.3	64
637	Sunitinib facilitates the activation and recruitment of therapeutic antiâ€tumor immunity in concert with specific vaccination. International Journal of Cancer, 2011, 129, 2158-2170.	2.3	127
638	Bivalent bendamustine and melphalan derivatives as anticancer agents. European Journal of Medicinal Chemistry, 2011, 46, 1604-1615.	2.6	21
639	Phosphatidylinositol 3′-kinase signaling pathway is essential for Rac1-induced hypoxia-inducible factor-1α and vascular endothelial growth factor expression. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 300, H2169-H2176.	1.5	18

#	Article	IF	CITATIONS
640	lon channels and transporters in cancer. 3. Ion channels in the tumor cell-microenvironment cross talk. American Journal of Physiology - Cell Physiology, 2011, 301, C762-C771.	2.1	57
641	The effects of recombinant human GH on promoting tumor growth depend on the expression of GH receptor in vivo. Journal of Endocrinology, 2011, 211, 249-256.	1.2	11
642	The requirement for fibroblasts in angiogenesis: fibroblast-derived matrix proteins are essential for endothelial cell lumen formation. Molecular Biology of the Cell, 2011, 22, 3791-3800.	0.9	391
643	Antitumor effect of endostatin overexpressed in C6 glioma cells is associated with the down-regulation of VEGF. International Journal of Oncology, 2011, 38, 465-71.	1.4	7
644	Treatment-Related Mortality With Bevacizumab in Cancer Patients. JAMA - Journal of the American Medical Association, 2011, 305, 487.	3.8	393
645	Bevacizumab Has Differential and Dose-Dependent Effects on Glioma Blood Vessels and Tumor Cells. Clinical Cancer Research, 2011, 17, 6192-6205.	3.2	148
646	Combined inhibitors of angiogenesis and histone deacetylase: Efficacy in rat hepatoma. World Journal of Gastroenterology, 2011, 17, 3623.	1.4	3
647	Pilot Pharmacokinetic and Dosimetric Studies of ^{18 < /sup>F-FPPRGD2: A PET Radiopharmaceutical Agent for Imaging α _{v < /sub>β < sub>3 < /sub>Integrin Levels. Radiology, 2011, 260, 182-191.}}	3.6	131
648	IL-6 Trans-Signaling in Formation and Progression of Malignant Ascites in Ovarian Cancer. Cancer Research, 2011, 71, 424-434.	0.4	184
649	Prognostic Significance of Angiogenesis in Relation to Ki-67, p-53, p-27, and bcl-2 Expression in Embryonal Tumors. Pediatric Neurosurgery, 2011, 47, 241-247.	0.4	11
650	Down-regulation of urokinase plasminogen activator and matrix metalloproteinases and up-regulation of their inhibitors by a novel nutrient mixture in human prostate cancer cell lines PC-3 and DU-145. Oncology Reports, 2011, 26, 1407-13.	1.2	11
651	SKLB1002, a Novel Potent Inhibitor of VEGF Receptor 2 Signaling, Inhibits Angiogenesis and Tumor Growth <i>In Vivo</i> . Clinical Cancer Research, 2011, 17, 4439-4450.	3.2	92
652	^{99m} Tc-Labeled Cyclic RGD Peptides for Noninvasive Monitoring of Tumor Integrin α _v β ₃ Expression. Molecular Imaging, 2011, 10, 7290.2011.00006.	0.7	58
653	Novel surface targets and serum biomarkers from the ovarian cancer vasculature. Cancer Biology and Therapy, 2011, 12, 169-180.	1.5	33
654	Efficient inhibition of an intraperitoneal xenograft model of human ovarian cancer by HSulf-1 gene delivered by biodegradable cationic heparin-polyethyleneimine nanogels. Oncology Reports, 2012, 27, 363-70.	1.2	5
655	Vandetanib Restores Head and Neck Squamous Cell Carcinoma Cells' Sensitivity to Cisplatin and Radiation <i>In Vivo</i> and <i>In Vitro</i> Clinical Cancer Research, 2011, 17, 1815-1827.	3.2	76
656	Apoptosis regulator through modulating IAP expression (ARIA) controls the PI3K/Akt pathway in endothelial and endothelial progenitor cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 9472-9477.	3.3	40
657	SV40 T/t-common polypeptide inhibits angiogenesis and growth of HER2-overexpressing human ovarian cancer. Cancer Gene Therapy, 2011, 18, 859-870.	2.2	2

#	Article	IF	CITATIONS
658	The Role of Traditional Chinese Medicine in Clinical Oncology. , 2012, , 405-429.		0
659	Phosphomimetic Mutants of Pigment Epithelium-Derived Factor with Enhanced Anti-Choroidal Melanoma Cell Activity In Vitro and In Vivo., 2012, 53, 6793.		10
660	High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity. Modern Pathology, 2012, 25, 1079-1085.	2.9	69
661	Design, Synthesis and Evaluation of Novel Benzimidazoles, Benzothiazoles and Benzofurans Incorporating Pyrazole Moiety as Antiangiogenic Agents. Arzneimittelforschung, 2012, 62, 63-74.	0.5	2
662	Prophylactic Vaccine Approach for Colon and Pancreatic Cancers: Present and Future. Current Medicinal Chemistry, 2012, 19, 3664-3678.	1.2	3
663	Biglycan is a specific marker and an autocrine angiogenic factor of tumour endothelial cells. British Journal of Cancer, 2012, 106, 1214-1223.	2.9	90
664	E10A, an adenovirus-carrying endostatin gene, dramatically increased the tumor drug concentration of metronomic chemotherapy with low-dose cisplatin in a xenograft mouse model for head and neck squamous-cell carcinoma. Cancer Gene Therapy, 2012, 19, 144-152.	2.2	12
665	MEG3 noncoding RNA: a tumor suppressor. Journal of Molecular Endocrinology, 2012, 48, R45-R53.	1.1	643
666	Antiangiogenesis therapy in the treatment of metastatic colorectal cancer. Therapeutic Advances in Medical Oncology, 2012, 4, 301-319.	1.4	26
667	Inhibitory Effects of SU5416, a Selective Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, on Experimental Corneal Neovascularization. Ophthalmic Research, 2012, 47, 13-18.	1.0	19
668	Stroma Targeting Nuclear Imaging and Radiopharmaceuticals. International Journal of Molecular Imaging, 2012, 2012, 1-23.	1.3	3
669	Targeted Ultrasound Imaging of Cancer: An Emerging Technology on its Way to Clinics. Current Pharmaceutical Design, 2012, 18, 2184-2199.	0.9	54
670	New Gene Therapy Strategies for Cancer Treatment: A Review of Recent Patents. Recent Patents on Anti-Cancer Drug Discovery, 2012, 7, 297-312.	0.8	44
671	Multimeric Cyclic RGD Peptides Useful for Development of Integrin α _v β ₃ -Targeted SPECT Radiotracers. , 2012, , 165-195.		0
672	Changes of tumor infiltrating lymphocyte subtypes before and after neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer patients – an immunohistochemical study of cd8+ and foxp3+ using double immunostaining with correlation to the pathobiological response of the patients. International Journal of Biological Markers, 2012, 27, 295-304.	0.7	33
673	Grape seed proanthocyanidins inhibit colon cancer-induced angiogenesis through suppressing the expression of VEGF and Angl. International Journal of Molecular Medicine, 2012, 30, 1410-1416.	1.8	50
674	Electrochemical Detection of Vascular Endothelial Growth Factor by an Aptamer-Based Bound/Free Separation System. Electrochemistry, 2012, 80, 348-352.	0.6	14
675	Modulation of u-PA, MMPs and their inhibitors by a novel nutrient mixture in human female cancer cell lines. Oncology Reports, 2012, 28, 768-776.	1.2	22

#	Article	IF	CITATIONS
676	Antitumor activity of Endostar combined with radiation against human nasopharyngeal carcinoma in mouse xenograft models. Oncology Letters, 2012, 4, 976-980.	0.8	21
677	Overcoming Resistance to Antiangiogenic Therapies. Oncologist, 2012, 17, 1039-1050.	1.9	53
678	miR-27b controls venous specification and tip cell fate. Blood, 2012, 119, 2679-2687.	0.6	107
679	Role of angiogenesis in the pathogenesis of cancer. Cancer Treatment Reviews, 2012, 38, 825-833.	3.4	76
680	Two cases of bowel perforation associated with sunitinib treatment for renal cell carcinoma. International Journal of Clinical Oncology, 2012, 17, 412-416.	1.0	10
681	Spatiotemporally Controlled Co-delivery of Anti-vasculature Agent and Cytotoxic Drug by Octreotide-Modified Stealth Liposomes. Pharmaceutical Research, 2012, 29, 2902-2911.	1.7	47
682	Monocyte chemotactic protein-induced protein (MCPIP) promotes inflammatory angiogenesis via sequential induction of oxidative stress, endoplasmic reticulum stress and autophagy. Cellular Signalling, 2012, 24, 2123-2131.	1.7	62
683	Reappraisal of the Role of Bevacizumab in the Therapeutic Strategy in Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2012, 10, 147-152.	0.9	3
684	Vascular density and endothelial cell expression of integrin alpha ν beta 3 and E-selectin in murine tumours. Tumor Biology, 2012, 33, 1709-1717.	0.8	29
685	ADAMTS5 Functions as an Anti-Angiogenic and Anti-Tumorigenic Protein Independent of Its Proteoglycanase Activity. American Journal of Pathology, 2012, 181, 1056-1068.	1.9	65
686	Battling Cancer: In the End What Matters the Most?. Disruptive Science and Technology, 2012, 1, 108-109.	1.0	4
687	Effects of estrogen depletion on angiogenesis in estrogen-receptor-positive breast carcinoma – an immunohistochemical study of vasohibin-1 and CD31 with correlation to pathobiological response of the patients in neoadjuvant aromatase inhibitor therapy. Expert Opinion on Therapeutic Targets, 2012, 16. S69-S78.	1.5	11
688	Positron emission tomography imaging of tumor angiogenesis and monitoring of antiangiogenic efficacy using the novel tetrameric peptide probe 64Cu-cyclam-RAFT-c(-RGDfK-)4. Angiogenesis, 2012, 15, 569-580.	3.7	27
689	Coronary collateral growth—Back to the future. Journal of Molecular and Cellular Cardiology, 2012, 52, 905-911.	0.9	51
690	Associations between hepatocyte growth factor, c-Met, and basic fibroblast growth factor and survival in endometrial cancer patients. British Journal of Cancer, 2012, 106, 2004-2009.	2.9	21
691	Tumor Endothelial Cells Acquire Drug Resistance by MDR1 Up-Regulation via VEGF Signaling in Tumor Microenvironment. American Journal of Pathology, 2012, 180, 1283-1293.	1.9	137
692	Heterogeneity of Tumor Endothelial Cells. American Journal of Pathology, 2012, 180, 1294-1307.	1.9	138
693	Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC). Cancer Treatment Reviews, 2012, 38, 173-184.	3.4	31

#	Article	IF	CITATIONS
694	A comparison of 3D-CTA and 4D-CE-MRA for the dynamic monitoring of angiogenesis in a rabbit VX2 tumor. European Journal of Radiology, 2012, 81, 104-110.	1.2	12
695	Serial measurements of serum PDGF-AA, PDGF-BB, FGF2, and VEGF in multiresistant ovarian cancer patients treated with bevacizumab. Journal of Ovarian Research, 2012, 5, 23.	1.3	29
696	A novel regulation of VEGF expression by HIFâ€lî± and STAT3 in HDM2 transfected prostate cancer cells. Journal of Cellular and Molecular Medicine, 2012, 16, 1750-1757.	1.6	24
697	Anti-angiogenic activity of thymoquinone by the down-regulation of VEGF using zebrafish (Danio) Tj ETQq $1\ 1\ 0$.7843]4 rg	gBT/Overlock
698	Targeted destruction of the orchestration of the pancreatic stroma and tumor cells in pancreatic cancer cases: Molecular basis for therapeutic implications. Cytokine and Growth Factor Reviews, 2012, 23, 343-356.	3.2	37
699	Growth factor signaling in metastasis: current understanding and future opportunities. Cancer and Metastasis Reviews, 2012, 31, 479-491.	2.7	27
700	Reduced expression of vasohibin-1 is associated with clinicopathological features in renal cell carcinoma. Medical Oncology, 2012, 29, 3325-3334.	1.2	23
701	Expression of Vascular Endothelial Growth Factor correlates with the advance of clinical osteosarcoma. International Orthopaedics, 2012, 36, 2307-2313.	0.9	39
702	Semaphorin 3A Suppresses Tumor Growth and Metastasis in Mice Melanoma Model. PLoS ONE, 2012, 7, e33633.	1.1	73
703	The Invasion and Metastasis Promotion Role of CD97 Small Isoform in Gastric Carcinoma. PLoS ONE, 2012, 7, e39989.	1.1	36
704	Dehydrocostuslactone Suppresses Angiogenesis In Vitro and In Vivo through Inhibition of Akt/GSK-3 \hat{l}^2 and mTOR Signaling Pathways. PLoS ONE, 2012, 7, e31195.	1.1	41
705	Plasma Vascular Endothelial Growth Factor Dysregulation in Defining Aggressiveness of Head and Neck Squamous Cell Carcinoma. Journal of Oncology, 2012, 2012, 1-7.	0.6	11
706	Magnetic Nanoparticles in the Imaging of Tumor Angiogenesis. Applied Sciences (Switzerland), 2012, 2, 525-534.	1.3	7
707	Recent Advances in Nasopharyngeal Carcinoma Research and Its Pathogenesis. , 2012, , 453-492.		1
708	Cancer Related Inflammation and Tumor Angiogenesis. , 0, , .		0
709	Membrane Trafficking and Endothelial-Cell Dynamics During Angiogenesis. , 0, , .		1
710	Safety profiles of current antiangiogenic therapies for metastatic colorectal cancer. OncoTargets and Therapy, 2012, 5, 133.	1.0	12
711	Liquiritigenin Inhibits Serumâ€induced HIFâ€1α and VEGF Expression via the AKT/mTORâ€p70S6K Signalling Pathway in HeLa Cells. Phytotherapy Research, 2012, 26, 1133-1141.	2.8	28

#	Article	IF	CITATIONS
712	Systemic Delivery of siRNA via LCP Nanoparticle Efficiently Inhibits Lung Metastasis. Molecular Therapy, 2012, 20, 609-615.	3.7	116
713	Evolving models of tumor origin and progression. Tumor Biology, 2012, 33, 911-917.	0.8	16
714	A highâ€fat diet increases angiogenesis, solid tumor growth, and lung metastasis of CT26 colon cancer cells in obesityâ€resistant BALB/c mice. Molecular Carcinogenesis, 2012, 51, 869-880.	1.3	75
715	Inhibition of transforming growth factor-β-activated kinase-1 blocks cancer cell adhesion, invasion, and metastasis. British Journal of Cancer, 2012, 107, 129-136.	2.9	26
716	Transforming growth factor-beta1 induces microvascular abnormalities through a down-modulation of neural cell adhesion molecule in human hepatocellular carcinoma. Laboratory Investigation, 2012, 92, 1297-1309.	1.7	22
717	Use of radioiodinated peptide Arg-Arg-Leu targeted to neovascularization as well as tumor cells in molecular tumor imaging. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2012, 24, 52-59.	0.7	7
718	A Study of Pipeline Drugs in Neuroendocrine Tumors. Journal of Gastrointestinal Cancer, 2012, 43, 296-304.	0.6	1
719	Clinical study on the recombinant human endostatin regarding improving the blood perfusion and hypoxia of non-small-cell lung cancer. Clinical and Translational Oncology, 2012, 14, 437-443.	1.2	15
720	Recombinant Human Endostatin Endostar Inhibits Tumor Growth and Metastasis in a Mouse Xenograft Model of Colon Cancer. Pathology and Oncology Research, 2012, 18, 315-323.	0.9	34
721	Imaging proliferation of 18F-FLT PET/CT correlated with the expression of microvessel density of tumour tissue in non-small-cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1289-1296.	3.3	30
722	Targeting the vasculature of visceral tumors: novel insights and treatment perspectives. Langenbeck's Archives of Surgery, 2012, 397, 569-578.	0.8	5
724	A dynamical model of apoptosis and its role in tumor progression. Communications in Nonlinear Science and Numerical Simulation, 2012, 17, 1795-1804.	1.7	3
725	Multifunctional unimolecular micelles for cancer-targeted drug delivery and positron emission tomography imaging. Biomaterials, 2012, 33, 3071-3082.	5.7	224
726	Megakaryocytes, malignancy and bone marrow vascular niches. Journal of Thrombosis and Haemostasis, 2012, 10, 177-188.	1.9	55
727	Structure–Activity Relationship Study of Collagenâ€Derived Antiâ€Angiogenic Biomimetic Peptides. Chemical Biology and Drug Design, 2012, 80, 27-37.	1.5	14
728	Proâ€opiomelanocortin gene delivery suppresses the growth of established Lewis lung carcinoma through a melanocortinâ€1 receptorâ€independent pathway. Journal of Gene Medicine, 2012, 14, 44-53.	1.4	31
729	Is advanced hepatocellular carcinoma amenable of cure by liver transplantation with sorafenib as a neoadjuvant approach plus mâ€₹OR inhibitors monotherapy?. Journal of Surgical Oncology, 2012, 105, 111-112.	0.8	9
730	Different combination schedules of gemcitabine with endostar affect antitumor efficacy. Cancer Chemotherapy and Pharmacology, 2012, 69, 239-246.	1.1	11

#	Article	IF	Citations
731	The chemokine receptor CCR4 promotes tumor growth and lung metastasis in breast cancer. Breast Cancer Research and Treatment, 2012, 131, 837-848.	1.1	72
732	Exosomes released by K562 chronic myeloid leukemia cells promote angiogenesis in a src-dependent fashion. Angiogenesis, 2012, 15, 33-45.	3.7	234
733	In vivo imaging of vessel diameter, size, and density: A comparative study between MRI and histology. Magnetic Resonance in Medicine, 2013, 69, 18-26.	1.9	59
734	Induction of acquired drug resistance in endothelial cells and its involvement in anticancer therapy. Journal of Hematology and Oncology, 2013, 6, 49.	6.9	38
735	Mitochondrial UQCRB regulates VEGFR2 signaling in endothelial cells. Journal of Molecular Medicine, 2013, 91, 1117-1128.	1.7	25
736	The soluble VEGF receptor 1 and 2 expression in cerebral spinal fluid as an indicator for leukemia central nervous system metastasis. Journal of Neuro-Oncology, 2013, 112, 329-338.	1.4	17
737	Imaging Tumor Angiogenesis: The Road to Clinical Utility. American Journal of Roentgenology, 2013, 201, W183-W191.	1.0	55
738	Modeling the connection between primary and metastatic tumors. Journal of Mathematical Biology, 2013, 67, 657-692.	0.8	8
739	Breast cancer as a systemic disease: a view of metastasis. Journal of Internal Medicine, 2013, 274, 113-126.	2.7	546
740	Molecular Imaging in Oncology. Recent Results in Cancer Research, 2013, , .	1.8	6
741	Host pigment epithelium-derived factor (PEDF) prevents progression of liver metastasis in a mouse model of uveal melanoma. Clinical and Experimental Metastasis, 2013, 30, 969-976.	1.7	30
742	A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer. Investigational New Drugs, 2013, 31, 910-917.	1.2	26
743	Predictive pharmacokinetic–pharmacodynamic modeling of tumor growth after administration of an anti-angiogenic agent, bevacizumab, as single-agent and combination therapy in tumor xenografts. Cancer Chemotherapy and Pharmacology, 2013, 71, 1147-1157.	1.1	30
744	Peptide-Based Targeting of the Platelet-Derived Growth Factor Receptor Beta. Molecular Imaging and Biology, 2013, 15, 212-221.	1.3	27
745	Agent-based Modeling. , 2013, , 13-13.		0
746	Imaging integrin $\hat{l}\pm v\hat{l}^2$ 3 positive glioma with a novel RGD dimer probe and the impact of antiangiogenic agent (Endostar) on its tumor uptake. Cancer Letters, 2013, 335, 75-80.	3 . 2	21
747	Role of Collagen Matrix in Tumor Angiogenesis and Glioblastoma Multiforme Progression. American Journal of Pathology, 2013, 183, 1293-1305.	1.9	143
748	CGKRK-modified nanoparticles for dual-targeting drug delivery to tumor cells and angiogenic blood vessels. Biomaterials, 2013, 34, 9496-9508.	5.7	68

#	ARTICLE	IF	Citations
749	PHD4 Stimulates Tumor Angiogenesis in Osteosarcoma Cells via TGF-α. Molecular Cancer Research, 2013, 11, 1337-1348.	1.5	20
750	Antitumor efficacy of a recombinant adenovirus encoding endostatin combined with an E1B55KD-deficient adenovirus in gastric cancer cells. Journal of Translational Medicine, 2013, 11, 257.	1.8	15
751	Chemotherapy with bevacizumab for metastatic colorectal cancer: a retrospective review of 181 Japanese patients. International Journal of Clinical Oncology, 2013, 18, 689-695.	1.0	5
752	A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer. Breast Cancer Research and Treatment, 2013, 140, 331-339.	1.1	22
753	Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors. Investigational New Drugs, 2013, 31, 751-759.	1.2	34
7 54	The antiangiogenic activities of ethanolic crude extracts of four Salvia species. BMC Complementary and Alternative Medicine, 2013, 13, 358.	3.7	24
755	Gene and isoform expression signatures associated with tumor stage in kidney renal clear cell carcinoma. BMC Systems Biology, 2013, 7, S7.	3.0	19
756	IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a STAT1-dominant pathway in human non-small cell lung cancer. Journal of Experimental and Clinical Cancer Research, 2013, 32, 97.	3.5	69
757	The relationship between lymphatic vascular density and vascular endothelial growth factor A (VEGF-A) expression with clinical-pathological features and survival in pancreatic adenocarcinomas. Diagnostic Pathology, 2013, 8, 170.	0.9	14
758	Systems Biology of Tumor Dormancy. Advances in Experimental Medicine and Biology, 2013, , .	0.8	9
759	Association Between Postoperative Complications and Clinical Cancer Outcomes. Annals of Surgical Oncology, 2013, 20, 4063-4066.	0.7	18
760	The role of vascular epithelial growth factor receptor–tyrosine kinase inhibitors in the treatment of advanced breast cancer: a meta-analysis of 12 randomized controlled trials. Current Medical Research and Opinion, 2013, 29, 1691-1699.	0.9	4
761	Bendamustine for indolent non-Hodgkin lymphoma in the front-line or relapsed setting: a review of pharmacokinetics and clinical trial outcomes. Expert Review of Hematology, 2013, 6, 525-537.	1.0	5
763	Inhibitory effects of isoliquiritigenin on the migration and invasion of human breast cancer cells. Expert Opinion on Therapeutic Targets, 2013, 17, 337-349.	1.5	89
764	Early Tumor Development Captured Through Nondestructive, High Resolution Differential Phase Contrast X-ray Imaging. Radiation Research, 2013, 180, 448-454.	0.7	3
765	Phase I, pharmacokinetic and pharmacodynamic evaluation of CYT997, an orally-bioavailable cytotoxic and vascular-disrupting agent. Investigational New Drugs, 2013, 31, 126-135.	1.2	18
766	Multifunctional Magnetic Resonance Imaging Probes. Recent Results in Cancer Research, 2013, 187, 151-190.	1.8	6
768	12-Deoxyphorbol 13-palmitate inhibit VEGF-induced angiogenesis via suppression of VEGFR-2-signaling pathway. Journal of Ethnopharmacology, 2013, 146, 724-733.	2.0	22

#	ARTICLE	IF	CITATIONS
769	GLP-1 promotes angiogenesis in human endothelial cells in a dose-dependent manner, through the Akt, Src and PKC pathways. Metabolism: Clinical and Experimental, 2013, 62, 1279-1286.	1.5	70
770	Angiogenesis, mediated by miR-21, is involved arsenite-induced carcinogenesis. Toxicology Letters, 2013, 223, 35-41.	0.4	36
771	Multi-objective multi-drug scheduling schemes for cell cycle specific cancer treatment. Computers and Chemical Engineering, 2013, 58, 14-32.	2.0	22
772	Time trends in survival from cancer of unknown primary: Small steps forward. European Journal of Cancer, 2013, 49, 2403-2410.	1.3	34
773	The <scp>F</scp> â€prostaglandin receptor is a novel marker for tumor endothelial cells in renal cell carcinoma. Pathology International, 2013, 63, 37-44.	0.6	15
774	Tumor Dormancy and Cancer Stem Cells: Two Sides of the Same Coin?. Advances in Experimental Medicine and Biology, 2013, 734, 145-179.	0.8	108
775	MSCs in Solid Tumors and Hematological Malignancies: From Basic Biology to Therapeutic Applications. , 2013, , 209-235.		0
776	The novel tumor suppressor NOL7 post-transcriptionally regulates thrombospondin-1 expression. Oncogene, 2013, 32, 4377-4386.	2.6	9
777	Targeted Therapy for Metastatic Colorectal Cancer: Role of Aflibercept. Clinical Colorectal Cancer, 2013, 12, 73-85.	1.0	33
778	Maslinic acid inhibits the metastatic capacity of DU145 human prostate cancer cells: possible mediation via hypoxia-inducible factor- $1\hat{l}\pm$ signalling. British Journal of Nutrition, 2013, 109, 210-222.	1.2	38
779	Novel cis-restricted \hat{l}^2 -lactam combretastatin A-4 analogues display anti-vascular and anti-metastatic properties in vitro. Oncology Reports, 2013, 29, 585-594.	1.2	19
780	<scp>SERPINA</scp> 3 <scp>K</scp> induces apoptosis in human colorectal cancer cells via activating the <scp>F</scp> as/ <scp>F</scp> as <scp>L</scp> /caspaseâ€8 signaling pathway. FEBS Journal, 2013, 280, 3244-3255.	2.2	28
781	Tumor-derived microvesicles: The metastasomes. Medical Hypotheses, 2013, 80, 75-82.	0.8	21
782	Targeting Ca ²⁺ transport in cancer: close reality or long perspective?. Expert Opinion on Therapeutic Targets, 2013, 17, 225-241.	1.5	50
783	Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis. World Journal of Surgical Oncology, 2013, 11, 306.	0.8	59
784	Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertension. Angiogenesis, 2013, 16, 289-295.	3.7	49
785	Acacetin Inhibits <i>In Vitro</i> and <i>In Vivo</i> Angiogenesis and Downregulates Stat Signaling and VEGF Expression. Cancer Prevention Research, 2013, 6, 1128-1139.	0.7	63
786	Gene Expression of VEGF-A and VEGF-C in Peripheral Blood Mononuclear Cells of Iranian Patients with Acute Myeloid Leukemia. Turkish Journal of Haematology, 2013, 30, 137-143.	0.2	7

#	Article	IF	CITATIONS
787	Designing gene therapy vectors targeting tumor cell endothelium. Turk Onkoloji Dergisi, 2013, 28, 179-186.	0.0	1
788	Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients. Acta Oncol $ ilde{A}^3$ gica, 2013, 52, 1202-1212.	0.8	40
789	Mechanism of Ursolic Acid-Mediated Inhibition of Proliferation in Vascular Endothelial Glioaytoma. Tropical Journal of Pharmaceutical Research, 2013, 12, .	0.2	0
790	Inhibition of angiogenesis. Anti-Cancer Drugs, 2013, 24, 781-791.	0.7	35
791	Basal caspase-3 activity promotes migration, invasion, and vasculogenic mimicry formation of melanoma cells. Melanoma Research, 2013, 23, 243-253.	0.6	36
792	The Functionalized Human Serine Protease Granzyme B/VEGF121 Targets Tumor Vasculature and Ablates Tumor Growth. Molecular Cancer Therapeutics, 2013, 12, 2055-2066.	1.9	11
793	TRAF6 Upregulates Expression of HIF-1 \hat{l} ± and Promotes Tumor Angiogenesis. Cancer Research, 2013, 73, 4950-4959.	0.4	85
794	Synstatin: a selective inhibitor of the syndecanâ€1â€coupled <scp>IGF</scp> 1 <scp>R</scp> â€"αvβ3 integrin complex in tumorigenesis and angiogenesis. FEBS Journal, 2013, 280, 2207-2215.	2.2	96
795	Subcompartmentalization of extracellular extravascular space (EES) into permeability and leaky space with local arterial input function (AIF) results in improved discrimination between high―and lowâ€grade glioma using dynamic contrastâ€enhanced (DCE) MRI. Journal of Magnetic Resonance Imaging, 2013, 38, 677-688.	1.9	29
796	MicroRNAs Regulate Tumor Angiogenesis Modulated by Endothelial Progenitor Cells. Cancer Research, 2013, 73, 341-352.	0.4	122
797	Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study. Blood Cancer Journal, 2013, 3, e162-e162.	2.8	56
798	Role of the nervous system in cancer metastasis. Oncology Letters, 2013, 5, 1101-1111.	0.8	74
799	Anti-metastatic Treatment in Colorectal Cancer: Targeting Signaling Pathways. Current Pharmaceutical Design, 2013, 19, 841-863.	0.9	12
800	Modulation of u-PA, MMPs and their inhibitors by a novel nutrient mixture in adult human sarcoma cell lines. International Journal of Oncology, 2013, 43, 39-49.	1.4	10
801	Tanshinone VI Inhibits the Expression of Intercellular Adhesion Molecule-1 and Vascular Cell Adhesion Molecule-1. International Journal of Immunopathology and Pharmacology, 2013, 26, 977-982.	1.0	4
802	Endothelialâ€rich microenvironment supports growth and branching morphogenesis of prostate epithelial cells. Prostate, 2013, 73, 884-896.	1.2	9
803	Modulation of u-PA, MMPs and their inhibitors by a novel nutrient mixture in human lung cancer and mesothelioma cell lines. International Journal of Oncology, 2013, 42, 1883-1889.	1.4	10
804	Modulation of u-PA, MMPs and their inhibitors by a novel nutrient mixture in pediatric human sarcoma cell lines. International Journal of Oncology, 2013, 43, 1027-1035.	1.4	9

#	Article	IF	CITATIONS
805	Integrin $\hat{l}\pm\langle \text{sub}\rangle v\langle \text{sub}\rangle \hat{l}^2\langle \text{sub}\rangle 3\langle \text{sub}\rangle -\text{Targeted Radiotracer}\langle \text{sup}\rangle 99m\langle \text{sup}\rangle \text{Tc-3P-RGD}\langle \text{sub}\rangle 2\langle \text{sub}\rangle \text{Useful for Noninvasive Monitoring of Breast Tumor Response to Antiangiogenic Linifanib Therapy but not Anti-Integrin \hat{l}\pm\langle \text{sub}\rangle v\langle \text{sub}\rangle \hat{l}^2\langle \text{sub}\rangle 3\langle \text{sub}\rangle \text{RGD}\langle \text{sub}\rangle 2\langle \text{sub}\rangle \text{Therapy. Theranostics, 2013, 3, 816-830.}$	4.6	27
806	Angiogenesis in liver metastasis of colo-rectal carcinoma. Frontiers in Bioscience - Landmark, 2013, 18, 1435.	3.0	12
807	Human Apurinic/Apyrimidinic Endonuclease siRNA Inhibits the Angiogenesis Induced by X-Ray Irradiation in Lung Cancer Cells. International Journal of Medical Sciences, 2013, 10, 870-882.	1.1	28
808	Impact of VEGF-C Gene Polymorphisms and Environmental Factors on Oral Cancer Susceptibility in Taiwan. PLoS ONE, 2013, 8, e60283.	1.1	18
809	Down-Regulated miR-30a in Clear Cell Renal Cell Carcinoma Correlated with Tumor Hematogenous Metastasis by Targeting Angiogenesis-Specific DLL4. PLoS ONE, 2013, 8, e67294.	1.1	50
810	Knockdown of the Sodium-Dependent Phosphate Co-Transporter 2b (NPT2b) Suppresses Lung Tumorigenesis. PLoS ONE, 2013, 8, e77121.	1.1	37
811	The Tumor Microenvironment Contribution to Development, Growth, Invasion and Metastasis of Head and Neck Squamous Cell Carcinomas. Journal of Cancer, 2013, 4, 66-83.	1.2	262
812	Update on oncolytic viral therapy & Depth of the same	1.0	16
813	A Composite Synergistic Systems Model for Exploring the Efficacies of Different Chemotherapeutic Strategies in Cancer. Computational Biology Journal, 2013, 2013, 1-26.	0.6	4
814	Results of a randomized and controlled clinical trial evaluating the efficacy and safety of combination therapy with Endostar and S-1 combined with oxaliplatin in advanced gastric cancer. OncoTargets and Therapy, 2013, 6, 925.	1.0	25
815	A Biomimetic Collagen Derived Peptide Exhibits Anti-Angiogenic Activity in Triple Negative Breast Cancer. PLoS ONE, 2014, 9, e111901.	1.1	12
816	Comprehensive Evaluation of the Anti-Angiogenic and Anti-Neoplastic Effects of Endostar on Liver Cancer through Optical Molecular Imaging. PLoS ONE, 2014, 9, e85559.	1.1	10
817	SHARP1 Suppresses Angiogenesis of Endometrial Cancer by Decreasing Hypoxia-Inducible Factor- $1\hat{l}_{\pm}$ Level. PLoS ONE, 2014, 9, e99907.	1.1	24
818	Roles of PI3K/Akt and c-Jun Signaling Pathways in Human Papillomavirus Type 16 Oncoprotein-Induced HIF-1α, VEGF, and IL-8 Expression and In Vitro Angiogenesis in Non-Small Cell Lung Cancer Cells. PLoS ONE, 2014, 9, e103440.	1.1	85
819	Anti-Tumor Effect of a Novel Soluble Recombinant Human Endostatin: Administered as a Single Agent or in Combination with Chemotherapy Agents in Mouse Tumor Models. PLoS ONE, 2014, 9, e107823.	1.1	16
820	Endothelial Cells Provide a Notch-Dependent Pro-Tumoral Niche for Enhancing Breast Cancer Survival, Stemness and Pro-Metastatic Properties. PLoS ONE, 2014, 9, e112424.	1.1	68
821	Prognostic Value of Microvessel Density in Hepatocellular Carcinoma Patients: A Meta-Analysis. International Journal of Biological Markers, 2014, 29, 279-287.	0.7	13
822	Brd4 and HEXIM1: Multiple Roles in P-TEFb Regulation and Cancer. BioMed Research International, 2014, 2014, 1-11.	0.9	61

#	Article	IF	CITATIONS
823	Prognostic relevance of angiopoietin-2, fibroblast growth factor-2 and endoglin mRNA expressions in chronic lymphocytic leukemia. Neoplasma, 2014, 62, 585-592.	0.7	4
824	Understanding the Role of Notch in Osteosarcoma. Advances in Experimental Medicine and Biology, 2014, 804, 67-92.	0.8	35
825	Imaging Integrin $\hat{l}\pm v\hat{l}^23$ and NRP-1 Positive Gliomas with a Novel Fluorine-18 Labeled RGD-ATWLPPR Heterodimeric Peptide Probe. Molecular Imaging and Biology, 2014, 16, 781-792.	1.3	41
826	Correlation of antiangiogenic, antioxidant and cytotoxic activities of some Sudanese medicinal plants with phenolic and flavonoid contents. BMC Complementary and Alternative Medicine, 2014, 14, 406.	3.7	51
827	Suppression of tumor angiogenesis by targeting the protein neddylation pathway. Cell Death and Disease, 2014, 5, e1059-e1059.	2.7	64
828	FHIT Suppresses Epithelial-Mesenchymal Transition (EMT) and Metastasis in Lung Cancer through Modulation of MicroRNAs. PLoS Genetics, 2014, 10, e1004652.	1.5	56
829	Targeting Angiogenesis and Tumor Microenvironment in Metastatic Colorectal Cancer: Role of Aflibercept. Gastroenterology Research and Practice, 2014, 2014, 1-13.	0.7	44
830	Bone marrow mononuclear cell angiogenic competency is suppressed by a high-salt diet. American Journal of Physiology - Cell Physiology, 2014, 306, C123-C131.	2.1	9
831	Angiogenesis in esophageal and gastric cancer: a paradigm shift in treatment. Expert Opinion on Biological Therapy, 2014, 14, 1319-1332.	1.4	12
832	Toxic Damage Increases Angiogenesis and Metastasis in Fibrotic Livers via PECAM-1. BioMed Research International, 2014, 2014, 1-11.	0.9	17
835	Targeting chemokine pathways in esophageal adenocarcinoma. Cell Cycle, 2014, 13, 3320-3327.	1.3	26
836	Metronomic Chemotherapy. , 2014, , .		3
837	Recombinant Human Kallistatin Inhibits Angiogenesis by Blocking VEGF Signaling Pathway. Journal of Cellular Biochemistry, 2014, 115, 575-584.	1.2	17
838	Metastatic Tumors to the Jaws and Mouth. Head and Neck Pathology, 2014, 8, 463-474.	1.3	134
839	PPARδ deficiency disrupts hypoxiaâ€mediated tumorigenic potential of colon cancer cells. Molecular Carcinogenesis, 2014, 53, 926-937.	1.3	22
840	Pathophysiology of isoprostanes in the cardiovascular system: implications of isoprostaneâ€mediated thromboxane <scp>A</scp> ₂ receptor activation. British Journal of Pharmacology, 2014, 171, 3115-3131.	2.7	119
841	Imaging Biomarkers and Surrogate Endpoints in Oncology Clinical Trials. , 2014, , 29-42.		1
842	Role of nontoxigenic Clostridium novyi in solid tumor therapy. Reviews in Medical Microbiology, 2014, 25, 71-76.	0.4	7

#	Article	IF	Citations
843	Akt-Activated Endothelium Constitutes the Niche for Residual Disease and Resistance to Bevacizumab in Ovarian Cancer. Molecular Cancer Therapeutics, 2014, 13, 3123-3136.	1.9	29
844	Stem Cell Therapy and Breast Cancer Treatment: Review of Stem Cell Research and Potential Therapeutic Impact Against Cardiotoxicities Due to Breast Cancer Treatment. Frontiers in Oncology, 2014, 4, 299.	1.3	10
845	Effect of biodegradability on CXCR4 antagonism, transfection efficacy and antimetastatic activity of polymeric Plerixafor. Biomaterials, 2014, 35, 5572-5579.	5.7	48
846	Wogonin inhibits H2O2-induced angiogenesis via suppressing Pl3K/Akt/NF-κB signaling pathway. Vascular Pharmacology, 2014, 60, 110-119.	1.0	36
847	9-Hydroxypheophorbide α-mediated photodynamic therapy induces matrix metalloproteinase-2 (MMP-2) and MMP-9 down-regulation in Hep-2 cells via ROS-mediated suppression of the ERK pathway. Photodiagnosis and Photodynamic Therapy, 2014, 11, 55-62.	1.3	14
848	PKA turnover by the REGÎ ³ -proteasome modulates FoxO1 cellular activity and VEGF-induced angiogenesis. Journal of Molecular and Cellular Cardiology, 2014, 72, 28-38.	0.9	28
849	Tumor perfusionâ€related parameter of diffusionâ€weighted magnetic resonance imaging: Correlation with histological microvessel density. Magnetic Resonance in Medicine, 2014, 71, 1554-1558.	1.9	115
850	Diagnostic and prognostic significance of peroxiredoxin 1 expression in human hepatocellular carcinoma. Medical Oncology, 2014, 31, 786.	1.2	48
851	Treatment-related mortality with aflibercept in cancer patients: a meta-analysis. European Journal of Clinical Pharmacology, 2014, 70, 461-467.	0.8	11
852	Isthmin targets cell-surface GRP78 and triggers apoptosis via induction of mitochondrial dysfunction. Cell Death and Differentiation, 2014, 21, 797-810.	5.0	61
853	Multitargeted antiangiogenic tyrosine kinase inhibitors combined to chemotherapy in metastatic breast cancer: a systematic review and meta-analysis. European Journal of Clinical Pharmacology, 2014, 70, 531-538.	0.8	10
854	Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core–shell nanoparticles. Biomaterials, 2014, 35, 5028-5038.	5.7	129
855	Inflammatory Angiogenesis and the Tumor Microenvironment as Targets for Cancer Therapy and Prevention. Cancer Treatment and Research, 2014, 159, 401-426.	0.2	33
856	CXCR2â€mediated tumorâ€associated neutrophil recruitment is regulated by IFNâ€Î². International Journal of Cancer, 2014, 134, 1346-1358.	2.3	152
857	Advances in Nutrition and Cancer. Cancer Treatment and Research, 2014, , .	0.2	11
858	Vascular Endothelial Growth Factor Inhibitor-Induced Hypertension: From Pathophysiology to Prevention and Treatment Based on Long-Acting Nitric Oxide Donors. American Journal of Hypertension, 2014, 27, 3-13.	1.0	45
859	Human DNA Tumor Viruses and Oncogenesis. , 2014, , 121-137.		0
860	The single nucleotide polymorphism +936 C/T VEGF is associated with human epidermal growth factor receptor 2 expression in Moroccan breast cancer women. Medical Oncology, 2014, 31, 336.	1.2	10

#	Article	IF	CITATIONS
861	Macrophages: Biology and Role in the Pathology of Diseases. , 2014, , .		13
862	Pyridoxine-derived bicyclic amido-, ureido-, and carbamato-pyridinols: synthesis and antiangiogenic activities. Organic and Biomolecular Chemistry, 2014, 12, 8702-8710.	1.5	9
863	Understanding the Pathobiology of Head and Neck Squamous Cell Carcinoma. Current Oral Health Reports, $2014,1,196-203.$	0.5	2
864	Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups. European Journal of Clinical Pharmacology, 2014, 70, 893-906.	0.8	49
865	The â^1154 G/A VEGF gene polymorphism is associated with the incidence of basal cell carcinoma in patients from northern Poland. Archives of Dermatological Research, 2014, 306, 539-544.	1.1	4
866	The role of Chinese medicine in clinical oncology. Chinese Journal of Integrative Medicine, 2014, 20, 3-10.	0.7	19
867	The role of anti-VEGF agents in the treatment of advanced gastric cancer: a meta-analysis of randomized controlled trials. Tumor Biology, 2014, 35, 7675-7683.	0.8	10
868	Bevacizumab terminates homeobox B9-induced tumor proliferation by silencing microenvironmental communication. Molecular Cancer, 2014, 13, 102.	7.9	20
869	Integration of molecular targeted therapy with radiation in head and neck cancer., 2014, 142, 88-98.		43
870	Influence of K-ras status and anti-tumour treatments on complications due to colorectal self-expandable metallic stents: A retrospective multicentre study. Digestive and Liver Disease, 2014, 46, 561-567.	0.4	16
871	Lipid droplets may lay a spacial foundation for vasculogenic mimicry formation in hepatocellular carcinoma. Medical Hypotheses, 2014, 83, 56-59.	0.8	6
872	Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. Lancet Oncology, The, 2014, 15, 620-630.	5.1	96
873	Circulating pro―and antiâ€angiogenic mediators in patients infected with hepatitis C at different stages of hepatocellular carcinoma. Journal of Medical Virology, 2014, 86, 1120-1129.	2.5	6
874	Challenging the future of siRNA therapeutics against cancer: the crucial role of nanotechnology. Cellular and Molecular Life Sciences, 2014, 71, 1417-1438.	2.4	25
875	MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras. Neuro-Oncology, 2014, 16, 1341-1353.	0.6	120
876	Tumor Microenvironment in Head and Neck Squamous Cell Carcinoma. Seminars in Oncology, 2014, 41, 217-234.	0.8	226
877	Melanoma metastasis: new concepts and evolving paradigms. Oncogene, 2014, 33, 2413-2422.	2.6	120
878	Synergic antitumor effect of SKLB1002 and local hyperthermia in 4T1 and CT26. Clinical and Experimental Medicine, 2014, 14, 203-213.	1.9	12

#	ARTICLE	IF	Citations
879	Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene, 2014, 33, 679-689.	2.6	358
881	Anisi stellati fructus extract attenuates the in vitro and in vivo metastatic and angiogenic potential of malignant cancer cells by downregulating proteolytic activity and pro-angiogenic factors. International Journal of Oncology, 2014, 45, 1937-1948.	1.4	9
882	Suprabasin as a novel tumor endothelial cell marker. Cancer Science, 2014, 105, 1533-1540.	1.7	37
884	Correlation of Tumor-Infiltrative Lymphocyte Subtypes Alteration with Neoangiogenesis before and after Neoadjuvant Chemotherapy Treatment in Breast Cancer Patients. International Journal of Biological Markers, 2014, 29, 193-203.	0.7	6
885	Extract of Cordyceps militaris inhibits angiogenesis and suppresses tumor growth of human malignant melanoma cells. International Journal of Oncology, 2014, 45, 209-218.	1.4	31
886	Downregulation of VEGF expression attenuates malignant biological behavior of C6 glioma stem cells. International Journal of Oncology, 2014, 44, 1581-1588.	1.4	11
887	<scp>MMP</scp> s and angiogenesis affect the metastatic potential of a human vulvar leiomyosarcoma cell line. Journal of Cellular and Molecular Medicine, 2015, 19, 2098-2107.	1.6	4
888	Effect of a nutrient mixture on the localization of extracellular matrix proteins in HeLa human cervical cancer xenografts in female nude mice. Experimental and Therapeutic Medicine, 2015, 10, 901-906.	0.8	7
889	Cigarette smoke modulates PC3 prostate cancer cell migration by altering adhesion molecules and the extracellular matrix. Molecular Medicine Reports, 2015, 12, 6990-6996.	1.1	12
890	Reduction of metastatic and angiogenic potency of malignant cancer by Eupatorium fortunei via suppression of MMP-9 activity and VEGF production. Scientific Reports, 2014, 4, 6994.	1.6	41
891	Association between the expression of T-cadherin and vascular endothelial growth factor and the prognosis of patients with gastric cancer. Molecular Medicine Reports, 2015, 12, 2075-2081.	1.1	9
892	Deciphering the anti-angiogenic effect of endostatin/cyclophosphamide to normalize tumor micrangium through notch signaling pathway in colon cancer. World Journal of Surgical Oncology, 2015, 14, 10.	0.8	5
893	Activated hepatic stellate cells promote angiogenesis via interleukin-8 in hepatocellular carcinoma. Journal of Translational Medicine, 2015, 13, 365.	1.8	46
894	CXCL12–CXCR7 axis is important for tumor endothelial cell angiogenic property. International Journal of Cancer, 2015, 137, 2825-2836.	2.3	64
895	The Contribution of Angiogenesis to the Process of Metastasis. Cancer Journal (Sudbury, Mass), 2015, 21, 267-273.	1.0	377
896	Tâ€cell immunoglobulin mucinâ€3 expression in bladder urothelial carcinoma: Clinicopathologic correlations and association with survival. Journal of Surgical Oncology, 2015, 112, 430-435.	0.8	56
897	Dynamic contrast-enhanced MRI in mice: An investigation of model parameter uncertainties. Magnetic Resonance in Medicine, 2015, 73, 1979-1987.	1.9	5
898	Adventures within the speckled band: heterogeneity, angiogenesis, and balanced inflammation in the tuberculous granuloma. Immunological Reviews, 2015, 264, 276-287.	2.8	46

#	Article	IF	CITATIONS
899	In vitro and in vivo anti-angiogenic activity of girinimbine isolated from Murraya koenigii. Drug Design, Development and Therapy, 2015, 9, 1281.	2.0	11
900	Increased risk of severe infections in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis. OncoTargets and Therapy, 2015, 8, 2361.	1.0	3
901	Overexpression of Trps1 contributes to tumor angiogenesis and poor prognosis of human osteosarcoma. Diagnostic Pathology, 2015, 10, 167.	0.9	20
902	Prognostic Value of Serum IL-17 and VEGF Levels in Small Cell Lung Cancer. International Journal of Biological Markers, 2015, 30, 359-363.	0.7	22
903	The Differential Expression of OCT4 Isoforms in Cervical Carcinoma. PLoS ONE, 2015, 10, e0118033.	1.1	41
904	Geraniol Suppresses Angiogenesis by Downregulating Vascular Endothelial Growth Factor (VEGF)/VEGFR-2 Signaling. PLoS ONE, 2015, 10, e0131946.	1.1	41
905	RGD-modified liposomes enhance efficiency of aclacinomycin A delivery: evaluation of their effect in lung cancer. Drug Design, Development and Therapy, 2015, 9, 4613.	2.0	6
906	A Hypothesis Concerning the Biphasic Dose-response of Tumors to Angiostatin and Endostatin. Dose-Response, 2015, 13, dose-response.1.	0.7	5
907	Gene Therapy with Endogenous Inhibitors of Angiogenesis for Neovascular Age-Related Macular Degeneration: Beyond Anti-VEGF Therapy. Journal of Ophthalmology, 2015, 2015, 1-12.	0.6	16
908	Indirubin and Indirubin Derivatives for Counteracting Proliferative Diseases. Evidence-based Complementary and Alternative Medicine, 2015, 2015, 1-12.	0.5	52
909	Lymphadenectomy promotes tumor growth and cancer cell dissemination in the spontaneous RET mouse model of human uveal melanoma. Oncotarget, 2015, 6, 44806-44818.	0.8	3
910	Ursolic acid benzaldehyde chalcone leads to inhibition of cell proliferation and arrests cycle in G1/G0 phase in ovarian cancer. Bangladesh Journal of Pharmacology, 2015, 10, 358.	0.1	0
911	The broad-spectrum anti-DNA virus agent cidofovir inhibits lung metastasis of virus-independent, FGF2-driven tumors. Oncotarget, 2015, 6, 4633-4648.	0.8	10
912	Pancreatic cancer stromal biology and therapy. Genes and Diseases, 2015, 2, 133-143.	1.5	110
913	Linifanib: current status and future potential in cancer therapy. Expert Review of Anticancer Therapy, 2015, 15, 677-687.	1.1	21
914	Physical supports from liver cancer cells are essential for differentiation and remodeling of endothelial cells in a HepG2-HUVEC co-culture model. Scientific Reports, 2015, 5, 10801.	1.6	38
915	Polymorphisms and Plasma Levels of Tissue Inhibitor of Metalloproteinase-3. Medicine (United States), 2015, 94, e2092.	0.4	31
916	Angiogenesis modulation by Plectranthus amboinicus leaf extract and its fractions on chorioallantoic membrane and tumor induced angiogenesis. Oriental Pharmacy and Experimental Medicine, 2015, 15, 257-276.	1.2	1

#	Article	IF	Citations
917	Imaging of the dispersion coefficient of Ultrasound contrast agents by Wiener system identification for prostate cancer localization. , 2015, , .		2
918	Study of prognostic significance of marrow angiogenesis assessment in patients with de novo acute leukemia. Hematology, 2015, 20, 504-510.	0.7	7
919	CecropinXJ inhibits the proliferation of human gastric cancer BGC823 cells and induces cell death in vitro and in vivo. International Journal of Oncology, 2015, 46, 2181-2193.	1.4	20
920	Modulation of uPA, MMPs and their inhibitors by a novel nutrient mixture in human colorectal, pancreatic and hepatic carcinoma cell lines. International Journal of Oncology, 2015, 47, 370-376.	1.4	11
921	Widdrol, a sesquiterpene isolated from Juniperus chinensis, inhibits angiogenesis by targeting vascular endothelial growth factor receptor 2 signaling. Oncology Reports, 2015, 34, 1178-1184.	1.2	10
922	Identification of immediate early response protein 2 as a regulator of angiogenesis through the modulation of endothelial cell motility and adhesion. International Journal of Molecular Medicine, 2015, 36, 1104-1110.	1.8	15
923	Dopamine is a safe antiangiogenic drug which can also prevent 5-fluorouracil induced neutropenia. International Journal of Cancer, 2015, 137, 744-749.	2.3	37
924	Angiogenesis in diabetes and obesity. Reviews in Endocrine and Metabolic Disorders, 2015, 16, 67-75.	2.6	91
925	The lymph node microenvironment and its role in the progression of metastatic cancer. Seminars in Cell and Developmental Biology, 2015, 38, 98-105.	2.3	140
926	Expression and clinical value of peroxiredoxin-1 in patients with pancreatic cancer. European Journal of Surgical Oncology, 2015, 41, 228-235.	0.5	42
928	Comparison study of in vivo dose response to laser-driven versus conventional electron beam. Radiation and Environmental Biophysics, 2015, 54, 155-166.	0.6	27
929	Pharmacokinetics of neamine in rats and anti-cervical cancer activity in vitro and in vivo. Cancer Chemotherapy and Pharmacology, 2015, 75, 465-474.	1.1	6
930	Dynamic contrast-enhanced (DCE) MRI assessment of microvascular characteristics in the murine orthotopic pancreatic cancer model. Magnetic Resonance Imaging, 2015, 33, 737-760.	1.0	12
931	Quantitative Contrast-Enhanced Ultrasonic Imaging Reflects Microvascularization in Hepatocellular Carcinoma and Prognosis after Resection. Ultrasound in Medicine and Biology, 2015, 41, 2621-2630.	0.7	7
932	Amniotic Membrane., 2015,,.		14
933	Bevacizumab increases the risk of infections in cancer patients: A systematic review and pooled analysis of 41 randomized controlled trials. Critical Reviews in Oncology/Hematology, 2015, 94, 323-336.	2.0	24
934	Famitinib enhances nasopharyngeal cancer cell radiosensitivity by attenuating radiation-induced phosphorylation of platelet-derived growth factor receptor and c-kit and inhibiting microvessel formation. International Journal of Radiation Biology, 2015, 91, 771-776.	1.0	9
935	Upregulation of Nuclear Heat Shock Factor 1ÂContributes to Tumor Angiogenesis and PoorÂSurvival in Patients With Non–Small CellÂLung Cancer. Annals of Thoracic Surgery, 2015, 100, 465-472.	0.7	20

#	Article	IF	Citations
936	Hypoxia-induced expression of phosducin-like 3 regulates expression of VEGFR-2 and promotes angiogenesis. Angiogenesis, 2015, 18, 449-462.	3.7	42
937	Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate <i>VEGFR2</i> in breast cancer cells. Genes and Development, 2015, 29, 1298-1315.	2.7	115
938	The cholesterol biosynthesis enzyme oxidosqualene cyclase is a new target to impair tumour angiogenesis and metastasis dissemination. Scientific Reports, 2015, 5, 9054.	1.6	56
939	Angiogenesis in Breast Cancer and its Correlation with Estrogen, Progesterone Receptors and other Prognostic Factors. Journal of Clinical and Diagnostic Research JCDR, 2015, 9, EC05-7.	0.8	12
940	Antineoplastic impact of leishmanial sphingolipid in tumour growth with regulation of angiogenic event and inflammatory response. Apoptosis: an International Journal on Programmed Cell Death, 2015, 20, 869-882.	2.2	7
941	cRGDyK-modified camretastain A4-loaded graphene oxide nanosheets for targeted anticancer drug delivery. RSC Advances, 2015, 5, 40258-40268.	1.7	5
942	Breast cancer cells promote a notch-dependent mesenchymal phenotype in endothelial cells participating to a pro-tumoral niche. Journal of Translational Medicine, 2015, 13, 27.	1.8	43
943	Anti-inflammatory, antiangiogenic, and apoptosis-inducing activity of DLBS1442, a bioactive fraction of Phaleria macrocarpa, in a RL95-2 cell line as a molecular model of endometriosis. International Journal of Women's Health, 2015, 7, 161.	1.1	19
944	Angiogenesis in glaucoma filtration surgery and neovascular glaucoma: A review. Survey of Ophthalmology, 2015, 60, 524-535.	1.7	48
945	AECHL-1, a novel triterpenoid, targets tumor neo-vasculature and impairs the endothelial cell cytoskeleton. Angiogenesis, 2015, 18, 283-299.	3.7	15
946	Activation of the mTOR signaling pathway in breast cancer MCF-7 cells by a peptide derived from Porphyra yezoensis. Oncology Reports, 2015, 33, 19-24.	1.2	34
947	High-calorie diet exacerbates prostate neoplasia in mice with haploinsufficiency of Pten tumor suppressor gene. Molecular Metabolism, 2015, 4, 186-198.	3.0	14
948	Anti-VEGF Molecular Targeted Therapies in Common Solid Malignancies: Comprehensive Update for Radiologists. Radiographics, 2015, 35, 455-474.	1.4	34
949	Incidence and risk of xerosis with targeted anticancer therapies. Journal of the American Academy of Dermatology, 2015, 72, 656-667.	0.6	39
950	Proteomic analysis of exosomes from nasopharyngeal carcinoma cell identifies intercellular transfer of angiogenic proteins. International Journal of Cancer, 2015, 137, 1830-1841.	2.3	84
951	The human Nox4: gene, structure, physiological function and pathological significance. Journal of Drug Targeting, 2015, 23, 888-896.	2.1	81
952	Expression of miR-200c in claudin-low breast cancer alters stem cell functionality, enhances chemosensitivity and reduces metastatic potential. Oncogene, 2015, 34, 5997-6006.	2.6	100
953	Evaluation of Tc-99Âm Labeled Dimeric GX1 Peptides for Imaging of Colorectal Cancer Vasculature. Molecular Imaging and Biology, 2015, 17, 661-670.	1.3	14

#	Article	IF	CITATIONS
954	Neutrophils: important contributors to tumor progression and metastasis. Cancer and Metastasis Reviews, 2015, 34, 735-751.	2.7	185
955	URG4/URGCP enhances the angiogenic capacity of human hepatocellular carcinoma cells in vitro via activation of the NF-κB signaling pathway. BMC Cancer, 2015, 15, 368.	1.1	17
956	Design of optimal light delivery system for co-registered transvaginal ultrasound and photoacoustic imaging of ovarian tissue. Photoacoustics, 2015, 3, 114-122.	4.4	32
957	Glioma Angiogenesis and Perfusion Imaging: Understanding the Relationship between Tumor Blood Volume and Leakiness with Increasing Glioma Grade. American Journal of Neuroradiology, 2015, 36, 2030-2035.	1.2	36
958	Synergistic antitumor efficacy of combined DNA vaccines targeting tumor cells and angiogenesis. Biochemical and Biophysical Research Communications, 2015, 465, 239-244.	1.0	26
959	Intraâ€epithelially entrapped blood vessels in ameloblastoma. Journal of Oral Pathology and Medicine, 2015, 44, 378-385.	1.4	4
960	Biodistribution of the 18F-FPPRGD2 PET radiopharmaceutical in cancer patients: an atlas of SUV measurements. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1850-1858.	3.3	43
961	Obesity and cancer phenotype: Is angiogenesis a missed link?. Life Sciences, 2015, 139, 16-23.	2.0	13
962	Amniotic Membrane in Cancer., 2015, , 139-152.		2
963	Peril in perishing pericytes. Journal of the National Cancer Institute, 2015, 107, djv254.	3.0	1
964	Mechanisms of Cancer Cell Dormancyâ€"Another Hallmark of Cancer?. Cancer Research, 2015, 75, 5014-5022.	0.4	168
965	Endostatin's emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications. Biochimica Et Biophysica Acta - General Subjects, 2015, 1850, 2422-2438.	1.1	133
966	Height and drinking status in relation to risk of anemia in rural adult healthy Japanese men: the Nagasaki Islands study. Aging Male, 2015, 18, 100-105.	0.9	14
967	A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors. Annals of Oncology, 2015, 26, 2341-2346.	0.6	30
968	Fas/FasL Complex Promotes Proliferation and Migration of Brain Endothelial Cells Via FADD–FLIP–TRAF–NF-κB Pathway. Cell Biochemistry and Biophysics, 2015, 71, 1319-1323.	0.9	13
969	Synergy of bone marrow transplantation and curcumin ensue protective effects at early onset of diabetes in mice 在早期å•病的糖尿病å°é¼ä¸ä½¿ç"¨éª¨é«"ç§»ææŒŒå§œé»"ç´è¾å•æ²»ç——å·æœ	:‰aäŒä¿e	æŠ a ½œç"".]
970	The zebrafish/tumor xenograft angiogenesis assay as a tool for screening anti-angiogenic miRNAs. Cytotechnology, 2015, 67, 969-975.	0.7	26
971	Hypoxia and angiogenesis: from primary tumor to bone metastasis. , 2015, , 177-189.		1

#	Article	IF	Citations
972	Phase II Study Evaluating the Effect of Concomitant Ramucirumab on the Pharmacokinetics of Docetaxel in Patients with Advanced Solid Tumors. Clinical Pharmacology & Biopharmaceutics, 2016, 5, \cdot	0.2	1
973	Angiogenesis and Antiangiogenesis Therapies: Spear and Shield of Pharmacotherapy. Journal of Pharmaceutical Care $\&$ Health Systems, 2016, 1 , .	0.1	0
974	Risk of adverse events with bevacizumab addition to therapy in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. OncoTargets and Therapy, 2016, 9, 2421.	1.0	13
975	Insights into the therapeutic potential of hypoxia-inducible factor-1α small interfering RNA in malignant melanoma delivered via folate-decorated cationic liposomes. International Journal of Nanomedicine, 2016, 11, 991.	3.3	21
976	Helicobacter pylori-infected MSCs acquire a pro-inflammatory phenotype and induce human gastric cancer migration by promoting EMT in gastric cancer cells. Oncology Letters, 2016, 11, 449-457.	0.8	12
977	Cancer cell CCL5 mediates bone marrow independent angiogenesis in breast cancer. Oncotarget, 2016, 7, 85437-85449.	0.8	26
978	Expression and prognostic significance of contactin 1 in human hepatocellular carcinoma. OncoTargets and Therapy, 2016, 9, 387.	1.0	18
979	Tubeimoside-1 suppresses tumor angiogenesis by stimulation of proteasomal VEGFR2 and Tie2 degradation in a non-small cell lung cancer xenograft model. Oncotarget, 2016, 7, 5258-5272.	0.8	37
980	Targeting angiogenesis in gastrointestinal tumors: current challenges. Translational Gastroenterology and Hepatology, 2016, 1, 67-67.	1.5	15
981	An Aqueous Extract of Marine Microalgae Exhibits Antimetastatic Activity through Preferential Killing of Suspended Cancer Cells and Anticolony Forming Activity. Evidence-based Complementary and Alternative Medicine, 2016, 2016, 1-8.	0.5	23
982	Appraisals of Bangladeshi Medicinal Plants Used by Folk Medicine Practitioners in the Prevention and Management of Malignant Neoplastic Diseases. International Scholarly Research Notices, 2016, 2016, 1-12.	0.9	12
983	Growth Hormone-Releasing Hormone and Its Analogues: Significance for MSCs-Mediated Angiogenesis. Stem Cells International, 2016, 2016, 1-12.	1.2	16
984	Biomarkers Discovery for Colorectal Cancer: A Review on Tumor Endothelial Markers as Perspective Candidates. Disease Markers, 2016, 2016, 1-11.	0.6	29
985	Risk of venous and arterial thromboembolic events associated with anti-VEGF agents in advanced non-small-cell lung cancer: a meta-analysis and systematic review. OncoTargets and Therapy, 2016, 9, 3695.	1.0	12
986	7 Perfusion imagingperfusion computed tomography (PCT)Perfusion computed tomography (PCT)overviews of Perfusion computed tomography (PCT)Perfusion Imaging: Perfusion CT., 2016,,.		0
987	Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients. Oncotarget, 2016, 7, 67661-67673.	0.8	43
988	A potent immunotoxin targeting fibroblast activation protein for treatment of breast cancer in mice. International Journal of Cancer, 2016, 138, 1013-1023.	2.3	91
989	Noncoding RNAs in Tumor Angiogenesis. Advances in Experimental Medicine and Biology, 2016, 927, 217-241.	0.8	33

#	Article	IF	CITATIONS
990	Sunitinib treatment reduces tumor growth and limits changes in microvascular properties after minor surgical intervention in an in vivo model of secondary breast cancer growth in bone. Journal of Surgical Oncology, 2016, 113, 515-521.	0.8	9
991	Sublingual Buprenorphine-Induced Psychomimetic Effects. American Journal of Therapeutics, 2016, 23, e242-e243.	0.5	6
992	Sigmoid Colon Perforation Related to Bevacizumab in a Patient With Glioblastoma. American Journal of Therapeutics, 2016, 23, e241-e242.	0.5	2
993	The Long and Short Non-coding RNAs in Cancer Biology. Advances in Experimental Medicine and Biology, 2016, , .	0.8	4
994	Resistance to Targeted Therapies Against Adult Brain Cancers. Resistance To Targeted Anti-cancer Therapeutics, 2016, , .	0.1	4
995	Impact of single-nucleotide polymorphisms on radiation pneumonitis in cancer patients. Molecular and Clinical Oncology, 2016, 4, 3-10.	0.4	17
996	Antiangiogenic and antihepatocellular carcinoma activities of the Juniperus chinensis extract. BMC Complementary and Alternative Medicine, 2016, 16, 277.	3.7	7
997	Tumour endothelial cells in high metastatic tumours promote metastasis via epigenetic dysregulation of biglycan. Scientific Reports, 2016, 6, 28039.	1.6	112
998	Targeting cellular and molecular drivers of head and neck squamous cell carcinoma: current options and emerging perspectives. Cancer and Metastasis Reviews, 2016, 35, 413-426.	2.7	44
999	BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2016, 17, 461-465.	1.1	37
1000	Effect of recombinant human endostatin onradiotherapy for esophagus cancer. Asian Pacific Journal of Tropical Medicine, 2016, 9, 86-90.	0.4	9
1001	Improvement and evaluation of a low-cost laser diode photoacoustic microscopy system for ovarian tissue imaging. , 2016, , .		2
1002	Review: the Contribution of both Nature and Nurture to Carcinogenesis and Progression in Solid Tumours. Cancer Microenvironment, 2016, 9, 63-69.	3.1	25
1003	Influence of Exposure to Chronic Persistent Low-Dose Ionizing Radiation on the Tumor Biology of Clear-Cell Renal-Cell Carcinoma. An Immunohistochemical and Morphometric Study of Angiogenesis and Vascular Related Factors. Pathology and Oncology Research, 2016, 22, 807-815.	0.9	5
1004	The anti-angiogenic effect of dexamethasone in a murine hepatocellular carcinoma model by augmentation of gluconeogenesis pathway in malignant cells. Cancer Chemotherapy and Pharmacology, 2016, 77, 1087-1096.	1.1	20
1005	5-Hydroxy-7-azaindolin-2-one, a novel hybrid of pyridinol and sunitinib: design, synthesis and cytotoxicity against cancer cells. Organic and Biomolecular Chemistry, 2016, 14, 4829-4841.	1.5	26
1006	Neuronavigation-assisted trajectory planning for deep brain biopsy with susceptibility-weighted imaging. Acta Neurochirurgica, 2016, 158, 1355-1362.	0.9	9
1007	Overexpression of CXCR7 induces angiogenic capacity of human hepatocellular carcinoma cells via the AKT signaling pathway. Oncology Reports, 2016, 36, 2275-2281.	1.2	21

#	ARTICLE	IF	Citations
1008	Incidence and risk of severe infections associated with aflibercept in cancer patients: a systematic review and metaâ€analysis. British Journal of Clinical Pharmacology, 2016, 81, 33-40.	1.1	15
1009	Lack of pharmacokinetic drug–drug interaction between ramucirumab and irinotecan in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2016, 78, 727-733.	1.1	2
1010	Targeted Therapy of Colorectal Cancer. Oncology Research and Treatment, 2016, 39, 796-802.	0.8	38
1011	Tumor endothelial cells express high pentraxin 3 levels. Pathology International, 2016, 66, 687-694.	0.6	11
1012	Tumor Growth Suppression Induced by Biomimetic Silk Fibroin Hydrogels. Scientific Reports, 2016, 6, 31037.	1.6	62
1013	Synthesis and Characterization of Injectable Sulfonate-Containing Hydrogels. Biomacromolecules, 2016, 17, 4064-4074.	2.6	20
1014	Ethanol extract of Lophatheri Herba exhibits anti-cancer activity in human cancer cells by suppression of metastatic and angiogenic potential. Scientific Reports, 2016, 6, 36277.	1.6	18
1015	Dual-functionalized liposomal delivery system for solid tumors based on RGD and a pH-responsive antimicrobial peptide. Scientific Reports, 2016, 6, 19800.	1.6	45
1016	Increased risk of hemorrhage in metastatic colorectal cancer patients treated with bevacizumab. Medicine (United States), 2016, 95, e4232.	0.4	16
1017	Targeting Angiogenesis in Colorectal Cancer. Cancer Journal (Sudbury, Mass), 2016, 22, 182-189.	1.0	29
1018	Adverse events risk associated with anti-VEGFR agents in the treatment of advanced nonsmall-cell lung cancer. Medicine (United States), 2016, 95, e3752.	0.4	7
1019	Modifying the tumor microenvironment using nanoparticle therapeutics. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2016, 8, 891-908.	3.3	30
1020	Utilizing Zebrafish to Identify Antiâ€(Lymph)Angiogenic Compounds for Cancer Treatment: Promise and Future Challenges. Microcirculation, 2016, 23, 389-405.	1.0	11
1021	EphA1 activation promotes the homing of endothelial progenitor cells to hepatocellular carcinoma for tumor neovascularization through the SDF-1/CXCR4 signaling pathway. Journal of Experimental and Clinical Cancer Research, 2016, 35, 65.	3.5	23
1022	Activation of multiple angiogenic signaling pathways in hemangiopericytoma. Brain Tumor Pathology, 2016, 33, 200-208.	1.1	6
1023	Platycodin D inhibits B16F10 melanoma metastasis via antiangiogenic activity. RSC Advances, 2016, 6, 10606-10614.	1.7	8
1024	Interactive role of miR-126 on VEGF-A and progression of papillary and undifferentiated thyroid carcinoma. Human Pathology, 2016, 51, 75-85.	1.1	34
1025	Combining dynamic contrast enhanced magnetic resonance imaging and microvessel density to assess the angiogenesis after PEI in a rabbit VX2 liver tumor model. Magnetic Resonance Imaging, 2016, 34, 177-182.	1.0	17

#	Article	IF	Citations
1026	Angiogenesis in melanoma: an update with a focus on current targeted therapies. Journal of Clinical Pathology, 2016, 69, 472-483.	1.0	55
1027	Tumor angiogenesisâ€"characteristics of tumor endothelial cells. International Journal of Clinical Oncology, 2016, 21, 206-212.	1.0	119
1028	The Mechanism of Adaptation of Breast Cancer Cells to Hypoxia: Role of AMPK/mTOR Signaling Pathway. Bulletin of Experimental Biology and Medicine, 2016, 160, 555-559.	0.3	5
1029	Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review. Seminars in Immunopathology, 2016, 38, 167-183.	2.8	96
1030	Pilot prospective evaluation of 18F-FPPRGD2 PET/CT in patients with cervical and ovarian cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1047-1055.	3.3	25
1031	Realistic biological approaches for improving thermoradiotherapy. International Journal of Hyperthermia, 2016, 32, 14-22.	1.1	10
1032	Heterogeneity of tumor endothelial cells and drug delivery. Advanced Drug Delivery Reviews, 2016, 99, 140-147.	6.6	88
1033	Molecular and Cellular Biology. , 2016, , 41-50.e2.		1
1034	Drug delivery approaches for the treatment of glioblastoma multiforme. Artificial Cells, Nanomedicine and Biotechnology, 2016, 44, 1365-1373.	1.9	36
1035	WISP-1 positively regulates angiogenesis by controlling VEGF-A expression in human osteosarcoma. Cell Death and Disease, 2017, 8, e2750-e2750.	2.7	60
1036	Overexpressed HSPA2 correlates with tumor angiogenesis and unfavorable prognosis in pancreatic carcinoma. Pancreatology, 2017, 17, 457-463.	0.5	23
1037	Predicting breast cancer response to neoadjuvant chemotherapy using pretreatment diffuse optical spectroscopic texture analysis. British Journal of Cancer, 2017, 116, 1329-1339.	2.9	35
1038	Tumor Dormancy and Relapse: From a Natural Byproduct of Evolution to a Disease State. Cancer Research, 2017, 77, 2564-2569.	0.4	87
1039	The CNGRCLLII(KLAKLAK)2 peptide shows cytotoxicity against HUVECs by inducing apoptosis: An in vitro and in vivo study. Tumor Biology, 2017, 39, 101042831770164.	0.8	0
1040	Correlation Between Microvessel Density and Morphological Features in Skin Squamous Cell Carcinoma. Prilozi - Makedonska Akademija Na Naukite I Umetnostite Oddelenie Za Medicinski Nauki, 2017, 38, 63-73.	0.2	2
1041	The effect of RCAN1 on the biological behaviors of small cell lung cancer. Tumor Biology, 2017, 39, 101042831770040.	0.8	14
1042	The inhibitory effect of anti-tumor polysaccharide from Punica granatum on metastasis. International Journal of Biological Macromolecules, 2017, 103, 1000-1010.	3.6	44
1043	Natural Compounds Are Smart Players in Context to Anticancer Potential of Receptor Tyrosine Kinases: An In Silico and In Vitro Advancement. Translational Medicine Research, 2017, , 177-202.	0.0	1

#	Article	IF	CITATIONS
1044	Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape. Journal of Neuro-Oncology, 2017, 134, 495-504.	1.4	160
1046	MicroRNA-377 suppresses initiation and progression of esophageal cancer by inhibiting CD133 and VEGF. Oncogene, 2017, 36, 3986-4000.	2.6	118
1047	Pericytes, an overlooked player in vascular pathobiology. , 2017, 171, 30-42.		165
1049	Integrin-Targeted Hybrid Fluorescence Molecular Tomography/X-ray Computed Tomography for Imaging Tumor Progression and Early Response in Non-Small Cell Lung Cancer. Neoplasia, 2017, 19, 8-16.	2.3	17
1050	The Function and Diagnostic Potential of Adipocyte-Derived Factors in the Tumor Microenvironment. , 2017, , 129-166.		0
1051	Vitamins and regulation of angiogenesis: [A, B1, B2, B3, B6, B9, B12, C, D, E, K]. Journal of Functional Foods, 2017, 38, 180-196.	1.6	22
1052	Human neutrophil elastase mediates fibrinolysis shutdown through competitive degradation of plasminogen and generation of angiostatin. Journal of Trauma and Acute Care Surgery, 2017, 83, 1053-1061.	1.1	24
1053	Spermatogenesis. , 2017, , 135-160.		0
1054	Modeling angiogenesis with micro- and nanotechnology. Lab on A Chip, 2017, 17, 4186-4219.	3.1	32
1055	Oligo-Fucoidan prevents IL-6 and CCL2 production and cooperates with p53 to suppress ATM signaling and tumor progression. Scientific Reports, 2017, 7, 11864.	1.6	32
1056	CLEC14a-HSP70-1A interaction regulates HSP70-1A-induced angiogenesis. Scientific Reports, 2017, 7, 10666.	1.6	20
1057	Increased PD-L1 expression and IL-6 secretion characterize human lung tumor-derived perivascular-like cells that promote vascular leakage in a perfusable microvasculature model. Scientific Reports, 2017, 7, 10636.	1.6	35
1058	HS-1793, a resveratrol analogue, downregulates the expression of hypoxia-induced HIF-1 and VEGF and inhibits tumor growth of human breast cancer cells in a nude mouse xenograft model. International Journal of Oncology, 2017, 51, 715-723.	1.4	33
1059	Comprehensive in situ co-detection of aneuploid circulating endothelial and tumor cells. Scientific Reports, 2017, 7, 9789.	1.6	59
1060	MCPIP1 Downregulation in Clear Cell Renal Cell Carcinoma Promotes Vascularization and Metastatic Progression. Cancer Research, 2017, 77, 4905-4920.	0.4	60
1061	Vessel-Targeted Chemophototherapy with Cationic Porphyrin-Phospholipid Liposomes. Molecular Cancer Therapeutics, 2017, 16, 2452-2461.	1.9	35
1062	Early prediction of tumor response to bevacizumab treatment in murine colon cancer models using three-dimensional dynamic contrast-enhanced ultrasound imaging. Angiogenesis, 2017, 20, 547-555.	3.7	26
1063	Fatigue associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis. International Journal of Clinical Oncology, 2017, 22, 807-816.	1.0	3

#	Article	IF	CITATIONS
1064	Serum sonic hedgehog (SHH) and interleukin-(IL-6) as dual prognostic biomarkers in progressive metastatic breast cancer. Scientific Reports, 2017, 7, 1796.	1.6	51
1065	Risk of venous and arterial thromboembolic events associated with VEGFR-TKIs: a meta-analysis. Cancer Chemotherapy and Pharmacology, 2017, 80, 487-495.	1.1	21
1066	STAT1 gene deficient mice develop accelerated breast cancer growth and metastasis which is reduced by IL-17 blockade. Oncolmmunology, 2017, 6, e1361088.	2.1	30
1067	Toosendanin demonstrates promising antitumor efficacy in osteosarcoma by targeting STAT3. Oncogene, 2017, 36, 6627-6639.	2.6	93
1068	Antitumoral effects of \hat{I}^3 CdcPLI, a PLA2 inhibitor from Crotalus durissus collilineatus via PI3K/Akt pathway on MDA-MB-231 breast cancer cell. Scientific Reports, 2017, 7, 7077.	1.6	17
1069	Mechanisms that drive inflammatory tumor microenvironment, tumor heterogeneity, and metastatic progression. Seminars in Cancer Biology, 2017, 47, 185-195.	4.3	114
1070	Radiolabeled Anti-Adenosine Triphosphate Synthase Monoclonal Antibody as a Theragnostic Agent Targeting Angiogenesis. Molecular Imaging, 2017, 16, 153601211773739.	0.7	6
1072	Oral Cancer Stem Cells Microenvironment. Advances in Experimental Medicine and Biology, 2017, 1041, 207-233.	0.8	11
1073	A Contrastâ€Enhanced Ultrasonographic Study About the Impact of Longâ€term Exercise Training on Mammary Tumor Vascularization. Journal of Ultrasound in Medicine, 2017, 36, 2459-2466.	0.8	6
1074	Targeted Disruption of JCAD (Junctional Protein Associated With Coronary Artery Disease)/KIAA1462, a Coronary Artery Disease–Associated Gene Product, Inhibits Angiogenic Processes In Vitro and In Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1667-1673.	1.1	25
1075	Cancer cells increase endothelial cell tube formation and survival by activating the PI3K/Akt signalling pathway. Journal of Experimental and Clinical Cancer Research, 2017, 36, 27.	3.5	101
1076	Entropy of Ultrasound-Contrast-Agent Velocity Fields for Angiogenesis Imaging in Prostate Cancer. IEEE Transactions on Medical Imaging, 2017, 36, 826-837.	5.4	26
1078	Predictive factors of renal toxicities related to anti-VEGFR multikinase inhibitors in phase 1 trials. Investigational New Drugs, 2017, 35, 79-86.	1.2	3
1079	A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas. Annals of Oncology, 2017, 28, 121-127.	0.6	24
1080	Ultrasound-contrast-agent dispersion and velocity imaging for prostate cancer localization. Medical Image Analysis, 2017, 35, 610-619.	7.0	45
1081	Cupressus sempervirens extract inhibited human basal cell carcinoma tumorigenesis, local invasion, and angiogenic property. Comparative Clinical Pathology, 2017, 26, 203-211.	0.3	7
1082	Anesthetic technique and cancer recurrence in oncologic surgery: unraveling the puzzle. Cancer and Metastasis Reviews, 2017, 36, 159-177.	2.7	103
1083	Informatics for cancer immunotherapy. Annals of Oncology, 2017, 28, xii56-xii73.	0.6	19

#	Article	IF	CITATIONS
1084	The Role of E-Cadherin/ \hat{l}^2 -Catenin in Hydroxysafflor Yellow A Inhibiting Adhesion, Invasion, Migration and Lung Metastasis of Hepatoma Cells. Biological and Pharmaceutical Bulletin, 2017, 40, 1706-1715.	0.6	18
1085	New Treatment Modalities for Neovascular Age-Related Macular Degeneration. Asia-Pacific Journal of Ophthalmology, 2017, 6, 514-519.	1.3	23
1086	Targeting Membrane Lipid a Potential Cancer Cure?. Frontiers in Pharmacology, 2017, 8, 12.	1.6	91
1087	CD155 expression and its correlation with clinicopathologic characteristics, angiogenesis, and prognosis in human cholangiocarcinoma. OncoTargets and Therapy, 2017, Volume 10, 3817-3825.	1.0	56
1088	Loss of Complement Factor H in Plasma Increases Endothelial Cell Migration. Journal of Cancer, 2017, 8, 2184-2190.	1.2	12
1089	Differential effects of sulforaphane in regulation of angiogenesis in a co-culture model of endothelial cells and pericytes. Oncology Reports, 2017, 37, 2905-2912.	1.2	8
1090	Luminescent/magnetic PLGA-based hybrid nanocomposites: a smart nanocarrier system for targeted codelivery and dual-modality imaging in cancer theranostics. International Journal of Nanomedicine, 2017, Volume 12, 4299-4322.	3.3	50
1091	Alginate hydrogels allow for bioactive and sustained release of VEGF-C and VEGF-D for lymphangiogenic therapeutic applications. PLoS ONE, 2017, 12, e0181484.	1.1	46
1092	Role of Nitric Oxide in Cancer Stem Cell Regulation and Metastasis. , 2017, , 179-189.		0
1093	Computational investigation of sphingosine kinase 1 (SphK1) and calcium dependent ERK1/2 activation downstream of VEGFR2 in endothelial cells. PLoS Computational Biology, 2017, 13, e1005332.	1.5	26
1094	Prognostic utility of differential tissue characterization of cardiac neoplasm and thrombus via late gadolinium enhancement cardiovascular magnetic resonance among patients with advanced systemic cancer. Journal of Cardiovascular Magnetic Resonance, 2016, 19, 76.	1.6	22
1095	The small vesicular culprits: the investigation of extracellular vesicles as new targets for cancer treatment. Clinical and Translational Medicine, 2017, 6, 45.	1.7	29
1096	Sema3A drastically suppresses tumor growth in oral cancer Xenograft model of mice. BMC Pharmacology & Samp; Toxicology, 2017, 18, 55.	1.0	18
1097	In vivo antitumor potential of extracts from different parts of Bauhinia variegata linn. Against b16f10 melanoma tumour model in c57bl/6 mice. Applied Cancer Research, 2017, 37, .	1.0	13
1098	Glioma stem cells-derived exosomes promote the angiogenic ability of endothelial cells through miR-21/VEGF signal. Oncotarget, 2017, 8, 36137-36148.	0.8	137
1099	Efficacy and safety of angiogenesis inhibitors in small-cell lung cancer. Oncotarget, 2017, 8, 1141-1155.	0.8	11
1100	Survivin expression, HPV positivity and microvessel density in oropharyngeal carcinomas and relationship with survival time. Archives of Medical Science, 2017, 6, 1467-1473.	0.4	7
1101	Immunohistochemical expression of pericytes and myofibroblasts in the extracellular matrix of oral actinic cheilitis and squamous cell carcinoma: a comparative study. Revista Odonto Ciencia, 2017, 32, 28.	0.0	0

#	Article	IF	CITATIONS
1102	Pituitary adenylate cyclase-activating polypeptide ameliorates vascular dysfunction induced by hyperglycaemia. Diabetes and Vascular Disease Research, 2018, 15, 277-285.	0.9	10
1103	Activation of <scp>AMPK</scp> by simvastatin inhibited breast tumor angiogenesis via impeding <scp>HIF</scp> â€iαâ€induced proâ€angiogenic factor. Cancer Science, 2018, 109, 1627-1637.	1.7	46
1104	Doxorubicin-DNA adduct entrenched and motif tethered artificial virus encased in pH-responsive polypeptide complex for targeted cancer therapy. Materials Science and Engineering C, 2018, 89, 387-400.	3.8	12
1105	Nanotherapeutic approaches targeting angiogenesis and immune dysfunction in tumor microenvironment. Science China Life Sciences, 2018, 61, 380-391.	2.3	15
1106	The role of bevacizumab on tumour angiogenesis and in the management of gynaecological cancers: A review. Biomedicine and Pharmacotherapy, 2018, 102, 1127-1144.	2.5	42
1107	MicroRNA-101 inhibits angiogenesis via COX-2 in endometrial carcinoma. Molecular and Cellular Biochemistry, 2018, 448, 61-69.	1.4	38
1108	LYG-202 inhibits activation of endothelial cells and angiogenesis through CXCL12/CXCR7 pathway in breast cancer. Carcinogenesis, 2018, 39, 588-600.	1.3	33
1109	Suppression of Metastasis by Primary Tumor and Acceleration of Metastasis Following Primary Tumor Resection: A Natural Law?. Bulletin of Mathematical Biology, 2018, 80, 519-539.	0.9	24
1110	LTBP3 promotes early metastatic events during cancer cell dissemination. Oncogene, 2018, 37, 1815-1829.	2.6	17
1111	\hat{l}^2 1,4-Galactosyltransferase V activates Notch1 signaling in glioma stem-like cells and promotes their transdifferentiation into endothelial cells. Journal of Biological Chemistry, 2018, 293, 2219-2230.	1.6	13
1112	3D Image Analysis of theÂMicrovasculature in Healthy and Diseased Tissues. Methods in Molecular Biology, 2018, 1731, 193-212.	0.4	0
1113	GV1001 Induces Apoptosis by Reducing Angiogenesis in Renal Cell Carcinoma Cells Both In Vitro and In Vivo. Urology, 2018, 113, 129-137.	0.5	8
1114	Proteases and Cancer. Methods in Molecular Biology, 2018, , .	0.4	1
1115	LncRNA PVT1 promotes angiogenesis via activating the STAT3/VEGFA axis in gastric cancer. Oncogene, 2018, 37, 4094-4109.	2.6	275
1116	Overexpression of miR-133 decrease primary endothelial cells proliferation and migration via FGFR1 targeting. Experimental Cell Research, 2018, 369, 11-16.	1.2	5
1117	Blocking H1/H2 histamine receptors inhibits damage/fibrosis in Mdr2–/– mice and human cholangiocarcinoma tumorigenesis. Hepatology, 2018, 68, 1042-1056.	3.6	50
1118	Dissecting Oncogenic RTK Pathways in Colorectal Cancer Initiation and Progression. Methods in Molecular Biology, 2018, 1765, 27-42.	0.4	4
1119	Different Adaptive Responses to Hypoxia in Normal and Multiple Myeloma Endothelial Cells. Cellular Physiology and Biochemistry, 2018, 46, 203-212.	1.1	34

#	Article	IF	CITATIONS
1120	Anti-angiogenic and pro-apoptotic effects of a small-molecule JFD-WS in in vitro and breast cancer xenograft mouse models. Oncology Reports, 2018, 39, 1711-1724.	1.2	2
1121	Size shrinkable drug delivery nanosystems and priming the tumor microenvironment for deep intratumoral penetration of nanoparticles. Journal of Controlled Release, 2018, 277, 35-47.	4.8	113
1122	Effects of cryopreservation on adipose tissueâ€derived microvascular fragments. Journal of Tissue Engineering and Regenerative Medicine, 2018, 12, 1020-1030.	1.3	24
1123	Liposomeâ€encapsulated chemotherapy: Current evidence for its use in companion animals. Veterinary and Comparative Oncology, 2018, 16, E1-E15.	0.8	13
1124	Late anastomotic breakdown with bevacizumab in colorectal cancers, a case-based review. Irish Journal of Medical Science, 2018, 187, 333-336.	0.8	7
1125	Abnormalities of tumor endothelial cells and cancer progression. Oral Science International, 2018, 15, 1-6.	0.3	12
1126	CCR6 promotes tumor angiogenesis via the AKT/NF-κB/VEGF pathway in colorectal cancer. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 387-397.	1.8	59
1127	ZEB1-repressed microRNAs inhibit autocrine signaling that promotes vascular mimicry of breast cancer cells. Oncogene, 2018, 37, 1005-1019.	2.6	49
1128	Multiparametric characterization of response to antiâ€angiogenic therapy using USPIO contrastâ€enhanced MRI in combination with dynamic contrastâ€enhanced MRI. Journal of Magnetic Resonance Imaging, 2018, 47, 1589-1600.	1.9	11
1129	Therapeutic potency of pharmacological adenosine receptor agonist/antagonist in angiogenesis, current status and perspectives. Journal of Pharmacy and Pharmacology, 2018, 70, 191-196.	1.2	16
1130	Circulating Tumor Cells in the Parallel Invasion Model Supporting Early Metastasis. Oncomedicine, 2018, 3, 15-27.	1.1	6
1131	Genetic variation determines VEGF-A plasma levels in cancer patients. Scientific Reports, 2018, 8, 16332.	1.6	10
1132	Factors Associated With Small Aggressive Non–Small Cell Lung Cancers in the National Lung Screening Trial: A Validation Study. JNCI Cancer Spectrum, 2018, 2, pkx010.	1.4	1
1133	Uniform intratumoral distribution of radioactivity produced using two different radioagents, 64Cu-cyclam-RAFT-c(-RGDfK-)4 and 64Cu-ATSM, improves therapeutic efficacy in a small animal tumor model. EJNMMI Research, 2018, 8, 54.	1.1	12
1134	Treatment with Src inhibitor dasatinib results in elevated metastatic potential in the 4T1 murine mammary carcinoma model. Tumor & Microenvironment, 2018, 1, 30.	0.7	6
1135	Anoikisâ€'resistant human osteosarcoma cells display significant angiogenesis by activating the Src kinaseâ€'mediated MAPK pathway. Oncology Reports, 2019, 41, 235-245.	1.2	12
1136	Isoliquiritin Apioside Suppresses in vitro Invasiveness and Angiogenesis of Cancer Cells and Endothelial Cells. Frontiers in Pharmacology, 2018, 9, 1455.	1.6	21
1137	FOXF1 promotes angiogenesis and accelerates bevacizumab resistance in colorectal cancer by transcriptionally activating VEGFA. Cancer Letters, 2018, 439, 78-90.	3.2	44

#	Article	IF	CITATIONS
1138	Inhibitory effect of <i>Labisia pumila</i> leaf extract on angiogenesis via down-regulation of vascular endothelial growth factor. Tropical Journal of Pharmaceutical Research, 2018, 17, 1087.	0.2	1
1139	Malignant Lesions. , 2018, , 185-214.		0
1140	The real-time ultrasonography for fusion image in glioma neurosugery. Clinical Neurology and Neurosurgery, 2018, 175, 84-90.	0.6	9
1141	RGD-modified nanoliposomes containing quercetin for lung cancer targeted treatment. OncoTargets and Therapy, 2018, Volume 11, 5397-5405.	1.0	27
1142	Successful treatment of relapsed testicular embryonal rhabdomyosarcoma with Endostar and traditional chemotherapy: a case report. OncoTargets and Therapy, 2018, Volume 11, 5287-5291.	1.0	3
1143	Imaging evaluation of sorafenib for treatment of advanced hepatocellular carcinoma. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2018, 30, 382-394.	0.7	2
1144	Efficacy and safety of rhâ€endostatin (Endostar) combined with pemetrexed/cisplatin followed by rhâ€endostatin plus pemetrexed maintenance in nonâ€small cell lung cancer: A retrospective comparison with standard chemotherapy. Thoracic Cancer, 2018, 9, 1354-1360.	0.8	14
1145	Establishment of a detection assay for DNA endonuclease activity and its application in the screening and prognosis of malignant lymphoma. BMC Biochemistry, 2018, 19, 6.	4.4	7
1146	Stretching Reduces Tumor Growth in a Mouse Breast Cancer Model. Scientific Reports, 2018, 8, 7864.	1.6	48
1147	Lymphangiogenesis, lymphatic systemomics, and cancer: context, advances and unanswered questions. Clinical and Experimental Metastasis, 2018, 35, 419-424.	1.7	9
1148	Molecular alterations of cancer cell and tumour microenvironment in metastatic gastric cancer. Oncogene, 2018, 37, 4903-4920.	2.6	52
1149	Plant-Derived Compounds in Cancer Therapy: Traditions of Past and Drugs of Future., 2018,, 91-127.		5
1150	Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling. International Journal of Oncology, 2018, 52, 2051-2060.	1.4	18
1152	Overview and Critical Appraisal of Arterial Spin Labelling Technique in Brain Perfusion Imaging. Contrast Media and Molecular Imaging, 2018, 2018, 1-15.	0.4	25
1153	Anti-angiogenic and anticancer effects of baicalein derivatives based on transgenic zebrafish model. Bioorganic and Medicinal Chemistry, 2018, 26, 4481-4492.	1.4	20
1154	Computational modeling of synergistic interaction between $\hat{l}\pm V\hat{l}^23$ integrin and VEGFR2 in endothelial cells: Implications for the mechanism of action of angiogenesis-modulating integrin-binding peptides. Journal of Theoretical Biology, 2018, 455, 212-221.	0.8	19
1155	Ultrasound-Stimulated Microbubbles Enhance Radiosensitization of Nasopharyngeal Carcinoma. Cellular Physiology and Biochemistry, 2018, 48, 1530-1542.	1.1	13
1156	Single and Multiphoton Responsive Nanomaterials for the Investigation of Cancer Microenvironment. , 2018, , 63-95.		0

#	ARTICLE	IF	CITATIONS
1157	Serum exosomes contain ECRG4 mRNA that suppresses tumor growth via inhibition of genes involved in inflammation, cell proliferation, and angiogenesis. Cancer Gene Therapy, 2018, 25, 248-259.	2.2	67
1158	Integrin \hat{l}^21 is an essential factor in vasculogenic mimicry of human cancer cells. Cancer Science, 2018, 109, 2490-2496.	1.7	61
1159	Phytoestrogens as a Natural Source for the Possible Colon Cancer Treatment. , 2018, , 259-281.		0
1160	Exploration for novel inhibitors showing back-to-front approach against VEGFR-2 kinase domain (4AG8) employing molecular docking mechanism and molecular dynamics simulations. BMC Cancer, 2018, 18, 264.	1.1	43
1161	Tumor heterogeneity and nanoparticle-mediated tumor targeting: the importance of delivery system personalization. Drug Delivery and Translational Research, 2018, 8, 1508-1526.	3.0	28
1162	Synthesis and in vitro experiments of carcinoma vascular endothelial targeting polymeric nano-micelles combining small particle size and supermagnetic sensitivity. International Journal of Medical Sciences, 2018, 15, 498-506.	1.1	10
1163	ADAMTS5 acts as a tumor suppressor by inhibiting migration, invasion and angiogenesis in human gastric cancer. Gastric Cancer, 2019, 22, 287-301.	2.7	27
1164	Metal ions and the extracellular matrix in tumor migration. FEBS Journal, 2019, 286, 2950-2964.	2.2	32
1165	Chemotherapy-Induced Metastasis: Molecular Mechanisms, Clinical Manifestations, Therapeutic Interventions. Cancer Research, 2019, 79, 4567-4576.	0.4	79
1166	Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer. Cancer, 2019, 125, 4139-4147.	2.0	299
1167	C-glyco"RGD―as αIIbβ3 and αvβ integrin ligands for imaging applications: Synthesis, in vitro evaluation and molecular modeling. Bioorganic and Medicinal Chemistry, 2019, 27, 4101-4109.	1.4	6
1168	<p>Targeting tumor cells and neovascularization using RGD-functionalized magnetoliposomes</p> . International Journal of Nanomedicine, 2019, Volume 14, 5911-5924.	3.3	29
1169	An improved kit formulation for oneâ€pot synthesis of [^{99m} Tc]Tcâ€HYNICâ€E[c(RGDfK)] ₂ for routine clinical use in cancer imaging. Journal of Labelled Compounds and Radiopharmaceuticals, 2019, 62, 823-834.	0.5	3
1170	PTBP3 contributes to colorectal cancer growth and metastasis via translational activation of HIF-1α. Journal of Experimental and Clinical Cancer Research, 2019, 38, 301.	3.5	30
1171	Identifying and targeting angiogenesis-related microRNAs in ovarian cancer. Oncogene, 2019, 38, 6095-6108.	2.6	40
1172	PinX1 represses renal cancer angiogenesis via the mir-125a-3p/VEGF signaling pathway. Angiogenesis, 2019, 22, 507-519.	3.7	30
1173	Synthesis and biological evaluation of novel benzylidene-succinimide derivatives as noncytotoxic antiangiogenic inhibitors with anticolorectal cancer activity inÂvivo. European Journal of Medicinal Chemistry, 2019, 179, 805-827.	2.6	22
1174	Education for Sustainable Development: Global Progress and China's Experience. Chinese Journal of Urban and Environmental Studies, 2019, 07, 1940001.	0.5	1

#	Article	IF	Citations
1175	Microstructureâ∈Based Modeling of Mechanical Properties and Deformation Behavior of DP600 Dual Phase Steel. Steel Research International, 2019, 90, 1900311.	1.0	6
1176	Dietary 2-deoxy-D-glucose impairs tumour growth and metastasis by inhibiting angiogenesis. European Journal of Cancer, 2019, 123, 11-24.	1.3	12
1177	Comparison of 68Ga-labeled RGD mono- and multimers based on a clickable siderophore-based scaffold. Nuclear Medicine and Biology, 2019, 78-79, 1-10.	0.3	17
1178	Expression and Characterization of Human Vascular Endothelial Growth Factor Produced in SiHa Cells Transduced with Adenoviral Vector. Protein Journal, 2019, 38, 693-703.	0.7	3
1179	Risk of Venous Thromboembolic Events in Patients With Cancer Treated With Aflibercept: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. American Journal of Therapeutics, 2019, 26, e549-e552.	0.5	6
1180	The antitumor efficacy of monomeric disintegrin obtustatin in S-180 sarcoma mouse model. Investigational New Drugs, 2019, 37, 1044-1051.	1.2	13
1181	Exploring binding mechanisms of VEGFR2 with three drugs lenvatinib, sorafenib, and sunitinib by molecular dynamics simulation and free energy calculation. Chemical Biology and Drug Design, 2019, 93, 934-948.	1.5	15
1182	The natural history of renal cell carcinoma with pulmonary metastases illuminated through mathematical modeling. Mathematical Biosciences, 2019, 309, 118-130.	0.9	3
1183	N-(2-hydroxyphenyl) acetamide (NA-2) elicits potent antitumor effect against human breast cancer cell line (MCF-7). Toxicology in Vitro, 2019, 60, 296-304.	1.1	6
1184	Non-contact co-culture with human vascular endothelial cells promotes epithelial-to-mesenchymal transition of cervical cancer SiHa cells by activating the NOTCH1/LOX/SNAIL pathway. Cellular and Molecular Biology Letters, 2019, 24, 39.	2.7	19
1185	Crosstalk between cancer and immune cells: Role of tumorâ€associated macrophages in the tumor microenvironment. Cancer Medicine, 2019, 8, 4709-4721.	1.3	211
1186	VEGFR1+ Metastasis–Associated Macrophages Contribute to Metastatic Angiogenesis and Influence Colorectal Cancer Patient Outcome. Clinical Cancer Research, 2019, 25, 5674-5685.	3.2	34
1187	Breast Cancer Brain Metastasis Response to Radiation After Microbubble Oxygen Delivery in a Murine Model. Journal of Ultrasound in Medicine, 2019, 38, 3221-3228.	0.8	26
1188	Optoacoustic imaging of the breast: correlation with histopathology and histopathologic biomarkers. European Radiology, 2019, 29, 6728-6740.	2.3	17
1189	Correlations between quantitative parameters of contrast-enhanced ultrasound and vasculogenic mimicry in murine tumor model: a novel noninvasive technique for assessment?. Biological Procedures Online, 2019, 21, 11.	1.4	4
1190	Rare case of a giant duodenal ulcer penetrating the pancreas during antiangiogenic treatment. BMJ Case Reports, 2019, 12, e228612.	0.2	3
1191	Deep Learning for Super-resolution Vascular Ultrasound Imaging. , 2019, , .		43
1192	Antitumor activity of ginsenoside Rg3 in melanoma through downregulation of the ERK and Akt pathways. International Journal of Oncology, 2019, 54, 2069-2079.	1.4	27

#	Article	IF	CITATIONS
1193	Gambogic acid impairs tumor angiogenesis by targeting YAP/STAT3 signaling axis. Phytotherapy Research, 2019, 33, 1579-1591.	2.8	15
1194	Endothelial Cell-Derived TGF- \hat{l}^2 Promotes Epithelial-Mesenchymal Transition via CD133 in HBx-Infected Hepatoma Cells. Frontiers in Oncology, 2019, 9, 308.	1.3	24
1195	Herbacetin suppressed MMP9 mediated angiogenesis of malignant melanoma through blocking EGFR-ERK/AKT signaling pathway. Biochimie, 2019, 162, 198-207.	1.3	39
1196	Phloretin suppresses metastasis by targeting protease and inhibits cancer stemness and angiogenesis in human cervical cancer cells. Phytomedicine, 2019, 62, 152964.	2.3	34
1197	Tumor-induced neoangiogenesis and receptor tyrosine kinases – Mechanisms and strategies for acquired resistance. Biochimica Et Biophysica Acta - General Subjects, 2019, 1863, 1217-1225.	1.1	9
1198	Bladder cancer cells interact with vascular endothelial cells triggering EGFR signals to promote tumor progression. International Journal of Oncology, 2019, 54, 1555-1566.	1.4	21
1199	miR-622 inhibits angiogenesis by suppressing the CXCR4–VEGFA axis in colorectal cancer. Gene, 2019, 699, 37-42.	1.0	39
1200	PMEPA1/TMEPAI knockout impairs tumour growth and lung metastasis in MDA-MB-231 cells without changing monolayer culture cell growth. Journal of Biochemistry, 2019, 165, 411-414.	0.9	13
1201	A Current Review of Spatial Fractionation: Back to the Future?. International Journal of Radiation Oncology Biology Physics, 2019, 104, 177-187.	0.4	90
1202	Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Diagnostic Tool in the Assessment of Tumour Angiogenesis in Urinary Bladder Cancer. Canadian Association of Radiologists Journal, 2019, 70, 254-263.	1.1	12
1203	Efficacy of Combined VEGFR1-3, PDGF $\hat{l}\pm\hat{l}^2$, and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer. Clinical Cancer Research, 2019, 25, 3811-3817.	3.2	10
1204	Tumorâ€derived exosomes: Implication in angiogenesis and antiangiogenesis cancer therapy. Journal of Cellular Physiology, 2019, 234, 16885-16903.	2.0	92
1205	The emerging roles of macrophages in cancer metastasis and response to chemotherapy. Journal of Leukocyte Biology, 2019, 106, 259-274.	1.5	80
1206	Angiopoietin-1 and Angiopoietin-2 Inhibitors: Clinical Development. Current Oncology Reports, 2019, 21, 22.	1.8	26
1207	Dynamic Modeling of the Angiogenic Switch and Its Inhibition by Bevacizumab. Complexity, 2019, 2019, 1-18.	0.9	8
1208	Antitumoral Effects of Metformin in Ovarian Cancer., 0, , .		1
1209	Correlation of vascular endothelial growth factor and vascular endothelial growth factor receptor-1 levels in serum and thyroid nodules with histopathological and radiological variables. Journal of Laboratory Physicians, 2019, 11, 051-057.	0.4	7
1210	GV1001 inhibits cell viability and induces apoptosis in castration-resistant prostate cancer cells through the AKT/NF-κB/VEGF pathway. Journal of Cancer, 2019, 10, 6269-6277.	1.2	10

#	Article	IF	CITATIONS
1211	Cancer Stem Cells and Neuroblastoma: Characteristics and Therapeutic Targeting Options. Frontiers in Endocrinology, 2019, 10, 782.	1.5	31
1212	Preparation of truncated tissue factor antineuropilin-1 monoclonal antibody conjugate and identification of its selective thrombosis in tumor blood vessels. Anti-Cancer Drugs, 2019, 30, 441-450.	0.7	3
1213	The metabolic engine of endothelial cells. Nature Metabolism, 2019, 1, 937-946.	5.1	70
1214	Extracellular Vesicles From Pathological Microenvironment Induce Endothelial Cell Transformation and Abnormal Angiogenesis via Modulation of TRPV4 Channels. Frontiers in Cell and Developmental Biology, 2019, 7, 344.	1.8	12
1216	Adipose tissue, angiogenesis and angio-MIR under physiological and pathological conditions. European Journal of Cell Biology, 2019, 98, 53-64.	1.6	14
1217	Melanoma tumour vasculature heterogeneity: from mice models to human. Journal of Cancer Research and Clinical Oncology, 2019, 145, 589-597.	1.2	9
1218	Obesity and cancer risk: Emerging biological mechanisms and perspectives. Metabolism: Clinical and Experimental, 2019, 92, 121-135.	1.5	821
1219	Estrogen-dependent DLL1-mediated Notch signaling promotes luminal breast cancer. Oncogene, 2019, 38, 2092-2107.	2.6	66
1220	Aspirin suppresses tumor cell-induced angiogenesis and their incongruity. Journal of Cell Communication and Signaling, 2019, 13, 491-502.	1.8	15
1221	TAZ Expression on Endothelial Cells Is Closely Related to Blood Vascular Density and VEGFR2 Expression in Astrocytomas. Journal of Neuropathology and Experimental Neurology, 2019, 78, 172-180.	0.9	11
1222	Tricyclic antidepressant amitriptyline inhibits autophagic flux and prevents tube formation in vascular endothelial cells. Basic and Clinical Pharmacology and Toxicology, 2019, 124, 370-384.	1.2	9
1223	Deletion of <i>Atm</i> in Tumor but not Endothelial Cells Improves Radiation Response in a Primary Mouse Model of Lung Adenocarcinoma. Cancer Research, 2019, 79, 773-782.	0.4	28
1224	Thymidine kinase-1/CD31 double immunostaining for identifying activated tumor vessels. Biotechnic and Histochemistry, 2019, 94, 60-64.	0.7	9
1225	<scp>LOXL /scp>2 promotes vasculogenic mimicry and tumour aggressiveness in hepatocellular carcinoma. Journal of Cellular and Molecular Medicine, 2019, 23, 1363-1374.</scp>	1.6	38
1226	Caspase-11 regulates the tumour suppressor function of STAT1 in a murine model of colitis-associated carcinogenesis. Oncogene, 2019, 38, 2658-2674.	2.6	21
1227	The element-free Galerkin method based on moving least squares and moving Kriging approximations for solving two-dimensional tumor-induced angiogenesis model. Engineering With Computers, 2020, 36, 1517-1537.	3.5	23
1228	Combined microwave ablation and antiangiogenic therapy to increase local efficacy. Minimally Invasive Therapy and Allied Technologies, 2020, 29, 107-113.	0.6	2
1229	Risk of hand-foot skin reaction associated with vascular endothelial growth factor–tyrosine kinase inhibitors: A meta-analysis of 57 randomized controlled trials involving 24,956 patients. Journal of the American Academy of Dermatology, 2020, 83, 788-796.	0.6	21

#	Article	IF	CITATIONS
1230	Impact of extreme events on conversion efficiency of wave energy converter. Energy Science and Engineering, 2020, 8, 3441-3456.	1.9	5
1231	A randomized phase 2 trial of apatinib vs observation as maintenance treatment following firstÂline induction chemotherapy in extensiveÂ-stage small cell lung cancer. Investigational New Drugs, 2020, 38, 148-159.	1.2	22
1233	Intravoxel incoherent motion diffusion-weighted imaging assessment of microvascular characteristics in the murine embryonal rhabdomyosarcoma model. Acta Radiologica, 2020, 61, 260-266.	0.5	9
1234	Variation in energy metabolism arising from the effect of the tumor microenvironment on cell biological behaviors of bladder cancer cells and endothelial cells. BioFactors, 2020, 46, 64-75.	2.6	8
1235	A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE). Neuro-Oncology, 2020, 22, 705-717.	0.6	47
1236	Dynamic contrast-enhanced magnetic resonance imaging for monitoring the anti-angiogenesis efficacy in a C6 glioma rat model. Acta Radiologica, 2020, 61, 973-982.	0.5	3
1237	Novel engineered TRAILâ€based chimeric protein strongly inhibits tumor growth and bypasses TRAIL resistance. International Journal of Cancer, 2020, 147, 1117-1130.	2.3	7
1238	Circ_0072088 Promotes Proliferation, Migration, and Invasion of Esophageal Squamous Cell Cancer by Absorbing miR-377. Journal of Oncology, 2020, 2020, 1-14.	0.6	19
1239	The murine Microenvironment Cell Population counter method to estimate abundance of tissue-infiltrating immune and stromal cell populations in murine samples using gene expression. Genome Medicine, 2020, 12, 86.	3.6	63
1240	Large-scale characterization of the microvascular geometry in development and disease by tissue clearing and quantitative ultramicroscopy. Journal of Cerebral Blood Flow and Metabolism, 2020, 41, 0271678X2096185.	2.4	10
1241	S1PR1 and VEGFR2 – a synergy that promotes tumor angiogenesis?. Molecular and Cellular Oncology, 2020, 7, 1746131.	0.3	3
1242	The KDR (VEGFR-2) Genetic Polymorphism Q472H and c-KIT Polymorphism M541L Are Associated With More Aggressive Behaviour in Astrocytic Gliomas. Cancer Genomics and Proteomics, 2020, 17, 715-727.	1.0	10
1243	<i>In Vivo</i> Imaging of Hypoxia and Neoangiogenesis in Experimental Syngeneic Hepatocellular Carcinoma Tumor Model Using Positron Emission Tomography. BioMed Research International, 2020, 2020, 1-10.	0.9	5
1244	Clinicopathological Evaluation of the Potential Anatomic Pathways of Systemic Metastasis from Primary Breast Cancer Suggests an Orderly Spread Through the Regional Lymph Nodes. Annals of Surgical Oncology, 2020, 27, 4810-4818.	0.7	14
1245	Novel mechanistic targets of forkhead box Q1 transcription factor in human breast cancer cells. Molecular Carcinogenesis, 2020, 59, 1116-1128.	1.3	7
1246	Chinese herbal medicines for prevention and treatment of colorectal cancer: From molecular mechanisms to potential clinical applications. Journal of Integrative Medicine, 2020, 18, 369-384.	1.4	30
1247	Anticancer Effect of Capsaicin and Its Analogues. , 0, , .		5
1248	A Prognostic Model Based on Six Metabolism-Related Genes in Colorectal Cancer. BioMed Research International, 2020, 2020, 1-16.	0.9	15

#	Article	IF	CITATIONS
1249	<p>Exosomal IncRNA RAMP2-AS1 Derived from Chondrosarcoma Cells Promotes Angiogenesis Through miR-2355-5p/VEGFR2 Axis</p> . OncoTargets and Therapy, 2020, Volume 13, 3291-3301.	1.0	50
1250	Oridonin exhibits anti-angiogenic activity in human umbilical vein endothelial cells by inhibiting VEGF-induced VEGFR-2 signaling pathway. Pathology Research and Practice, 2020, 216, 153031.	1.0	10
1251	Long non-coding RNA HNF1A-AS1 upregulates OTX1 to enhance angiogenesis in colon cancer via the binding of transcription factor PBX3. Experimental Cell Research, 2020, 393, 112025.	1.2	20
1252	Angiogenic biomaterials to promote therapeutic regeneration and investigate disease progression. Biomaterials, 2020, 255, 120207.	5.7	34
1253	Proapoptotic and Antiangiogenic Activities of <i>Arctium Lappa</i> L. on Breast Cancer Cell Lines. Scientifica, 2020, 2020, 1-14.	0.6	11
1254	Indoor dust extracellular vesicles promote cancer lung metastasis by inducing tumour necrosis factorâ€Î±. Journal of Extracellular Vesicles, 2020, 9, 1766821.	5.5	9
1255	Roles of Lipids in Cancer. , 0, , .		5
1256	Discovery of small molecules targeting GRP78 for antiangiogenic and anticancer therapy. European Journal of Medicinal Chemistry, 2020, 193, 112228.	2.6	10
1257	Endosialin (TEM1) as a Diagnostic, Progression, and Prognostic Serum Marker for Patients With Colorectal Cancerâ€"A Preliminary Study. Cancer Control, 2020, 27, 107327482090335.	0.7	6
1258	Apatinib exhibits cytotoxicity toward leukemia cells by targeting VEGFR2-mediated prosurvival signaling and angiogenesis. Experimental Cell Research, 2020, 390, 111934.	1.2	10
1259	The current paradigm and challenges ahead for the dormancy of disseminated tumor cells. Nature Cancer, 2020, 1, 672-680.	5.7	132
1260	Role of Apelin/APJ axis in cancer development and progression. Advances in Medical Sciences, 2020, 65, 202-213.	0.9	45
1261	Encapsulation of gemcitabine in RGD-modified nanoliposomes improves breast cancer inhibitory activity. Pharmaceutical Development and Technology, 2020, 25, 640-648.	1.1	9
1262	DHPAC, a novel microtubule depolymerizing agent, suppresses angiogenesis and vasculogenic mimicry formation of human nonâ€small cell lung cancer. Journal of Cellular Biochemistry, 2020, 121, 4756-4771.	1.2	8
1263	Fucoidan from Laminaria japonica exerts antitumor effects on angiogenesis and micrometastasis in triple-negative breast cancer cells. International Journal of Biological Macromolecules, 2020, 149, 600-608.	3.6	58
1264	Synergism of 4HPR and SAHA increases anti-tumor actions in glioblastoma cells. Apoptosis: an International Journal on Programmed Cell Death, 2020, 25, 217-232.	2.2	8
1265	Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself. Angiogenesis, 2020, 23, 279-298.	3.7	30
1266	Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial. Experimental Hematology and Oncology, 2020, 9, 7.	2.0	11

#	Article	IF	CITATIONS
1267	Allogenic mouse cell vaccine inhibits lung cancer progression by inhibiting angiogenesis. Human Vaccines and Immunotherapeutics, 2021, 17, 35-50.	1.4	2
1268	The oncogenic potential of NANOG: An important cancer induction mediator. Journal of Cellular Physiology, 2021, 236, 2443-2458.	2.0	35
1269	Preoperative normalized iodine concentration derived from spectral CT is correlated with early recurrence of hepatocellular carcinoma after curative resection. European Radiology, 2021, 31, 1872-1882.	2.3	6
1270	Gastric carcinogenesis: a comprehensive review of the angiogenic pathways. Clinical Journal of Gastroenterology, 2021, 14, 14-25.	0.4	18
1271	FOXM1D potentiates PKM2â€mediated tumor glycolysis and angiogenesis. Molecular Oncology, 2021, 15, 1466-1485.	2.1	30
1273	Current status of targeted microbubbles in diagnostic molecular imaging of pancreatic cancer. Bioengineering and Translational Medicine, 2021, 6, e10183.	3.9	15
1274	Influence of VEGFR2 gene polymorphism on the clinical outcomes of apatinib for patients with chemotherapy–refractory extensive-stage SCLC: a real-world retrospective study. International Journal of Clinical Oncology, 2021, 26, 670-683.	1.0	4
1275	A Correlative Study Between IVIM-DWI Parameters and the Expression Levels of Ang-2 and TKT in Hepatocellular Carcinoma. Frontiers in Oncology, 2020, 10, 594366.	1.3	10
1276	Novel Small Molecules in the Treatment of Lymphomas. , 2006, , 413-460.		1
1277	Oridonin Suppresses Human Gastric Cancer Growth <i>in Vitro</i> and <i>in Vivo via</i> Inhibition of VEGF, Integrin β3, and PCNA. Biological and Pharmaceutical Bulletin, 2020, 43, 1035-1045.	0.6	12
1278	PERK Regulates the Proliferation and Development of Insulin-Secreting Beta-Cell Tumors in the Endocrine Pancreas of Mice. PLoS ONE, 2009, 4, e8008.	1,1	50
1279	A Novel Xenograft Model in Zebrafish for High-Resolution Investigating Dynamics of Neovascularization in Tumors. PLoS ONE, 2011, 6, e21768.	1.1	101
1280	In Vivo Evolution of Tumor-Derived Endothelial Cells. PLoS ONE, 2012, 7, e37138.	1.1	28
1281	Bmi-1 Promotes Glioma Angiogenesis by Activating NF-κB Signaling. PLoS ONE, 2013, 8, e55527.	1.1	45
1282	Dynamic Quantitative Intravital Imaging of Glioblastoma Progression Reveals a Lack of Correlation between Tumor Growth and Blood Vessel Density. PLoS ONE, 2013, 8, e72655.	1.1	23
1283	Tryptanthrin Inhibits Angiogenesis by Targeting the VEGFR2-Mediated ERK1/2 Signalling Pathway. PLoS ONE, 2013, 8, e82294.	1.1	49
1284	HIF-1 Alpha Overexpression Correlates with Poor Overall Survival and Disease-Free Survival in Gastric Cancer Patients Post-Gastrectomy. PLoS ONE, 2014, 9, e90678.	1.1	44
1285	Associations of VEGF-C Genetic Polymorphisms with Urothelial Cell Carcinoma Susceptibility Differ between Smokers and Non-Smokers in Taiwan. PLoS ONE, 2014, 9, e91147.	1.1	15

#	ARTICLE	IF	CITATIONS
1286	Oridonin Inhibits Tumor Growth and Metastasis through Anti-Angiogenesis by Blocking the Notch Signaling. PLoS ONE, 2014, 9, e113830.	1.1	49
1287	Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer. PLoS ONE, 2015, 10, e0134731.	1.1	38
1288	Tumor-Associated Macrophage (TAM) and Angiogenesis in Human Colon Carcinoma. Open Access Macedonian Journal of Medical Sciences, 2015, 3, 209-214.	0.1	39
1289	Angiogenesis Markers in Breast Cancer - Potentially Useful Tools for Priority Setting of Anti-Angiogenic Agents. Asian Pacific Journal of Cancer Prevention, 2013, 14, 7651-7656.	0.5	15
1290	Enhanced Antitumor Effect of Curcumin Liposomes with Local Hyperthermia in the LL/2 Model. Asian Pacific Journal of Cancer Prevention, 2013, 14, 2307-2310.	0.5	14
1291	Risk of Serious Neutropenic Events in Cancer Patients Treated with Bevacizumab: A Meta-analysis. Asian Pacific Journal of Cancer Prevention, 2013, 14, 2453-2459.	0.5	6
1292	Efficacy and Safety of Endostar \hat{A}^{\otimes} (sup>Combined with Chemotherapy in Patients with Advanced Soft Tissue Sarcomas. Asian Pacific Journal of Cancer Prevention, 2013, 14, 4255-4259.	0.5	12
1293	Association of +405C>G and +936C>T Polymorphisms of the Vascular Endothelial Growth Factor Gene with Sporadic Breast Cancer in North Indians. Asian Pacific Journal of Cancer Prevention, 2014, 15, 257-263.	0.5	11
1294	Targeting EGFL7 Expression through RNA Interference Suppresses Renal Cell Carcinoma Growth by Inhibiting Angiogenesis. Asian Pacific Journal of Cancer Prevention, 2014, 15, 3045-3050.	0.5	17
1295	The Pringle Maneuver Accelerates Liver Metastasis by Over-Expression of Tumor Vasculature in a Murine Model of Colon Cancer. Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of) Tj ETQq1 1 0.78	343 0 4orgBT	 Qverlock
1296	The Recruitment of Bone Marrow-Derived Cells to Sites of Pancreatic ^ ^beta;-cell Injury and the Restoration of Endocrine Function. The Showa University Journal of Medical Sciences, 2005, 17, 95-103.	0.1	0
1297	Liver Metastases. , 2013, , 141-161.		0
1298	Hepatocellular Carcinoma Microvessel Density Quantitation with Image Analysis: Correlation with Prognosis. Journal of Analytical Oncology, 0, , .	0.1	0
1299	A Review of the Expression of Genes Involved in Sex Steroid Hormone Metabolism in Prostate Tissue: A Need for Epigenetic Information. Journal of Analytical Oncology, 0, , .	0.1	0
1300	Hot-water Extract of Rubus Coreanus Miquel Suppresses VEGF-induced Angiogenesis. Journal of Life Science, 2014, 24, 1345-1355.	0.2	0
1304	Cavitation induced shear and circumferential stresses on blood vessel walls during photo-mediated ultrasound therapy. AIP Advances, 2020, 10, 125227.	0.6	9
1305	Preclinical Quantification of Prostate Cancer-Associated Vascular Alterations in the Bone Microenvironment in vivo. European Surgical Research, 2020, 61, 188-200.	0.6	0
1307	Extracellular Vesicles from Esophageal Squamous Cell Carcinoma Promote Angiogenesis and Tumor Growth. Journal of Biomaterials and Tissue Engineering, 2022, 12, 293-298.	0.0	2

#	Article	IF	CITATIONS
1308	Tolerance and Pharmacokinetics of Recombinant Human Endostatin Administered as Single-Dose or Multiple-Dose Infusions in Patients With Advanced Solid Tumors: A Phase I Clinical Trial. Technology in Cancer Research and Treatment, 2021, 20, 153303382110644.	0.8	2
1309	Hyperglycemia-induced oxidative stress promotes tumor metastasis by upregulating vWF expression in endothelial cells through the transcription factor GATA1. Oncogene, 2022, 41, 1634-1646.	2.6	9
1310	COMBINING IN VITRO AND IN OVO ASSAYS TO SCREEN FOR ANTI-CANCER AND ANTI-ANGIOGENIC EFFECTS OF THE LEAF EXTRACTS OF Mallotus cumingii Mull.Arg. (EUPHORBIACEAE). , 2022, 51, 73-82.		1
1311	A Fokker–Planck feedback control framework for optimal personalized therapies in colon cancer-induced angiogenesis. Journal of Mathematical Biology, 2022, 84, 23.	0.8	4
1312	Role of Exosomes in Tumor Induced Neo-Angiogenesis. , 0, , .		1
1313	An Important Component of Tumor Progression: Fatty Acids. Biochemistry, 0, , .	0.8	0
1314	Breaking the niche: multidimensional nanotherapeutics for tumor microenvironment modulation. Drug Delivery and Translational Research, 2023, 13, 105-134.	3.0	1
1317	Changes in kinetic heterogeneity of breast cancer via computer-aided diagnosis on MRI predict the pathological response to neoadjuvant systemic therapy. European Radiology, 2023, 33, 440-449.	2.3	2
1318	Modeling ATP-mediated endothelial cell elongation on line patterns. Biomechanics and Modeling in Mechanobiology, 0 , , .	1.4	0
1319	Metabolic Vestiges of Conflict Mediation in Modern Biology. , 2022, , 97-117.		0
1320	NF-kB Signaling in the Macroenvironment of Cancer Cachexia. , 2022, , 119-135.		0
1321	Inhaled Indomethacin-Loaded Liposomes as Potential Therapeutics against Non-Small Cell Lung Cancer (NSCLC). Pharmaceutical Research, 2022, 39, 2801-2815.	1.7	7
1323	MECHANIZMY PROWADZĄCE DO ANGIOGEGNEZY W NOWOTWORACH., 2019, 17, 60-65.		0
1324	Molecular Features, Prognostic Value, and Cancer Immune Interactions of Angiogenesis-Related Genes in Ovarian Cancer. Reproductive Sciences, 0, , .	1.1	1
1325	Emerging Graphene-Based Nanomaterials for Cancer Nanotheranostics. Materials Horizons, 2023, , 1091-1126.	0.3	1
1326	Could senescence phenotypes strike the balance to promote tumor dormancy?. Cancer and Metastasis Reviews, 2023, 42, 143-160.	2.7	2